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Abstract 
Background: Host resistance to pulmonary tuberculosis is 
associated with the induction of IFN-y secreting T cells in the 
lung. Recombinant viruses used in heterologous prime-boost 
immunisation regimens can evoke powerful T cell immune 
responses and are promising candidates for novel tuberculosis 
vaccmes. In this thesis, the immunogenicity and protection 
protective efficacy of viral vectors expressmg the 
immunodominant antigen, 85A were investigated in murine and 
macaque models of tuberculosis disease. 
Results: Recombinant modified VaCC11lla VIruS Ankara, 
expressing the M.vcohacterium tuherculosis antigen HSA 
(MY A85A), strongly boosted BCG-induced antigen H5A 
specific- CD4+ and CD8~ T cell responses in BALB/c and 
C57BLl6 mice. A comparison of intranasal and parenteral 
immunisation of BCG showed that whilst both routes elicited 
comparable T cell responses in the spleen, only intranasal 
delivery elicited specific T cell responses in the lung lymph 
nodes and these responses were further boosted by intranasal 
delivery of MY A85A. 
Following aerosol challenge of BALB/c with Mycohaclerillm 
tuherculosis, intranasal boosting of BCG with eithcr Be(i or 
MY A85A afforded unprecedented levels of protection in both 
the lungs (2.5 log) and spleens (I.S log) compared to naive 
controls. Protection in the lung correlated with the induction of 
antigen 85A specitic IFN-y secreting T cells in the lung lymph 
nodes. 
In rhesus macaques, aerosol delivery of BeG induced 
comparable kinetics and frequencies of T cells in the peripheral 
blood compared to intradermal BCG without producing 
abnormal pathology. MVA85A vaccination induced low level 
Ag85A-specific CD4+ and CD8; T cell responses in the blood. 
Further vaccination with another attenuated poxvirus, Fowlpox 
expressing antigen 85A significantly increased 8SA-specific T 
cell response In 5 of 6 outbred macaques. Analysis of 
lymphocytes 10 broncheo-alveolar lavage showed that 
vaccination with either BeG or M.8SA/F .SSA induced high 
frequencies of 85A-specific T cells in the respiratory 
compartment. 
Conc!u\'ions: These findings support further evaluation of 
mucosally targeted prime-boost vaccination approaches for 
tuberculosis. 
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7 
Introduction 
1.1 Global Tuberculosis Epidemic 
Overview 
Tuberculosis in humans is predominantly caused by the bacillus, Mycohacterium 
tuberculosis (M. tuberculosis). M. tuberculosis is a respiratory pathogen passed from 
an infected to non-infected individual typically through coughing. The earliest 
reports of infection of humans with M tuberculosis infection date from 5000BC (I). 
Tuberculosis has spread world-wide with reports of disease in all inhabited 
continents. At the tum of last century, tuberculosis was a plague on the industrial 
world, but over the following 80 years improved public health, better diagnostics, 
widespread immunisation with the BCG vaccine and the introduction of 
chemotherapy led to a steep decline of disease incidence world-widc. Tuberculosis 
related morbidity and mortality again increased in the late 1980's and in 1993, 
tuberculosis was declared a global epidemic by the World Health Organisation. 
Eight million people are newly infected with M tuberculosis annually and 2 million 
die each year predominately from pulmonary disease (http://www.who.int/ gtbl 
publications I globrepOI lindex.html). These numbers gain even greater import in the 
developing world where 95% of tuberculosis cases occur (2). Thc re-emergence of 
tuberculosis as a global health threat results from a combination of factors, including 
limited access to chemotherapeutic drugs in developing countries, the failure of the 
BeG vaccine to protect from pulmonary disease in the tropics and the significantly 
increased progression to tuberculosis disease in individuals who arc infected with 
Humian Immunodeficiency Virus (HIV). Today, health organisations have 
implemented a variety of programmes to both prevent and cure tuberculosis disease. 
A major goal is the development of a more efficacious vaccine to prevent pulmonary 
disease. 
Factors decreasing the number of tuberculosis cases 
Diagnostics 
Early detection of tuberculosis is a central issue in minimising transmission. A 
definitive diagnosis of tuberculosis requires the recovery of M tuberculosis 
organisms from a patient's body fluids or tissues. The key test for pulmonary 
tuberculosis is multiple sputum samples testing positive by microscopy. Sputum 
microscopy has some limitations. The sensitivity of this test is low (I x I ()4 bacilli / 
ml), and therefore functions best in more advanced cases of disease. It also performs 
poorly in HIY+ individuals and is inadequate for paediatric (where it is difficult to 
obtain sputum) and extra-pulmonary tuberculosis. X-ray is also employed in the 
confirmation of pulmonary lesions and in determining the extent of disease 
particularly when the M. tuberculosis has undergone extra-pulmonary spread. 
Skin Testing 
The tuberculin skin test (TST) involves intradermal or subcutaneous injection of 
purified culture filtrate proteins of M tuberculosis, commonly referred to as 
tuberculin. Prior M. tuberculosis exposure produces a delayed-type hypersensitivity 
(DTH) response to the tuberculin 48 to 72 hours after infection. The DTH response 
results from an influx of activated macrophages that accumulate and surround the 
site of infection. The size of the DTH response is taken as a measure of the degree of 
exposure to M. tuberculosis, but does not correlate with protection from disease (3, 
4). Tuberculin conversion is routinely used as an assay of recent M. tuhercu/osis 
exposure, but its application is limited because it can not reliably distinguish M. 
tuberculosis infection from BeG vaccination, and/or exposure to environmental 
mycobacteria. The US and The Netherlands rely heavily on the TST for contact 
tracing following M. tuberculosis exposure. Both countries have ended BeG 
vaccination programmes so as to not compromise the diagnostic value of the TST. 
DOTS programme 
The 'directly observed therapy - short course' approach or DOTS programme was 
initiated by the World Health Organisation (WHO). The programme aims to ensure 
that tuberculosis positive patients comply with chemotherapy regimens through 
regular supervision by trained health care workers. The targets for control include 
curing 85% of newly detected smear-positive cases of pulmonary TB and detecting 
70% of existing cases by 2005 (5). The advantages originally forecast for the DOTS 
programme were increased cure rate, decreased incidence of multiple-drug resistant 
tuberculosis, increased longevity in patients suffering from Acquired Immune 
Deficiency Syndrome (AIDS) and increased cost-effectiveness. The programme has 
proved highly successful. Today, of the 22 countries reporting the highest 
tuberculosis burdens, 16 have cure rates greater than 70% (5). In India alone, 200 
000 lives and US$ 400 million have been saved since the introduction of the DOTS 
programme in the late 1990s (5). A remaining area of concern is the low smear-
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positive detection rates. Only 4 of the 22 high burden countries have achieved smear 
positive detection rates over 60%. Therefore despite high cure rates, a significant 
proportion of patients remain symptomatic and infectious for months before 
successful diagnostic testing (5). 
Therapeutic - chemotherapy 
The development of combination chemotherapy has had the greatest impact on 
decreasing tuberculosis incidence in the world. Anti-tuberculosis drugs work by 
inhibiting metabolic pathways of M tuberculosis, examples being cell wall and 
protein synthesis. 
Two factors are essential to successful chemotherapy; combination therapy (2 or 
more drugs) and adherence to treatmcnt programmes which typically last 6 months 
(reviewed in (6». Combination therapy was introduced after high levels of resistant 
strains developed following single drug treatment using streptomycin (7, R). Adult 
pulmonary disease requires treatment for 6 months or more to significantly decrease 
the rate of relapse of disease (9). This length of treatment is necessary to achieve 
either sterilizing immunity or decrease the bacillary load to a level where the host 
immune response can contain or eradicate any residual bacilli. 
Prophylaxis - BeG Vaccine 
The only licensed vaccine against M. tuberculosis is the bacillus of Calmette and 
Guerin (BCG) (10). BCG is a live attenuated strain of Mycobacterium bovis and in 
developing countries is typically administered intradermally as a single dose to 
newborn infants. Each year, 80% of al1 infants born receive BeG 
(http://www.who.inVinf-fs/enifactl04.html). 
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Vaccine efficacy is measured in terms of the percentage reduction in disease among 
vaccinated individuals that is attributable to vaccination (II). The review of many 
studies, suggests that BCG vaccination is protective against childhood meningeal 
tuberculosis and systemic forms of the disease. Adult pulmonary disease is the major 
cause of tuberculosis mortality, and it is here, that BCG efficacy is most variable, 
ranging from 77% in the UK to 0% in Chingleput, India (12). The theories 
surrounding the variability of BCG protective efficacy are discussed is Section 1.5. 
Factors increasing the number of tuberculosis cases 
Host Genetics 
Over 90% of immunocompetent, M tuberculosis positive individuals do not develop 
tuberculosis (Fig. 1). The factors that control susceptibility in the remaining IOlX) are 
unknown. Studies describing an increased progression to tuberculosis in identical 
compared with non-identical twins demonstrated host genetics play a role in 
susceptibility to tuberculosis (13-15). With the exception of mutations within the 
IFN-y receptor pathway (discussed in section 1.4) that appear to exert monogenic 
control over susceptibility to mycobacterial disease, tuberculosis susceptibility may 
require polymorphisms in several genes. Various genes have now been described 
that influence resistance and susceptibility to tuberculosis in certain ethnic 
populations. These include MHC genes and genes encoding proteins that may be 
involved in macrophage mediated killing of M tuberculosis like natural resistance 
associated macrophage protein -1 (Nramp -1) and TNF-a (16-19). 
Socio-economic factors and poor implementation of programmes 
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Both poverty and malnutrition have clear associations with tuberculosis incidence 
and the severity of clinical disease (20, 21). Overcrowding and poor venti lation can 
also contribute to increased transmission within a community 
(html://www.who.int/gtb). 
Multiple-drug resistant strains of tuberculosis 
MUltiple drug resistant (MDR) tuberculosis is defined as resistance to at least 
isoniazid and rifampicin (22). The major selection factors in the development of 
MDR tuberculosis are inadequate drug treatment and poor adherence to 
recommended treatment regimens (23,24). 
Globally, the prevalence of MDR tuberculosis is low. In 2000, MDR tuberculosis 
accounted for 3.2% of all new cases (25). However, regions of high MDR 
tuberculosis incidence have emerged (26, 27). 
The major problem of treating MDR tuberculosis is the cost, which has been 
estimated at greater than 50 times the cheapest short-course regimen for drug-
susceptible M tuberculosis (28). 
Human Immunodeficiency Virus epidemic 
Human Immunodeficiency Virus type I (HIY -I) infection is characterised by the 
progressive loss of CD4+ T cells. Human Immunodeficiency Virus positivity (Hlyt) 
is the strongest risk factor for the progression from infection to active tuberculosis, 
increasing the risk of developing disease from 5-10% over one's lifetime to 5-10% 
per year (29). Not surprisingly, tuberculosis is a leading cause of death amongst 
HIV+ -individuals (30). At the end of 2000, one third of HIY"+ people were co-
infected with M. tuberculosis and 8.4 million (70%) lived In sub-Saharan Africa 
(31 ). 
Traditional TB control measures effectively blunt the impact of HIY on tuberculosis 
but despite active BeG vaccination and DOTS programmes in sub-Saharan A [rica, 
tuberculosis incidence continues to rise (32, 33). The increasing number of 
tuberculosis cases In HIY+ people poses an increased risk of tuberculosis 
transmission to the general community whether HIY+ or negative. New initiatives 
have been proposed to act as an adjunct to the DOTS programme (31) and include 
intensified case-finding, cure and preventive treatments as well as intervention 
against HIY. This involves the promotion of voluntary HIY testing, counselling to 
decrease high risk sexual behaviour, provision of condoms, treatment for sexually 
transmitted infections, and provision of highly active antiretroviral treatment 
(HAART). The development of any new tuberculosis vaccine should therefore be 
safe for use in immunocompromised individuals. 
1.2 The Bacillus 
M tuberculosis - genomic structure 
Epidemiology 
Mycobacteria include both saprophytes and pathogens with a host range spanning 
plants to man. The M. tuberculosis complex refers to a group of mycobacteria that 
show greater than 99% homology at the nucleotide level and are identical at the 16S 
rRNA level (34, 35). Members include, M. tuberculosis, M. hovis, M. cannelli, M. 
jortuitum and M ajricanum, which whilst genetically similar, exhibit wide species 
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preferences. The high level of conservation at the amino acid level within members 
of the M tuberculosis complex produces complexity In tuberculosis vaccine 
development. Many of the immunodominant proteins in M tuherculosis are also 
expressed by environmental mycobacteria that can induce cross-reactive Immune 
responses against vaccine antigens and inhibit vaccine efficacy. 
The members of the M. tuberculosis complex most likely descended from a common 
soil mycobacterium (36). The host range of the M tuberculosis bacillus is limited to 
humans except for rare reports of infections in elephants (37). M tuberculosis was 
formerly believed to have evolved from M. hovis, following the domestication of 
cattle by man (36). Recent genomic analysis argues that M tuberculosis did not 
descend from M bovis and that the common ancestor to both mycobacteria was 
already a human pathogen at the time when M. bovis split from the M. tuherculosis 
lineage. It is proposed that after this split, M. bovis acquired a broader host range, 
which today includes most mammals (38). 
Structure and functions 
Growth Characteristics 
M. tuberculosis is a gram positive intracellular bacillus 2-4J.lm x O.2-0.SJ.lm in size. It 
is characterised by slow growth, a complex cell envelope and mechanisms that 
enable it to persist within the human host. M. tuberculosis can be grown in broth 
culture and following 3-4 weeks culture on semi-solid media produces visible otT-
white, roughened colonies (39). 
Analysis of the genome 
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The spontaneous mutation frequency of M. tuherculosis is comparable to othcr 
bacteria (40). However, the allelic variation at the amino acid Ievcl is vcry low, with 
most variation associated with genes implicated in drug resistance (35). This affords 
a benefit to vaccine development because antigens used in vaccines will share a vcry 
high level of homology with antigens in field strains. 
The H37Rv strain (H37Rv accession number AL123456) of M. tuherculosis is the 
strain most commonly used in tuberculosis research because it retains full virulence 
in animal models. The full sequence of H37Rv was published in 1998 (41). Thc M. 
tuberculosis genome contains almost 4000 genes has the ability to synthcsise all 
essential amino acids, vitamins, enzymes and co-factors (41, 42). 
The M tuberculosis cell envelope has an additional layer beyond peptidoglycan, 
which is very rich in unusual lipids, glycolipids and polysaccarides. (icnomic 
sequencing revealed that M. tuberculosis has extensive capacity for the biosynthesis 
and degradation of lipids with around 250 enzymes involvcd in fatty acid 
metabolism. The bacillus also has intact pathways for enzyme glycolysis, the pentose 
phosphate pathway, tricarboxylic acid cycle and glycoxylate cycles. Under aerobic 
conditions, it can generate adenosine triphosphate by oxidative phosphorylation, 
possesses components of several anaerobic phosphorylative electron transport chains 
and genes that encode haemoglobin-like proteins that may protect against oxidative 
stress. 
Screening of novel M. tuberculosis genes is underway to identify candidate antigens 
for vaccine development or as targets for chemotherapy (43) 
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1.3 Clinical Aspects of Tuberculosis 
Transmission 
M. tuberculosis is transmitted by droplets of 5Jlm or less generated by individuals 
with tuberculosis by speaking or coughing. Estimates suggest 1-10 bacilli arc 
contained in each droplet and the infectious dose can range from 5-200 bacilli (6). 
Transmission of M. tuberculosis is inefficient (Fig. I). Only 25-50(% of household 
contacts of patients with active pulmonary disease become infected (44). The 
probability of infection increases with exposure (45) and is dependant on a number 
of factors including the number of organisms in the contact's sputum, the degree of 
exposure, ventilation, dilution effects and exposure to sunlight (6). 
Index Case 
M. tulwrculosis 
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Figure I: Schematic of the rates of progression to tuberculosis disease following 
M. tuherculosis exposure. Host factors encompass both acquired and genetic 
factors. 
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I X 
Primary Disease 
Once inhaled, the bacilli that escape muco-cilliary clearance in the bronchioles and 
airways lodge in the alveoli or terminal air passages of the lung and may establish a 
local focus of disease. The infection of resident alveolar macrophages is followed by 
the recruitment of uninfected monocytes, neutrophils and the complement 
component, C5a. Cytokines are also released by thc alveolar macrophagcs. Some 
bacilli are transported probably by dendritic cells to regional lymph nodes and an 
additional focus of disease develops (46). 
The disease focus is called a granuloma that is a compact collection of cells 
comprising of many layers surrounding the bacillus. The granulatomous response to 
M tuberculosis infection is perceived as protective, walling off the baciIli and 
preventing multiplication until such time the body can fully resolve the granuloma. 
Individual granulomas can exhibit different patterns of cytokinc production and 
immunopathology within a patient suggesting that each lesion is an independent 
micro-environment distinct from adjacent granulomas (47). The core contains 
macrophages that resemble epithelial cells and are called epithelioid cells. Some 
macrophages fuse to form multinuclear giant cells. Surrounding this is a zone 
containing lymphocytes including Natural Killer (NK), up and y8 T cells that are 
responsible for macrophage activation. The majority of bacilli are killed by activated 
macrophages but a proportion may survive. Replication of bacilli induces apoptosis 
and results in central necrosis in the encasing granuloma (48). In humans, the 
metabolically active macrophages consume the oxygen diffusing into the granuloma 
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so that the necrotic interior becomes acidic and anoxic producing in caseous (cheesc-
like) centre which is thought to further inhibit the mycobacterial growth. The 
necrotic region solidifies and the lesion usually resolves by calcification and 
resorption without treatment and can leave a very small, calcificd scar in thc 
pulmonary parenchyma and calcification of hilar lymph node. As a result of primary 
infection, the individual develops delayed type hypersensitivity (DTH) to tuberculin 
(2-4 weeks after injection) and can also develop life-long immunity to disease. 
Post Primary Disease 
Post-primary disease occurs m approximately 5% of cases in immunocompetent 
individuals (Fig. I). Here, the caseous core of the granuloma does not resolve but 
liquefies breaking down the granuloma. Liquefaction is, in part, mediated by 
enzymes produced by surrounding epithelioid cells. The granuloma can discharge its 
contents into bronchioles that can infect other parts of the lung. The large cavity that 
is left is C02 enriched and neutralises acid conditions and is highly permissive for 
extra-cellular M. tuberculosis growth. This stage is referred to as open or cavitatory 
tuberculosis. At this stage, patients are highly infectious because of bacilli in the 
bronchioles. The ability to combat the disease is severely limited because cell-
mediated immune responses cannot target extracellular bacilli; which, being at vcry 
high numbers also increases the incidence of mutations within the flora and may lead 
to the development of antibiotic resistant mutants. M. tuberculosis can also undergo 
miliary dissemination, meaning spread through the bloodstream (usually gaining 
access via the lymphatics) and can seed in any organ of the body, including other 
areas of the lungs. Miliary disease can occur during primary infection or after re-
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activation of disease. M. tuberculosis exhibits a preference for regIons of high 
oxygen tension most commonly in the meninges but also bones, liver, splcen, brain 
and kidneys. Like the lung, most sites of disease can heal by granulomatous 
encapsulation, sometimes with calcification and necrosis. 
Reactivation of quiescent primary disease and re-infection 
Half of all immunocompetant individuals, who do develop tuberculosis, do not 
present with clinical disease until years after initial infection (Fig. I). This 
phenomenon is referred to as reactivation disease and the period between primary 
infection and disease manifestation is described as latent infection. 
The development of techniques to routinely type sub-strains of M. tuberculosis like 
spoligotyping and DNA fingerprinting have shown that a significant proportion of 
cases of recurrent tuberculosis arise from exogenous re-infection rather than 
reactivation. In non-tuberculosis endemic areas, the majority of recurrence of 
tuberculosis arises from reactivation of disease (49-51 ), whereas in endemic regions, 
the proportion of recurrent tuberculosis stemming from re-infection ranges from 12-
75% (52-55). The risk of recurrent tuberculosis arising from re-infection is greater 
still in HlY -1 + individuals (56). 
1.4 Host Immune Response 
Overview 
Resistance to tuberculosis disease is multi-factorial, invoking innate and adaptive 
immune responses to both contain infection and also kill bacilli. Overlapping 
mechanisms are involved in the control of M. tuberculosis infection. The first is 
21 
incoming antigen specific T cells that secrete cytokines like IFN-y to activate locally 
infected macrophages and restrict bacterial growth. The second is the mounting of a 
OTH-like reaction in which non-infected macrophages accumulate and differentiate 
into a field of epithelioid cells, resulting in the containment of the infection within 
the granulomatous lesion and reduced dissemination (57). 
The Phagocyte 
Phagocytosis of M. tuberculosis 
Phagocytosis refers to the process in which particulate material is internalised into 
large vacuoles called phagosomes. From the phagosome, material is transported to 
the late stages of the endosomal J lysosomal pathway where the phagosomal content 
is degraded. Phagocytes are predominately macrophages, dendritic cells and 
neutrophils. Following inhalation, M tuberculosis bacilli are phagocytosed by a 
subset of alveolar macrophages (58). Phagocytosis of M tuberculosis occurs via 
mannose receptor interactions or by complement receptors binding to complement 
components fixed to mycobacteria on the host cell surface (59, 60). Phagocytosis 
also requires the accumulation of cholesterol at the site of bacterial entry (61). 
Activation of Macrophage 
Activation of a macrophage results from infection and, or cytokine effects. An 
activated macrophage has greatly augmented microcidal activity. Infection of 
macrophages with M tuberculosis activates Toll-like receptors 2 & 4 in a ('014 
independent manner (62, 63). Toll-like receptors (TLR) are expressed on the cell 
surface of mammalian cells but particularly phagocytes. Binding of microbial 
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ligands to TLRs activates the cell by facilitating translocation the transcription 
factor, NF-K~ to the nucleus. This results in the transcription of genes with direct 
anti-microbial activity including nitric oxide (NO), genes that induce apoptosis and 
tissue injury like TNF-a, and cytokines that influence the adaptive immune response, 
like IL-12 (reviewed in (64». Patients with defects in NF-K~ activation or phagocyte 
microcidal pathways present with disseminated mycobacterial diseases (65). 
Macrophages can also be activated directly by type I cytokines, including IFN-y and 
TNF-a secreted by lymphocytes. IFN-y and TNF-a work synergistically to augment 
IL-12 production in human phagocytes and increase NO production in mice (63, 66-
69). 
Dendritic Cells 
Dendritic cells (DCs) have been detected in the lymphocyte areas of the tuberculosis 
granulomas (70) and are present at high density in airway epithelia and arc 
associated with alveoli (71). Whilst DCs can phagocytose M. tuberculosis, they are 
poor antibacterial effector cells (72). Their main role may be the presentation of M. 
tuberculosis derived glycolipids and peptides to CDl- and MHC class I and II 
restricted T cells to induce an adaptive immune response following infection. Two 
papers have recently shown that the uptake of mycobacteria by DCs is mediated by 
the c-type lectin, DC- specific ICAM-3-grabbing nonintegrin (DC-SIGN) and 
identified DCs associated with M. tuberculosis derived material in the lymph nodes 
of patients with tuberculosis (46, 73). 
BCG infected DCs induce potent antigen specific T cell responses in the mediastinal 
lymph nodes and afford equivalent protection to BCG vaccination following a M. 
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tuberculosis challenge in mice (74, 75). DCs may also produce inflammatory 
chemokines that attract activated lymphocytes and NK cells to the site of infection 
(76). 
Neutrophils 
In many mouse strains exhibiting increased susceptibility to M. tuberculosis 
infection, polymorphonuclear neutrophils are recruited in high numbers in place of 
mononuclear phagocytes (77-81). Saunders and Cooper proposed that the influx of 
phagocytic neutrophils have a functional role in disease as a compensatory 
mechanism by the host to contain infection in circumstances where normal host 
immunity is compromised (82). 
Cytokines 
The IL-12 / IFN-y secretion pathway is important in human resistance to microbial 
infection 
In humans, I L-12/1FN -y signalling is important to resistance from mycobacterial 
disease caused by infections with environmental mycobacteria, M. bovis and M. 
tuberculosis (Fig. 2) (65). Casanova and colleagues observed that the level of IFN-y 
signalling (from total to partial to none) within patients correlated with clinical 
outcome. Patients with complete IFN-y receptor deficiency all developed 
disseminated disease following BCG vaccination. No mature mycobacterial 
granulomas were observed. In patients with partial deficiencies in IFN-y signalling, 
the clinical phenotype and occurrence of mycobacterial disease was less severe and 
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following BeG infection, fully differentiated tuberculoid granulomas were observed 
(65). Most of the reported cases of mycobacterial disease in patients resulting from 
deficiencies in IFN-y signalling have resulted from infections with environmental 
mycobacteria or BeG vaccination and not from M. tuberculosis infection. This 
probably results from the exposure of the patient to environmental mycobacteria or 
BeG before infection with M. tuberculosis. 
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Figure 2: The IFN-y signalling pathway is important in host resistance to mycobacteria l 
disease. Molecules shaded yellow have been found mutated in certain patients with severe 
mycobacterial infection. Asterisks (*) indicate molecules that have been deleted in mouse 
models that following M. tuberculosis challenge show decreased survival compared to 
wild-type controls .. 
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IL-12 
Bioactive IL-12 is a heterodimeric molecule, comprised of constitutively expressed 
p35 and inducible p40 subunits. In human granulomas, I L-12p40 is predominately 
produced by myeloid cells and a small percentage of CDX t T cells (47, 83). IFN-y 
deficiency is a consequence of IL-12 deficiency. The clinical phenotype of IL-12 
deficient individuals is less severe than complete IFN-y receptor deficiency that 
could be explained by IL-12 independent secretion of IFN-y (65). Both BeG disease 
and environmental mycobacterial disease protected patients with I L-12 or I L-12 
receptor deficiency against subsequent mycobacterial disease (84). This suggests that 
IL-12 is redundant for adaptive immunity to mycobacteria within most patients. 
Whilst studies in humans have shown that type I cytokines are important In 
resistance to mycobacterial disease predominately caused by infection by 
environmental mycobacteria, studies in mouse models have shown that type I 
cytokines are necessary for resistance to M. tuberculosis infection. IL-12 gene 
deletion mice cannot control bacterial growth, exhibit a significantly decreased 
survival times and a very severe phenotype following M. tuberculosis infection. 
Compared to wild-type controls, IL-12- - mice exhibited lower T cell infiltration into 
the lung following infection and produced minimal granuloma formation, even less 
than lymphocyte deficient SCID mice (85, 86). In normal mice supplemental I L-12 
enhanced the clearance of mycobacteria and prevented reactivation of tuberculosis in 
steroid treated mice (87,88). 
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IFN-y 
IFN-y is produced by activated macrophages and lymphocytes expressing al3 1'8 and 
NK associated markers (47, 83). Antigen specific an T ce lIs are considered primary 
producers of IFN-y following M tuberculosis infection with CD4+ T cells providing 
bulk of this cytokine (89, 90). 
IFN-y can activate type 2 nitric oxide synthase in macrophages. This leads to the 
production of reactive nitrogen intermediates that are toxic for intracellular 
mycobacteria, induce enzymatic production of calcitrol (from Vitamin 03), scnsitisc 
macrophage to TNF-a and facilitate acidification of mycobacterial vacuoles in both 
de novo and established infections (91). 
In mice the major role in of IFN-y is limiting mycobacterial growth but is also 
involved in limiting early granulocyte accumulation at inflammatory site (82, 92). 
TNF-a and TNF-13 
TNF-a is secreted predominately by monocytes and macrophages but also by Des, 
NK and T cells (47, 83, 93). Its main role appears to be in macrophage activation. 
Anti-TNF-a antibody treatment (used for the treatment of rheumatoid arthritis) of 
patients, induced reactivation of tuberculosis, which suggested an important role for 
this cytokine in the control of latent infection (94, 95). 
M tuberculosis challenge of TNF-a-i - mice resulted in rapid death of mice, with 
massive bacterial load in lung and widespread dissemination to other tissues 
suggesting that TNF-a has a role in controlling mycobacterial growth (77). TNF-
mice have disorganised granulomas with few epithelioid macrophages, impaired 
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macrophage activity and lymphocytes that fail to migrate to infected tissue (77, 82). 
TNF!- mice challenged with less virulent mycobacteria produced less chemokines 
than wild-type mice, including factors chemotactic for macrophages and 
lymphocytes. Together with studies of human granulomas showing an association of 
TNF-a with necrotic lesions this suggests TNF-a may also have a role in granuloma 
formation and/or maintenance (83). 
A possible role of TNF-a in the pathogenesis of tuberculosis has emerged from 
human in vitro model that showed that TNF-a supports the growth of M. 
tuberculosis in the first few days following infection of alveolar macrophages (58). 
Even so, it is clear that this cytokine plays an important role in host immunity. 
TNF-~, also called Iymphotoxin-a, is a member of the TNF family and also binds to 
the TNF-a receptor. TNF-~ is primarily secreted by CD4+ T cells, B cells and NK 
cells. Deletion of this molecule increased susceptibility to M. tuberculosis infection 
in mice although TNF-a secretion was unimpaired (96). 
Type II cytokines 
Resistance to tuberculosis is most clearly associated with the secretion of TH ) -type 
cytokines. IFN-y, IL-12 and TNF-a, but several studies have suggested that the 
susceptibility to disease may be associated with TH2-cytokines, particularly IL-4 and 
TGF-p. 
IL-4 
Rook et al (97) argued that expression of IL-4 and IL-13 and M. tuberculosis 
specific IgE production (which is IL-4 and IL-13 dependent) correlated with disease 
severity in tuberculosis (98-100). Conflicting studies describe depressed TH 1 but not 
enhanced TH2 cytokine profiles in PBMCs of patients suffering from active 
tuberculosis (10 I). Within the tuberculosis granuloma, I L-4 has been detccted but 
never in the absence of IFN-y. In those studies, the presence or absencc of IL-4 did 
not correlate with clinical outcome (47). 
From animal studies, there is little evidence of a functional role of IL-4 in control of 
bacillary load. IL-4- - mice on a C57BLl6 background exhibit no increase in bacterial 
burden or histopathology different from wild-type controls even in chronic M. 
tuberculosis infection (102, 103). Conversely, following M. tuberculosis challenge in 
IFN-y- or IL-12- -mice, no shift to TH2 cytokine production was observed (S6). 
TGF-fJ 
TGF-~ is expressed by Langerhans and epithelioid cells in TB pulmonary 
granulomas and by blood monocytes of patients with TB (104). In vitro studies 
demonstrated that TGF-~ was increased in blood monocytes following stimulation 
by mycobacterial antigens and could suppress T cell responses and deactivate 
macrophage effector functions. Antibodies that inhibit TGF-~ normalised T cell 
proliferation and enhanced IFN-y production (105). 
Studies examining the effects of the administration of TGF- ~ or inhibition of TGF-
~ bioactivity in animal models suggest that this cytokine may impair innate and 
adaptive immune responses and may increase mycobacterial growth and persistence 
(106, 107). 
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IL-IO 
In humans, IL-IO reduced the ability of DCs to present mycolic lipid antigens to 
CDI- restricted T cells in vitro (72). IL-IO induces a macrophage like phenotype in 
DCs that have superior antimicrobial activity than immature Des (72). 
IL-JO deficient mice are no more susceptible to M. tuberculosis than wild-type mice 
in acute challenge (102). In the chronic stage of infection, mice over-expressing I L-
10 showed evidence of reactivation associated with macrophage dominated Icsions 
and decreased TNF-a, IL-12p40 and antigen specific IFN-y production (lOX). 
The cellular response is mainly mediated by T cells 
B cells 
Humoral immunity affords little contribution to resistance from tuberculosis. 
Glatman-Freedman et al (109) reviewed over 100 publications examining the clinical 
impact of antibody mediated immunity in tuberculosis; many presenting conflicting 
data on the therapeutic affects of serum therapy in humans. M. luherculosis infection 
does generate specific antibody responses but overall in humans the effectiveness of 
serum treatment was limited to early localised disease and relied on long periods of 
serum therapy (109). This suggests that the role, if any of the humoral response in 
human tuberculosis is minor. 
B cells playa role in maintaining integrity of granulomas 
B cells are abundant in murine granulomas (l03). Several studies have been 
published showing M. tuberculosis challenge of B cell deficient mice, reporting no 
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difference In bacterial load between them and wild-type mIce (103, 110, 111). 
However, granulomas in B-1 - mice were disorganised and contained fewer 
lymphocytes. Mice also exhibited delayed dissemination to the spleen (103, 111). 
Reconstitution of B-1- mice with naIve B cells restored the wild-type phenotype, 
suggesting B cells playa role in integrity of granuloma (111). 
T Cells 
The increased risk of TB disease within patients with impaired T cell functions (eg 
old age, corticosteroids or AIDS) demonstrates the pivotal role of T cells to 
resistance to tuberculosis (112-115). 
a~ T cells 
CD4+ T cells 
Human Studies 
The majority of T lymphocytes in human tuberculosis granulomas express aB TCR 
with about twice the number of CD4+ to CD8 t T cells (83, 116). There is a clear 
inverse correlation with CD4+ T cell number and risk of tuberculosis in Hlyl 
individuals (117). Post-mortem analysis of co-infected patients showed that 
increasing CD4+ lymphocytopenia is associated with loss of macrophage activation 
at the site of M tuberculosis infection and loss of granuloma formation and higher 
bacterial loads (118). Similar observations have been made in SlY and M. 
tuberculosis co-infection experiments in macaques (119). 
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Murine studies 
In mice, antibody depletion experiments, adoptive transfer and gene deletion studies 
have shown that CD4+ T cells are required to control infection (120-123). The major 
effector cytokine of CD4+ T cells is IFN-y that functions to activate macrophages 
(124). Several reports have suggested that CD4+ T cells may play other important 
roles in containing M. tuberculosis in both acute and latent infection. In CD4- -mice, 
3 weeks following M. tuberculosis infection, IFN-y levels appeared similar to wild-
type mice because of compensatory secretion by CD8t T and NK cells (123, 125). 
Even so, these mice exhibited disrupted granuloma formation characterised by the 
influx of macrophages rather than blood monocytes suggesting that CD4 t T cells 
have a role in recruitment of cells to the site of infection (125). In a model of latent 
M tuberculosis infection, CD4+ T cell depletion caused reactivation of disease 
despite the overall levels of IFN-y being equivalent to that observed in non CD4 t T 
cell depleted, non-reactivated mice (126). 
Flynn et al (127), proposed that CD4+ T cells may also contribute to resistance from 
tuberculosis by providing CD40-dependant enhancement of DC presentation of M. 
tuberculosis antigenic ligands, provide co-stimulatory activity through CD4 + T cell 
priming and maintenance of CD8+ T cells or B cell help. Cells may also produce 
other cytokines such as IL-2, TNF-a, FasL, perforin and granulysin which may be 
involved induce apoptosis of infected macrophages. 
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CDS t T cells 
Human Studies 
Albert et al solved the apparent paradox of CD8+ T cell recognition of intra-vacuolar 
pathogens by demonstrating that DCs can acquire antigen from apoptotic cells and 
induce CD8+ specific cytotoxic T cells (128). Subsequent studies have also shown 
that 70kDa particles can leak out of vacuoles into the cytosol (129) and 
mycobacterial infection of macro phages results in membrane-permeable phagosomes 
(130). 
CDS+ restricted T cell lines, specific for several M. tuberculosis proteins have now 
been derived from infected patients, healthy contacts and BCG vaccinees (131-133). 
The presence of M tuberculosis CD8+ T cells does not in itself demonstrate a role 
for these cells in human disease. M. tuberculosis specific CDS+ T cell lines secrete 
IFN-yand may function like CD4+ cells by activating macrophages (134). Even so, 
the increased susceptibility of HIY+ patients to tuberculosis disease implies that 
CDS+ T cells induced following infection cannot fully compensate for significant 
decreases in the CD4+ T cell population. 
Murine studies 
A clear role CD8+ T cells has been demonstrated in mice In the control of M. 
tuberculosis. Sousa and colleagues investigated the susceptibility of a number of 
mice harbouring deletions in Class I pathways and demonstrated both classical and 
non-classical MHC I restricted T cells are involved in protection from M 
tuberculosis infection (135). The induction of specific T cells has been shown to 
protect mice from challenge with M. tuberculosis (136). CD8+ T cells have been 
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implicated in prevention of reactivation (137). Recently Turner el al showed that 
early resistance to M tuberculosis in old mice (12-24 months) is mediated by CDX I 
T cells (81). This implies that vaccination regimens that can effectively boost low-
level M. tuberculosis specific C081 T cells may be particularly effective in 
maintaining long-term protection from disease. 
Cytotoxic T cell killing 
In viral infections, C08+ T cells and NK cells, in addition to cytokine secretion are 
characterised by their cytotoxic functions, including the induction of apoptosis of 
infected cells through C095/C095 L interactions, and direct killing by production of 
granzymes, perforin, TNF and possibly granulysin. In mice, gene deletion of 
perforin, granzyme or C095 did not increase susceptibility in acute M. tuberculosis 
infection, which suggested that cytotoxic effector functions may be redundant in 
C08+ T cell mediated control of tuberculosis (135, 138, 139). 
Later studies showed that C095/C095L deficient mice gradually lose ability to 
control bacterial growth despite no impairment in the ability to generate IFN-y. 
Kaufman argued (140) that cytolytic functions are necessary in the control of 
tuberculosis. He hypothesised that in chronic infection, cells exist that either do not 
express or have greatly decreased Class II expression, and are refractory to IFN-y. 
These cells may activate cytotoxic mechanisms following presentation of peptidcs in 
a class I restricted manner. 
In vitro studies of human cells have demonstrated direct T cell mediated kil1ing of 
M tuberculosis by granulysin. Granulysin is expressed in C04 t and CD8+ T cells, 
although at a higher level in C08+ T cells. Granulysin is also produced by yo, C01-
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restricted T cells (141, 142). Granulysin killed M. tuherculosis cxtracellularly in a 
dose dependent manner by inducing osmotic lysis of the bacilli (143, 144). Another 
study showed that the production of granulysin by CD8' T cells could also kill 
intracellular mycobacteria in a perforin dependent manner, although the levels 
needed to induce specific lysis were at non-physiological concentrations ( 143). 
CD 1- restricted Natural Killer T ce lis 
Natural Killer T (NKT) cells recognise COl-glycolipid complexes presented by 
APCs including dendritic cells. NKT cells can produce type I cytokines including 
IFN-y and exhibit cytotoxic effector functions. COl-restricted T cell proliferation 
and lytic responses in guinea pigs following stimulation with crude M. tuherculosis 
extracts have been demonstrated (145). Even so, a M. tuberculosis specific CD I 
ligand has not been reported in humans or rodent models. 
COl d-I - mice do not differ from wild-type mice in survival following M. tuherculosis 
infection (146). Similarly, NKT cell deficient mice successfully develop 
granulomatous lesions in lungs following M tuberculosis challenge (147). The only 
COl restricted ligand so far identified that can activate NKT cells IS a-
galactosylceramide (a-gal-cer) which is derived from the marine sponge (148). 
Specific activation of NKT cells by a-gal-cer significantly protected susceptible 
mice from tuberculosis, increasing survival and decreasing bacterial burden and 
tissue injury (146). These studies indicate that specific activation of N KT cclls may 
play a protective role against M. tuberculosis and be a good target for vaccine 
development. 
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yo T cells 
yo T cells recognise non-peptide organophosphate alkylamine antigens secreted by 
bacteria in a TCR-dependent and MHC- and CD 1- unrestricted manner. In humans, 
y'6 cells constitute 1-5% of CD3+ T cells in lymphoid organs but are the dominant T 
cell population within epithelial tissues, including skin, gut and airways (149). 
A recent report in macaques suggested that y'6 T cells might play a role in the 
protective adaptive immune response to M tuberculosis infection (150). The authors 
demonstrated that BCG-vaccinated macaques produced a yo T cell recall response 
following a second BCG vaccination or M. tuberculosis infection that correlated with 
clearance of BCG bacilli and resistance to infection. Similarly in humans, Hoft ef at 
(151) showed that following BCG vaccination, y'6 T cells constitute the dominant T 
cell population expanding following whole BCG stimulation. 
The mechanism of action of y'6 T cells is unknown. No M. tuberculosis derived 
presentation molecules are known. Secretion of IFN-y and TNF-a by y'6 T cells can 
increase monocyte-mediated killing within two hours after exposure to live bacterial 
products (152). y'6 T cells can also induce direct cell-to-cell cytotoxicity by the 
production of granulysin and perforin. y'6 T cells are more efficient at producing 
IFN-y cytokine on per cell basis than a~ T cells (152), but y'6 T cell depletion from 
PBMCs did not significantly decrease the total IFN-y secretion indicating CD4 t T, 
CDS+ T and NK cells are the major sources of IFN -y (151). 
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Saunders et al (153) argues that in mice yo T cells have a role in recruitment of 
macrophages to site of mycobacterial infection where they arc then activated by aB 
T cells. 
In summary, whilst studies have shown that yo T cells respond to mycobacterial 
infection and can secrete IFN-y, no functional role for this T cell subset has been 
demonstrated in host resistance to tuberculosis. 
Natural Killer (NK) Cells 
So far, there is no clear role of NK cells in disease susceptibility. Nirmala el al 
observed no difference in the relative frequencies of NK cells in normal individuals, 
patients with pulmonary TB, HIY+/TB+ patients and healthy contacts (154). 
Mycobacterial disease in patients that have complete deficiency in IFN-y is more 
severe than in patients that lack autologous T cells (65). This suggests that other cells 
capable of IFN-y signalling, like NK cells, may contribute to resistance to 
mycobacterial infections in immunosuppressed. 
M tuberculosis immune evasion mechanisms 
Inhibition of endosomal / lysosomal fusion 
M. tuberculosis bacilli are able to survive and even multiply within alveolar 
macrophages (155). M. tuberculosis actively arrests phago-Iysosome fusion by 
retaining TACO (tryptophane aspartate-containing coat protein), release of which 
correlates with normal phagosome maturation and acidification (156-158). M. 
tuberculosis therefore actively restricts microcidal activity of macrophages 
particularly lysosomal hydrolase activity and avoids NO mediated killing. This 
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mechanism also sequesters MHC II molecules that are contained in the endosome 
and blocks antigen presentation in chronically infected macrophages (159), 
Production of the 19kDa protein expressed by M. tuberculosis has been reported to 
reduce MHC II mRNA accumulation and surface expression on macrophages, but it 
is unclear whether this benefits the host or pathogen (160). 
Down-regulation of cell surface receptors 
In vitro infection of human PBMC derived APC with live M. tuberculosis was 
shown to downregulate another cell surface receptor, CD I, which subsequently 
decreased JFN-y release by a COl b restricted T cell line (161). 
Countering reactive oxygen intermediates 
The host cell can produce highly reactive toxic molecules particularly oxygen and 
nitrogen radicals, which are toxic for the microbe (162). Glycolipids associated with 
the cell wall of M. tuberculosis cell wall like lipoarabinmannan and phenolic 
glycolipid-I, are potent oxygen radical scavengers that may counter the 
antimicrobial mechanisms of reactive oxygen intermediates (ROJ) (163, 164). 
Effects on cytokines 
Cytokine inhibition 
M. tuberculosis infection, as has been observed in other bacterial infections, actively 
inhibits IL-12 secretion in human blood derived monocytes (165) (166, 167). There 
is some evidence in in vitro systems that the mycobacterial 19kDa lipoprotein and 
30kDa proteins inhibit type 1 cytokine production by macrophages, possibly 
decreasing T cell activation (168, 169). 
39 
Mycobacterial persistence 
During latent infection, M. tuberculosis persists within granulatomous lesions in a 
non-replicating or low-replicating state capable of surviving the bacteriocidal actions 
of chemotherapy (170, 171). 
Persistent mycobacteria are not well characterised although the trigger is thought be 
oxygen depletion in the granuloma causing the bacilli to shut down many metabolic 
pathways until more favourable conditions arise (171). Mycobacterial infection of 
macrophages also results in membrane-permeable phagosomes that may enable it to 
gain access to nutrients in chronic infection (130). 
A recent study has shown that some M. tuberculosis genes may secure survival of 
the bacilli by responding specifically to host immunity. Isocitrate lyase (ICl) is a 
protein involved in fatty acid metabolism that is required for survival and persistence 
of M. tuberculosis in animal models (172). The expression of ICl is increased in 
response to activation of host macrophages and the secretion of IFN-y but is not 
essential to survival of the pathogen in the absence of IFN-y signalling (172). 
1.5 The BeG Vaccine 
Growth and Strains 
Numerous sub-strains of BeG have been derived from the original Pasteur strain and 
been used in vaccination programmes over the past 70 years. The BCG sub-strains 
differ both genetically and in their vaccine preparations (173). Several regions of the 
M bovis genome are missing from BeG sub-strains but only one, the RDI, is 
missing from every BeG sub-strain so far analysed. Conversely it is present in every 
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analysed M. tuberculosis strain (174). Loss of the RDI region deleted 7 genes and 
truncated two others. None of the genes have any known function but the region 
itself is necessary for virulence of M. tuberculosis in animal models (175). 
There is no clear evidence as to whether the strain evolution of BeG has impacted 
on vaccine efficacy against tuberculosis in man. The only trial to directly compare 
two BCG sub-strains reported no protective efficacy with either sub-strain (176). 
Some reports have suggested BCG sub-strains have attenuated with time because of 
decreased reactogenicity and shortened survival of bacilli at the site of vaccination 
(reviewed in (173». No information is available on whether this has translated to 
decreased protection in man. 
How does BeG protect? 
Protection is reliant on replication of the bacillus 
BCG must be live to mediate protection against M. tuberculosis (177). Replication 
appears necessary to produce sufficient antigen to induce an immune response by the 
host, particularly to secreted antigens which are highly immunogenic proteins (17R-
181 ). 
BCG induces a T cell response that is CD4+ T cen dominated 
BCG vaccination induces a strong adaptive type 1 immune response that is 
predominately CD4+ T cell dependent. CDS+ dependent T cell responses have also 
been detected although at much lower frequencies (134). Stimulation of BeG 
specific T cells in vitro induced strong IFN-y secretion (134). Studies show that in 
the memory immune (BCG vaccinated or M. tuberculosis challenged then antibiotic 
treated) animals, in response to an M. tuberculosis challenge, IFN-y secreting T cells 
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migrated to the lung, in higher numbers and much faster than in nai"ve animals ( I X2, 
183). Recruitment of cells to the lung correlated with decreased bacterial burden and 
reduced immunopathology (182). 
BCG protects from tuberculosis disease not infection 
Autopsy studies identified tuberculosis foci in patients vaccinated in their youth and 
who died from causes other than tuberculosis, suggesting that that BeG vaccination 
does not prevent establishment of M tuberculosis infection (184). Studies in animal 
models show that BCG vaccination does not inhibit M. tuberculosis growth in the 
first 10 days following infection but affords significant protection in terms of 
survival following challenge and lower bacterial burdens in organs during chronic 
stages of infection (185). 
BCG protection from other mycobacterial diseases 
The mechanism of BCG protection against M. tuberculosis IS dependent on 
homology between proteins inducing cross-reactive immune responses. BeG 
protects against other mycobacterial diseases, such as leprosy. There is also evidence 
that BCG provides some protection against M. ulcerans infection and glandular 
disease attributable to various other environmental mycobacteria in particular M. 
avium-intracellulare (186-188). BCG vaccination affords 50% protection against 
leprosy, including in countries where BCG is not protective against M. tuberculosis 
(189-191). Why BCG protects people from leprosy but not tuberculosis remains 
unknown. 
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Theories for BeG variable efficacy 
Environmental mycobacteria 
Wilson et af observed that geographic latitude has accounted for greater than 40(% of 
between-study variance in BeG mediated protection, with protection decreasing 
closer to the equator (t 2, 192,193). A hypothesis has emerged that higher levels of 
infection by environmental mycobacteria may induce cross-reactive T cell responses 
to BeG, which ameliorate the protective effects of BeG (194, 195). In humans and 
animal models, certain species of environmental mycobacteria can provide levels of 
protective efficacy against tuberculosis similar to that provided by BeG ( 196-1(8). 
In mice, prior immunisation with M. avium inhibited subsequent BeG replication 
(199). 
The immunological basis for this hypothesis was investigated in comparing the IFN-
"( responses to PPO in UK (where BeG protects) and in Malawi (where BeG is not 
protective). Prior to BCG vaccination, PPO-specific IFN-"( secretion and DTH 
distribution to tuberculin showed that the Malawian population had a greater prior 
sensitisation to mycobacterial antigens, compared to the UK individuals. Thc 
average change in IFN-"( response to PPO (measured as the post-vaccination / prc-
vaccination ratio) was significantly higher in the UK than Malawian cohort and 
correlated to the stronger protective effect of BeG in the UK than Malawi (200). 
It is not only the amount of exposure to environmental mycobacteria but also the 
types of mycobacteria that may inhibit BCG- mediated protection. M. kansaii in 
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gumea pigs offers greater protection than M. .!ortuitum against M. tuhercu/osis 
challenge and induces much greater TST reactivity to tuberculin (198, 199). 
This implies that a successful tuberculosis vaccine must be able to induce higher 
levels of IFN-y secreting T cells in individuals previously exposed to mycobacteria 
including prior BeG vaccination. Therefore, unlike BeG, future vaccines should not 
be growth inhibited by cross-reactive immune responses to environmental 
mycobacteria. 
Protection wanes with time 
Hart et al estimated the protective efficacy of BeG to last 10-15 years in the British 
population (196). No studies have been performed in humans correlating loss of 
BeG specific T cell responses and protection. Booster immunisations are commonly 
employed in vaccination regimens to expand the existing memory antibody and T 
cell pools. In one study, multiple BeG vaccinations did not increase protection 
against pulmonary tuberculosis, however in this region a single BeG vaccination 
also failed to protect (189). In contrast, repeated BeG immunisation did significantly 
increase protection over a single BeG vaccination against leprosy ( 191 ). 
1.6 Strategies in Vaccines Development 
Overview 
Chemotherapy against tuberculosis is highly effective, but despite a global effort to 
treat tuberculosis disease, the number of new cases of disease reported in the 
developing world continues to rise. As such, a prophylactic vaccine is required to 
interrupt the cycle of M. tuberculosis transmission. Any such vaccine regimen must 
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protect where BeG has failed, namely 1) protection in the developing world, 2) 
protection from pulmonary disease and 3) protection beyond childhood and against 
adult disease. These are difficult goals but solid sterile immunity from M. 
tuberculosis infection and disease may not be necessary. Vaccines that can increase 
the duration of protection and decreased tuberculosis disease by 50(% are predicted to 
afford significant savings in terms of life and cost (201,202). 
Whilst no immune correlate of protection has been identified against tuberculosis the 
induction of type-1 cytokines and antigen specific T cells that can activate 
macrophage microbial killing are strongly implicated in protection from diseasc. 
Research has focused on usmg vaccme vcctors that effectively adjuvant the 
induction of type-l cytokines and the production of antigen specific T cells. Several 
antigens in M. tuberculosis such as the antigen 85 complex have been targeted 
because they are highly expressed and elicit strong T cell responses in humans and 
animal models. Finally, induction of T cells responses in the respiratory 
compartment is increasingly being investigated with a view to increasing protection 
from pulmonary disease. 
Animal Models of Tuberculosis 
Development of a vaccine requires appropriate animal models of disease which has 
proved difficult because animals differ in their susceptibility to M. tuherculosis, in 
the disease pathology produced by infection and in the availability of reagents to 
study the immunological aspects of disease. The current approach to developing a 
vaccine against tuberculosis is to test vaccines in more than one mouse strain and in 
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other animal models, always including a BCG vaccinated group as a benchmark of 
protective efficacy. 
Mouse Models 
Over the past 5 years, most TB research groups have moved from systemic to 
aerosol challenge models of M tuberculosis. Following low dose aerosol delivery 
(typically 50-500 CFU deposited in the lung), bacilli exhibit clear lag, log and 
stationary phases of growth (203). Aerosol challenge of M. tu/Jl!rculosis is more 
virulent, induces more rapid lung pathology and significantly earlier death in mice 
than an intravenous challenge (204). 
Protective efficacy of tuberculosis vaccines is determined either by histopathology, 
comparisons of survival plots or the bacillary load within organs at different time-
points after challenge. BALB/c and C57BLl6 mice are most commonly used in 
vaccine studies. These strains exhibit similar kinetics of M. tuberculosis growth and 
very similar survival plots (surviving 225-400 and 175-325 days respectively) (205). 
Most vaccinology studies have focused on acute M tuberculosis infection, which 
best parallels progressive post-primary disease in man. Increasingly models of latent 
infection and reactivation induced by immunosuppression have been developed but 
are costly and place great demands on Category III facilities. 
Non-human Primates 
The macaque is a highly relevant animal model for tuberculosis vaccine studies. 
Macaques are naturally susceptible to tuberculosis (206) and, like humans, transmit 
the bacillus via aerosolised droplets, produced by coughing. Lung challenge of 
macaques produces pathology similar to that observed in tuberculosis disease in 
46 
humans including lesions in bronchial and hilar lymph nodes, caseating lesions in the 
lung with eventual calcification and disseminated disease (207, 20X). 
Two studies have shown that following a high dose M. tuberculosis challenge, rhesus 
macaques are much more susceptible to disease than cynomolgus monkeys, and 
BCG vaccination produces significantly less protection from disease in rhesus than 
cynomolgi (207, 208). 
A difficulty with the use of the cynomolgus macaque for vaCCine studies in 
tuberculosis is that BCG vaccination, despite being highly protective, produces very 
low levels of specific IFN-y following PPD stimulation of PBMCs (207). This 
contrasts to studies in humans and rhesus macaques where following BeG 
vaccination PPD and Antigen 85 (Ag85A) specific IFN-y secretion is routinely 
detectable. 
The benefit of using non-human primates as opposed to rodent models is that their 
physiology is closer to man and their larger size allows tracking of immune 
responses over time in the blood compartment. The availability of immune assays 
and reagents for the study of monkeys is increasing. Monkeys are also more relevant 
for safety and toxicity studies of vaccines. 
Guinea Pig 
The guinea pig is more susceptible to M. tuberculosis infection than mice. Guinea 
pigs develop a granulomatous pathology similar to that observed in human disease 
(203). Protection is usually measured by vaccine-enhanced survival, which has the 
benefit of allowing study of the effects of vaccines on chronic pathology. 
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V accine Vectors 
DNA 
Intramuscular or intradermal vaccination with DNA plasm ids can induce both 
specific T cell and IgG2a antibody responses against the target antigen in mice and 
non-human primates (209). Huygen et af showed that DNA can express 
mycobacterial genes, and that vaccination with these plasmids could induce both 
CD4+ and CD8+ T cells specific for the recombinant antigen (210). Induction of 
immune responses in animals typically requires multiple vaccinations. 
Clinical trials with DNA have now been performed in both the developed and 
developing world. Whilst plasmid DNA vaccination appears to be well tolerated in 
man, the strong immunogenicity and protective efficacy produced in mice and 
macaque models has not translated to humans (211). Methods are currently being 
developed to try to improve the efficiency of delivery of DNA to humans and 
increase its immunogenicity by the inclusion of genes encoding cytokines. 
DNA still holds great potential as a vaccine vector, particularly in thc developing 
world. DNA is lyophi11isable and heat stable and enables elimination of the cold 
chain (209). 
Poxviruses are potent inducers of T cells 
Poxviruses have a large, linear double stranded DNA genome and are characterised 
by a complex enveloped brick-shaped virion. They replicate in the cytoplasm of cells 
and do not integrate to host DNA or undergo a latent intracellular stage (212). They 
rely on expression of viral proteins to evade host immune responses. 
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Modified Vaccina Virus - Ankara Strain 
Modified Vaccinia Virus Ankara (MV A) is an attenuated poxvirus derived following 
over 500 passages in chick embryo fibroblast cells (213, 214). Generation of MV A 
resulted in six major deletions and the loss 30 kilobases representing 151% of the 
genome (215, 216), including genes that encode proteins responsible for immune 
evasion such as soluble receptors for IFN-y, IFN aJ~, TNF and chemokines (217). 
MV A can express foreign genes under early-late promoters in human cell lines but 
proteolytic processing of late viral polypeptides is blocked resulting in a t~lilllre to 
form mature virions (218). 
Safety 
MV A demonstrates good safety in humans and immunocompromised animal 
models. Non-recombinant MV A has been administered parenterally to 120000 
people. Vaccination produced no side effects, despite deliberate vaccination of old, 
young and eczematous patients (219-221). MV A was avirulent in neonatal and 
irradiated mice, irradiated rabbits and irradiated macaques (220. 222. 223). MV A 
induces type I IFN that restricts its virulence (224). 
/mmunogenicity 
Recombinant MV A can induce high frequencies of IFN-y secreting CDS I and CD4 I 
T cells against the target antigen in rodent and macaque models (225). MV A has 
been typically given intradermally and appears most effective as a boosting 
vaccination following a protein particle, DNA or other viral vector priming 
immunisation. These strategies are commonly referred to as heterologous prime-
boost regimens. 
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Recombinant MVA is a poor inducer of antibodies. At high vaccine doses specific 
antibodies have been detected in mice that are predominately IgG2a sub-type (222). 
Fowlpox 
Fowlpox (FP) is an avipoxvirus that can also express foreign proteins in mammalian 
cells (226). Fowlpox is unable to replicate in mammalian cells. Conservation of 
genetic organisation exists between FP and vaccinia virus. Both viruses share 
extensive amino acid homologies despite divergent nucleotide sequence divergence. 
Promoter sequences function equivalently. 
Fowlpox strains can strongly induce both CD4 t and CDX I T cell responses in mice 
and macaque models (227). DNA / FP protected against SlY infection in a macaque 
model (228). Recombinant FP is now in Phase [ trials in humans although on Iy 
cancer trial results have been published (229). Like MV A, recombinant FP 
vaccination is a poor inducer of antibodies in mice and macaque models (230). 
Recombinant protein vaccine 
The efficacy of recombinant protein vaccines is dependent on the choice of adjuvant. 
Promising vaccine candidates are being developed that induce type I immune 
responses. Subunit protein vaccines also strongly induce specific antibodies. The 
main advantage of protein vaccines compared to live vectors is greater safety in 
immunocompromised hosts. 
Live Bacterial Vaccines 
Live bacterial vaccines are good candidates for tuberculosis vaccines as they are 
cheap to manufacture. These include recombinant BeG vaccines expressing 
50 
immunodominant antigens and or cytokines (231), attenuated strains of At. 
tuberculosis (232, 233), non-pathogenic mycobacteria including M. v(/('('{/e and M. 
microti, and non-mycobacterial vectors sueh as Salmonella and Shigella expressing 
immunodominant mycobacterial antigens. 
Antigen Targets 
M tuberculosis secreted proteins 
Over 200 proteins are released into the broth during the eulture of M. tuberculosis 
(234). This group of proteins is collectively called eulture filtrate proteins (CFPs). 
eFPs are characterised by their immunodominance. Immunisation with eFrs 
induces strong T cell responses and protection following M. tuherculosis challenge 
in animal models. Several eFPs have been now been purified for use in vaccines 
and/or diagnostic assays. 
The 85 complex 
Mueh attention has focused on the highly immunogenic Antigen 85 complex. This is 
a family of proteins comprising antigens 85A, 858 and S5e secreted by M. 
tuberculosis, 8eG and many other species of mycobacteria. All three proteins arc 
mycolyl transferases and are essential in cell wall synthesis (235). 858 and S5A that 
share 80% homology at the aa level, together account for over 40'Yo of extracellular 
protein in broth culture (236). All three proteins are expressed in human 
macrophages (237) and are detectable both in the bacterial cell wall and in the 
phagolysosomal space (238) 
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Studies in this laboratory had previously focused on DNA vaccination followed by 
boosting with a modified vaccinia virus Ankara (MVA) expressing antigen X5A 
(Ag85A). DNA -MVA prime-boost strategies produce high levels of specific T cells 
against malarial and HIV antigens and can protect against the relevant challenge in 
animal models. In mice, DNA85A - MV A85A vaccination, whilst inducing high 
frequencies of Ag85A specific IFN-y secreting T cells, did not achieve greater 
protection than BeG following M tuberculosis challenge ( 136). HOf\vitz el al have 
recently developed a recombinant vaccine, which elicited greater protection than low 
dose BeG in a guinea pig model (239, 240). This vaccine is a recombinant BeG that 
over-expresses antigen 85B, suggesting that the inclusion of BeG may facilitate the 
design of future and more efficacious vaccines against tuberculosis. 
ESA T-6 and CFP-/ 0 
The genes encoding ESA T -6 and CFP-I 0 are found in the RD I region that is deleted 
from all BeG strains. Vaccination of mice and guinea pigs with ESAT-6 and CFP-IO 
can induce strong antigen specific T cell responses and protection equivalent to 
BeG. 
These antigens also hold strong diagnostic value and studies showing the IFN-y 
response to these antigens can show higher specificity and sensitivity than the 
prevailing TST in non-tuberculosis endemic regions (241,242). 
M tuberculosis Cellular Proteins 
Vaccination with M. tuberculosis heat shock proteins (HSPs) were protective in 
latent models of infection in mice but concerns have been raised over the safety of 
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microbial HSP vaccines because of potential immune cross-reactivity with human 
HSPs (88). 
Proteins expressed during latent infection 
One promising vaccine candidate is 16kDa also called a-crystallin, which is a 
secreted chaperone protein induced during latent infection. T cell responses to 16kDa 
have been detected in humans and mice models (243, 244). The development of 
latent models of tuberculosis will allow testing of genes expressed during latent 
infection. 
Inducing T cell responses in the lung and regionallytllph nodes 
Inducing T cell responses in the lung 
The lung, like the gastrointestinal and genital tissue, is part of the mucosal immune 
system. Mucosal membranes are in direct contact with the environment and are the 
site of entry for the majority of infectious pathogens. Antigens cross the mucosa via 
dendritic cells (DCs) resident in the epithelium or through M cells that overlay 
mucosal associated lymphoid tissue (MALT), rich in Des and lymphocytes. Des can 
migrate from the airways to the T cell zones of the thoracic lymph nodes but have 
also been shown to migrate directly to the spleen (245, 246). Once in the lymph 
nodes, DCs present antigen to circulating naIve T cells (247, 248). 
Memory T cell homing 
Once induced, antigen specific CD4+ and CD8' T cells can migrate into lymph nodes 
but preferentially circulate through or reside in non-lymphoid tissues (248, 249). The 
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extravasation of memory T cells, from the circulation into organs is controllcd by 
adhesion molecules and chemoattractant signals. These molecules are expressed by 
high endothelial venules and postcapillary venular endothelium in an organ-specific 
manner. 
In the gut, lymphocyte trafficking is controlled by the addressin molecule MadCam-
I that is specifically expressed on the gut endothelium (250). T cells expressing 
a4~7 integrins bind MadCam-1 and extravasate into the gut parenchyma (251). 
To date, no molecule specific to the lung endothelium has been identified but T eells 
recovered from the lung and broncheoalveolar-Iavage express a distinctive pattern of 
adhesion and chemokine homing receptors that distinguish them from T cells found 
in other organs, particularly skin and gut (252). Comparisons of particular M. 
tuberculosis-susceptible and -resistant mice strains showed that whilst the splenic 
immune response was similar between the strains, protection in the resistant mouse 
strain correlated with the influx oflFN-ysecreting a~ T cells to the lung (253). 
Lung vaccination studies also provide evidence of a separate lung T cell homing 
pathway. Rosenthal and Gallichan demonstrated that the route of vaccination was 
important in inducing T cell responses in the mucosal compartment in murine 
models (254). They and others have demonstrated that intranasal vaccination but not 
intraperitoneal or subcutaneous vaccination induced long-lived antigen specific T 
cells in the lung and lung lymphoid system (254, 255). In both macaque and guinea 
pigs, aerosol vaccination of BCG has been reported to offer greater protection than 
intradermally delivered BCG (256, 257). However, these experiments did not control 
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for the effect of persistent BeG in the lung inducing innate immune responses that 
may also have contributed to the protection observed. 
ss 
1.7 Thesis Aims 
The aims of this thesis were to to: 
" develop assays to examine the immunity in the lung, 
'I< develop methods of delivery of vaccines into the lung, 
" develop mouse and macaque models for T cell vaccinology and tuberculosis 
disease, and 
10 to use the above models to produce novel vaccme regImens against 
tuberculosis usmg recombinant subunits vaccines expressing the M. 
tuberculosis immundominant antigen 85A 
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2 Development of an aerosol 
challenge model of M. tuberculosis 
2.1 Results 
Description of apparatus and challenge 
An initial goal of this study was to develop an aerosol challenge model of M. 
tuberculosis in mice, which was comparable to published models in terms of number 
of bacilli deposited into lungs, infection rate (100%) and kinetics of M. tuherculosis 
growth in lungs and spleens. A summary of published studies of murine aerosol 
challenge models is shown in Table 2.1. For these studies, an adapted, Henderson 
Apparatus was used to generate the aerosol of M. tuberculosis (258). In all 
challenges performed, mice were exposed to the aerosol for 20 minutes. During this 
time, mice were individually restrained to permit nose-only exposure that would 
minimise delivery of bacilli outside the respiratory compartment (259). Mice were 
not restrained for greater than 45 minutes. Up to 35 mice could fit in the nebulizer 
chamber. In challenges using greater than 35 mice, mice were randomly a'isigned to 
runs in order to control for any variation in intra-run M. tuberculosis deposition. M. 
tuberculosis stocks were cultured before and after challenge. Cultures typically lost 
0.5 log viability over the period of the challenge (1-2 hours) (data not shown). 
Subsequent to the challenge and release from restraints, mice wcre active and 
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immediately groomed and fed, which are indicators that they coped with the stress of 
the procedure (260). 
" 
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Table 2.1: Comparison of published data examining the growth rates of M tuberculosis in mice organs following low dose aerosol delivery 
Study Reference! 2 3 4 5 6 
Mouse Strain C57BL!6 BALB/c C57BL!6 C57BL!6 C57BL!6 C57BL!6 
Age at time of challenge 6-8 weeks 6-8 weeks 
Apparatus Tri Instuments Middlebrook Middlebrook Glas-Col, 
Airborne Infection Airborne Infection 
Apparatus Apparatus 
M tuberculosis strain H37Rv H37Rv H37Rv Erdman Erdman Erdman 
Bacilli deposited in lung 200 100 80 100 100 50-100 
Bacilli counts Day Lung Spleen Lung Spleen Lung Spleen Lung Spleen Lung Spleen Lung Spleen 
(logIOCFU/organ) 
1_22 : 2.0 0.0 1.0 <1.0 <2.0 <2.0 0 <2.0 
10 I 4.5 0.0 
14/15 0 3.0 
20 6.0 4.0 6.1 3.5 3.75 4.5 
30 7.5 4.5 4.5 
50-60 5.9 4.5 6.2 4.5 4.3 5.0 
80-90 4.5 4.25 5.0 
100 6.0 5.5 6.2 3.5 
150-160 5.8 5.0 4.8 
11= (89); 2 = (261); 3= (74); 4= (138); 5= (57); 6= (262). 
2 days following aerosol challenge on which bacillary load in organs enumerated 
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Growth and induced histopathology following low dose aerosol 
challenge with H3 7R v M tuberculosis 
Growth of M tuberculosis IS a function of the number of bacilli 
deposited in the lungs 
The primary assay to determine infection levels in mice exposed to M. tuherculosis 
is the enumeration of the bacterial load in lungs and spleen at different time-points 
after challenge. The numbers of bacilli in the lung is a measure of the extent of lung 
disease and is proportional to length of survival in inbred mice strains (263). The 
bacterial burden in the spleen correlates with the extent of systemic dissemination of 
mycobacteria from the lungs (86). 
Mice were challenged with increasing concentrations of M. tuherculosis (I O~-I 07 
CFU/ml M. tuberculosis) to determine the optimal dose for future challenges (Fig. 
3). Bacillary load was measured at 24 hours and 8 weeks post challenge (Fig. 
3A&B). The results demonstrate that the mean CFU in both the lungs and spleens, 8 
weeks post challenge was proportional to the concentration of the original inoculum 
in mice. These data concur with observations made in previous studies (204). 
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Figure 3: Reproducible aerosol delivery of M. tuberculosis to mice lungs is dose 
dependent. BALB/c mice were challenged by aerosol for twenty minutes by 
nebulising 10\ )06 and 107 CFU/ml of M. tuberculosis. Lungs were harvested at 24 
hours post challenge (A) and lungs. spleen and liver at 8 weeks post chalkngc (Bl. 
Total CFU in the lung are shown for individual mice in (A). In (8). the loglO(mean 
CFU) +/- SEM is shown for each organ (n=lO) 
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The challenge dose of 105 CFU/ml was too variable, producing an infection of only I 
of 3 mice at 8 weeks post challenge. Both the 106 and 107 CFU challenge doses 
produced 100% infection of mice. The bacterial burdens in the lungs and sp leens at X 
weeks post challenge in the 106 CFU/ml group showed low intra-group variability 
and mean loads that were comparable to published studies described in Table 2.1. 
The titre of 107 CFU/ml was more virulent and produced bacterial burdens in the 
organs 2-3 logs higher than similar time-points in published studies (Table 2.1). 
Challenge titres around 106 CFU/ml best agreed with published studies and were 
used for further experiments to examine the kinetics of M. tuherculosi.\' growth in 
this model. 
Kinetics of M. tuherculosis growth in BALB/c mice lungs and spleen 
Lung 
Mice were challenged with 106 CFU/ml of M. tuberculosis by aerosol. Forty-eight 
hours after infection an average of 100 CFU of M. tuherculosis was recovered from 
the lungs of an individual mouse (n=5) (Fig. 4). M. tuberculosis bacilli entered 
logarithmic growth between day 8 and 15 following challenge. Beyond day IS, 
growth slowed and was stationary from day 26 to day 60. 
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Figure 4: M. tuherculosis delivered as an aerosol undergoes lag. log and stationary 
phases of growth in mice lungs. BALB/c mice were challenged for 20 minutes with 
nebulised M. tuherculosis (2 x 106 CFU Iml). The number of M. tuherculosis colonies in 
lungs and spleens were enumerated at different time-points after challcnge and arc 
expressed as loglO(mean CFU) +1- SEM (n=5) 
Spleen 
Colonies were first detected in the spleen at day 15, and grew logarithmically over 
the next 10 days (Fig. 4). Growth stabilised between day 26 and 33 but small though 
significant increases in bacterial burden were observed at day 46 (P < 0.0 I) and 60 
(P < 0.01). Similar observations (gradual increase in splenic the mean [CFU]) have 
been made in C57BLl6 mice (reviewed in Table 2.1, studies I & 6). 
Histopathology following M tuberculosis infection in BALB/c mice 
Gross Pathology 
Lungs were visibly normal at day IS. By day 26, all mice had numerous abscesses 
(2-4 mm long) on their lungs. At this time-point and thereafter, mediastinal lymph 
nodes (MLN) (that drain the lung) and spleens were enlargcd in all micc. 
Histopathology 
Granulomata (tubercular lesions with central epithelioid cells and peripheral 
lymphocytes) with ZN positive organisms were first detected in the MLN at day 15 
(Table 2.2). At subsequent time points, all mice analysed contained ZN positive 
granulomata in their MLN. 
Lungs remained histologically normal until 8 days following infection (Table 2.2). 
By day 15, inflammatory cells were observed in the lung parenchyma and AFB 
bacilli detected. By day 26, mice lungs contained peribronchial/perivascular 
lymphocytic infiltrates and pyogranulomata (granulomata that also contain some 
polymorphs). Similar pathology was observed in all mice at later time points. 
Disease pathology in the spleens was first detected 26 days post challenge, when 
pyogranulomata but no ZN positive organisms were detected in one animal {Table 
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2.2). At day 33, one of two mice had pyogranulomata with ZN positive organisms. 
At days 49 and 60, all mice spleens contained pyogranulomata with ZN positive 
organisms. 
"'&.',,~-,,:-
Table 2.2: Histopathology report following aerosol M tuberculosis challenge ofBALB/c mice1.2 
Days post Lung 
challenge 
ZN 
+ve 
Day I 
Day 8 
Day 15 
Day 26 
Day 33 
Day 49 
Day 60 
bronchioles normal range - no inflammatory 
cells seen. 
bronchioles normal range. 
bronchioles normal range. very occasional 
herophiI and aveolar macrophages seen. 
Focal, mild acute inflammation with ZN+ve y4 
bacteria Focal, subacute pneumnitis with ZN+ve 
bacteria. foci of necrosis and lymphocyte and 
heterolphil infiltrates with ZN+ve bacilli 
perivascular cuffing with lymphocytes. Y 
Pygraulomatous pneumomtIs with ZN+ve 
bacilli peribronchial/perivascular cuffing with 
lyphocytes. Pyogranulomatous pneumonitis 
with ZN+ve mycobacteria. 
Peribronchiallperivascular cuffing with Y 
lymphocytes. Pyogranulomatous pneumonitis 
with ZN+ve mycobacteria. 
PeribronchiaVperivascular cuffing with Y 
lymphocytes. Pyogranulomatous pneumonitis 
with ZN+ve mycobacteria. 
Mediastinal lymph node 
NiAJ 
N/A 
NiA 
mycobacterial granulomatous 
lymphadenitis 
mycobacterial granulomatous 
lymphadenitis 
mycobacterial granulomatous 
lymphadenitis 
mycobacterial granulomatous 
lymphadenitis 
ZN 
+ve 
Y 
Y 
Y 
Y 
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Spleen ZN 
+ve 
nonnal range. 
nonnal range. 
nonnal range. 
nonnal range one sample 
pyogranulomatous splenitis. 
mild 
normal range, possible increased platelet Y 
production no ZN +ve bacteria. mild e 12) 
mycobacterial pyograulomatous splenitis. ZN 
+ve bacilli in pyogranulomata 
mild mycobacterial pyograulomatous splenitis. Y 
ZN +ve bacilli in pyogranulomata. normal range 
or possibly increased heaopiesis. . ZN +ve 
bacilli 
normal range, possible increased platelet Y 
production no ZN +ve bacteria. mild 
mycobacterial pyograulomatous splenitis. ZN 
+ve bacilli in pyogranulomata 
T Blinded examination H&E and ZN stained wax embedded sections performed RCVS Specialist in Veterinary Pathology 
2 BALBic mice infected by aerosol deposition of60 CFU AI. tuberculosis. 
3 N (A = sample not available 
4 Y = ZN positive bacteria detected by ZN staining 
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BeG mediated protection m lungs and spleen following aerosol M. 
tuberculosis infection 
Parenteral BCG vaccination of inbred mice affords significantly greater protection in 
lungs and spleens compared with non-vaccinated animals (264). BALB/c mice were 
vaccinated with BCG then challenged by aerosol using a titre of 2x 10(, CFU/ml M. 
tuberculosis. The parameters of the experiment, BCG vaccination in the footpad 
giving a dose 5x 1 05 CFU of Pasteur BCG and challenge 4 weeks later had been used 
in a number of published studies (265). Bacterial loads were determined in lungs and 
spleens 4, 6 and 8 weeks after challenge (Fig. 5 A&B). Again, in accordance with 
published studies, significant protection was observed in both the lungs and splccns 
in BCG vaccinated mice compared to naIve controls at all time-points examined (~~ 
<0.001). 
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Figure S: BeG induces significant protection from an aerosol M. tuherculosis 
challenge in the lungs and spleen. Total eFU burden is shown in lungs (A) and 
spleen (B) of naive or BCG (5 x IO~ CFU in footpad) vaccinated mice at different 
time-points following aerosol challenge with M. tuherculosis (l x I06 CFU/ml). CFU 
burden is expressed as loglo mean CFU +1- SEM (n=IO). 
2.2 Discussion 
These studies established that a titre of I x 106 CFU/ml of M. tuberculosis delivered 
as an aerosol for 20 minutes would infect 100% of micc. In this modcl, the standard 
deviation within groups with respect to organ bacillary load was small and enabled 
significant differences to be calculated between naIve and BCG-immunised mice at 
all time-points tested after challenge. The kinetics of growth of M. tuhaculosis 
following challenge with 106 CFU I ml M. tuberculosis is in accordance with 
published studies (204). Following infection, the M. tuberculosis showed clear lag, 
log and stationary phases of growth in lungs and spleens with dissemination of 
bacilli to the spleen occurring around day 15 post challenge (reviewed in Table 2.1 ). 
The disease pathology induced in this model, was also characteristic of M. 
tuberculosis infection in other murine models, involving lung peribronchial and 
perivascular lymphocytic infiltrates and pyogranulomata In the lung, 
pyogranulomatous splenitis and granulomatous lymphadenitis of the mediastinal 
lymph nodes (266). 
The analysis of BCG vaccinated mice in the lungs and spleen at diffcrent time-points 
following M tuberculosis challenge demonstrated the strong protective efficacy of 
BCG in acute infection. BCG remains the gold standard against which all 
vaccination regimens are compared in tuberculosis challenge models. Chapters 4 and 
5 of this thesis deal with the development of new vaccination regimens against 
tuberculosis in mice. In the challenge model developed in this study the protection in 
the spleen produced by BCG Pasteur strain at 4 weeks, which is a time-point often 
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used in other published studies, was below the limit of detection of the assay. This 
implied that a comparison of bacterial burdens in the spleen between alternate 
vaccine regimens and BCG might have been uninformative at the 4 week time point. 
As such, in the challenge studies performed in Chapters 4 and 5, organs were 
harvested 6 weeks post challenge to ensure all BeG-vaccinated mice had M. 
tuberculosis burdens in both the lungs and spleens significantly above the limit of 
detection of the assay. 
3 Inducing antigen specific T 
cells in the respiratory compartment 
3.1 Background to Chapter 
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Immunogenicity assays, dissection and vaccination techniques for this project were 
developed in mice using malaria vaccines. These techniques were then applied to the 
development of tuberculosis vaccines strategies described in Chapters 4 and 5. 
In BALB/c mice, the induction of specific CD8+ T cells, arc crucial to protection 
from pre-erythrocytic liver stage malaria. Intravenous vaccination with DNA then 
MY A, both expressing the circumsporozoite (CS) gene from Plasmodium herghei 
(P. berghei) afforded complete protection from a subsequent sporozoite challenge 
(267). This protection was mediated by a single immunodominant COX I T cell 
restricted epitope called pb9, which is recognised by H2d BALB/c mice following 
vaccination (268). The magnitude of the splenic T cell response to pb9 following 
vaccination is a correlate of protection from P. berghei challenge that enables the 
comparison of different vaccination regimens (including different routes of 
vaccination) within this model. Other studies by this group had shown that 
intradermal (ear) or intravenous vaccination with DNA / Adenovirus, 
Adenovirus/MY A, DNA/Fowlpox (FP9), MY A /FP9 or FP9/MY A expressing CS 
afforded full or partial protection following a P. berghei parasite challenge (269, 
270). 
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The specific aims of this chapter were to investigate 1) whether lung delivery of 
recombinant viral or DNA vaccine constructs is immunogenic in the spleen and the 
respiratory compartment and 2) and if immunogenic, whether lung immunisation of 
these malaria vaccines could afford protection against a P. berghei challenge. 
3.2 Results 
Description of the regional lymph nodes in mice 
Regional lymph nodes were identified in BALB/c mice (Fig. 6) (271) (272). The 
same lymph node sets were identified in C57BU6 mice with the exception of MLN, 
which were not visible, even after intranasal influenza A (A/PR/8/34) infection. The 
patterns of afferent and efferent lymphatic drainage to and from lymph node sets in 
rodents were first described by Tilney et al (271). The lymphatic drainage of those 
LNs that are relevant to these studies is described in Table 3.1. 
Table 3.1. The lymphatic drainage of regional lymph nodes in rodents. Adapted 
from Tilney et al (1971) (271) 
Lymph Nodes 
Facial Lymph Nodes 
Superficial Cervical Lymph 
Node 
"Internal Jugular, Paratracheal 
and Mediastinal Lymph Node 
Inguinal Lymph Node 
Description 
drain the skin of head and ventral aspect of 
sides of neck 
drain tongue and nasolabial lymphatic plexus 
pooled LNs drain the lung and pharynx, larynx 
and proximal part of oesophagus through 
pharyngeal lymphatics 
draining the thigh and genital mucosa, 
" these regional lymph nodes are pooled and collectively called lung lymph nodes 
(LLN) in the text 
Superficial 
cervical LN 
Facial LN 
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Axillary LN 
.. "" ... " ............. "............... Internal Jugular LN I 
Paratraeheal LN 
Mediastinal LN 
Lungs 
Spleen 
Inguinal LN 
• o 
IlIi ac LN 
Popliteal LN 
Lymph node visible following removal of skin 
Lymph node underlying organs I ti sues 
Figure 6: Anatomical positioning of lymph node sets found in BALB/c mice. 
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Intranasal MV A.CS vaccination induces pb9-specific responses in the 
draining lung lymph nodes 
8-10 week old female BALB/c mice were immunised oncc with 106 PFU MY A.CS 
intranasally (i.n-), intradermally in the ear (i.d-) or intravenously (i. v-) in the lateral 
tail vein (Table 3.2). Intranasal immunisations were given in IOJlI and SOJlI volumes 
to identify the minimum volume necessary to achieve optimal induction of specific T 
cells in the lower lung. Previous studies had reported that volumes of 30JlI or greater 
were necessary to deposit virus in the lung and also induce T cell responses in the 
lung and draining lymph nodes (272, 273). 
Five and ten days after vaccination, facial lymph nodes (FLN), lung lymph nodes 
(pooled paratracheal and mediastinal lymph nodes) (LLN), inguinal lymph nodes 
(lLN) were taken from mice from each group, pooled and assayed by IFN-y 
ELiSPOT. Spleens were also removed and assayed individually. 
Intranasal vaccination in a 1 OJlI bolus did not induce any pb9-specific T cells in the 
lymph nodes and produced only a few spots at day 5 in the spleen. The SOJlI bolus 
induced strong, specific T cell responses in the LLN (185 SFCII 06 cells) and low but 
detectable responses in the spleen at day 5. 
Table 3.2 The induction of pb9-specitic IFN-y responses in lymph 
nodes· is dependent on route of immunisation of 106 PFU MY A.CS 
D 5 b . 10" . 50J . d I~ ay J.n- J.n- J. - .:ar J.V 
FLN 0 7 2RO ~2 
LLN 0 IRS 7 ~ 
ILN 0 0 0 X.5 
Spleen e 3 (2) 25 (8) 380 (121) X75 (160) 
Day lOb i.n-IO i.n-50 i.d-Ear I.V 
FLN 0 0 33 0 
LLN 0 23 6 0 
ILN 0 0 0 0 
Spleen 0 0 9R (4) 52 (19) 
a SFC I 106 ceIls in pooled lymph node ceIls of 3 mice taken 5 or 10 
days post vaccination 
b day organs removed and assayed by ex-vivo ELISPOT 
"i.n-J 0 - MY A.CS given intranasally in 10111 
d i.n-50 - MY A.CS given intranasally in 50111 
e average of SFC lIOn ceIls in 3 spleens +/- SEM shown in brackets 
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Both i.d- and i.v- MYA.CS immunisation elicited strong pb9 specific responses in 
the spleen 5 days after vaccination (267). Antigen specific responses in the draining 
lymph nodes differed between these routes of vaccination. Intravenous vaccination 
produced low level pb9-specific responses in all LNs assayed 5 days after 
vaccination. In contrast, i.d-MY A.CS vaccination in the ear produced strong 
responses in the FLNs, which drain the head, including the ears. Low level responses 
were also detected in the LLN and are probably due to antigen specific T cells in the 
paratracheal LN which also drain cells from the FLN (271). No responses were 
detected in the ILN that drain the flank and genital mucosa (Table 3.2). 
The induction of pb9-specific T cells and draining LNs typically decreased by 10-
fold between day 5 and 10 days post vaccination. 
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Intranasal FP9.CS vaccination induces pb9 specific responses III the 
draining lung lymph nodes 
Having shown that a 50111 bolus of MYA.CS was a sufficient volume to induce T 
cell responses in the LLN, similar experiments were conducted with FP9.CS. 
Cervical lymph nodes (CLN) that drain the nasal mucosa were also assayed to 
determine whether i.n- vaccination also induced antigen specific responses in the 
nasal mucosa. Mice were i.v- or i.n- (50Il\) vaccinated and the CLN, LLN and ILN 
were removed 5 and 10 days after vaccination (Table 3.3). Intravenous immunisation 
of FP9.CS induced low level pb9-specific T cell responses in the ILN and CLN and 
strong responses in the spleen. Intranasal vaccination of FP9.CS, as was observed 
with MY ACS induced responses primarily in the LLN and to a lesser extent in the 
CLN and showed that vaccination at this volume induces T cell responses primarily 
in the respiratory compartment. As was observed following i.n-MVA.CS, I.n-
FP9.CS vaccination also induced low level responses in the spleen. 
Table 3.3. The induction of pb9 specific 
IFN-y responses in lymph nodes" IS 
dependent on route of immunisation of 
106 PFU FP9.CS 
Day 5 
CLN 
LLN 
ILN 
Spleen C 
Day 10 
CLN 
LLN 
ILN 
Spleen"! 
i.n-50b 
24.5 
149 
o 
45 (7) 
i.n-50 
5 
23 
o 
33( 14) 
I.V 
IS 
o 
2.5 
327 (94) 
i.v 
o 
o 
5.5 
103(15) 
a Day 5 - average of 2 independent 
experiments. In each experiment lymph 
node cells from 3 mice were pooled. Day 
10 - SFC / 106 cells in pooled lymph node 
cells of 3 mice 
h i.n-50 - FP9.CS given intranasally in 
50111 
C average of SFC !l On cells in 6 spleens 
+1- SEM shown in brackets 
d average of SFC 1106 cells in 3 spleens 
+/- SEM shown in brackets 
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CLN and LLN cells were also cultured separately with pb9 peptide for 7 days. A 
51 Cr release assay was performed using P8IS cells incubated with pb9 as targets and 
compared to non-specific lysis of target cells pulsed with an irrelevant K" restricted 
nucleoprotein peptide (Fig. 7). Intravenous FP9.CS vaccination induced detectable 
lysis above background in both the LLN and CLN cell cultures (Fig. 7A). Intranasal 
vaccination in a SOIlI bolus induced specific lysis in the CLN to similar levels as 
intravenous vaccination but lysis in the cultured lung lymph nodes was 2-fold greater 
than that produced by i. v-FP9.CS vaccination (Fig. 7 B). These results support the 
ELISPOT data that i.n- vaccination with recombinant poxviruses targets the 
respiratory compartment. 
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Figure 7: Intranasal delivery of FP9.CS induces pb9-specific CTLs in the lung lymph nodes. 
Lymph nodes from the lung and upper thoracic region were removed from mice (n=3), 5 days 
after receiving FP9.CS (lOh PFU) given either intravenously (i.v) (A) or intranasally (i.n) (B). 
Individual 51Cr release assays were performed on pb9 peptide stimulated lung lymph node 
(LLN) and cervical lymph node (CLN) 7 day old cultures. The average % specific lysis of 
P81S target cells pulsed with pb9 or an irrelevant 9 aa flu peptide, N P are shown. 
Intranasal delivery of naked DNA.CS does not induce detectable T cell 
responses in the lung lymph nodes 
Mice were immunised with 50llg of DNA expressing (,S (DNA.CS) either i.n-
(50111), or intramuscularly (i.m). The DNA was suspcnded in sterile PBS without 
adjuvants. No pb9-specific T cell responses were detected in ELlSPOT in thc LLN 
following 1,2 or 3 vaccinations with i.n-DNA.CS, where each vaccination was given 
2 weeks apart (data not shown). Splenocytcs from mice vaccinated with i.n- or i.m-
with DNA.CS were taken 10 days after the third vaccination, and cultured with pb9 
peptide. Cells were then tested for their ability to specifically lyse pb9-pulsed target 
cells (Fig. 8). Cultured cells taken from i.m-DNA.CS immunised animals produced 
about 60% lysis at the highest effector: target (100: 1) ratio. Specific lysis induced by 
i.n-DNA.CS immunisation was lower at 20% but demonstrated that i.n- DNA 
immunisation can, albeit inefficiently induce T cell responses in the spleen. 
xo 
70 1 
60 1 
~ 
50 ~ 
'" ~
40 ~ v <.:: 
·13 30
1 
., 
~ 
20 ;.;': 
10 
I 
o i 
100:1 33: 1 10:1 3: 1 1:1 
E:T ratio 
-+- 3x i.n-DNA.CS ___ 3x 1.I1l-DNA.l'S 
figure 8: Repeated intranasal administration of naked plasmid DNA induces low 
level pb9-specific CTL in the spleen. Mice were immunised 3 times with SO!lg 
DNA.CS given 2 weeks apart either intranasally (i.n) or intramuscularly (i.m). 10 
days following the last vaccination, spleens were harvested, cultured for 7 days with 
pb9 peptide and 51Cr release assays were performed. Results are expressed as the 
average % specific lysis of P8IS target cells pulsed with ph9 minus the average '~:. 
specific lysis of P8IS target cells cells pulsed with an irrelevant 9 aa flu peptide, N P. 
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Heterologous vaccination of recombinant viral vectors delivered 
intranasally induces higher frequencies of T cells than homologous 
intranasal vaccination. 
Parallel studies within the laboratory had shown that heterologous i. v-MY A.CS/ i. v-
FP9.CS or i.v-FP9.CS / i.v-MYA.CS vaccination produced significantly higher pbl)-
specific T cell responses in the spleen that homologous vaccination of either vaccine 
(270). Heterologous MY A.CS / FP9.CS prime-boost regimens were tested in 
combination with i.n- delivery of vaccines to investigate whether, CS-specitic CDX I 
T cells could be expanded at the level of the LLN. Mice were vaccinated with i.n-
FP9.CS and immunised two weeks later either with FP9.CS given i.n- or i.v- or with 
MVA.CS given i.n- or i.v-. Ten days later, LLN and spleens were assayed by IFN-y 
ELISPOT (Fig. 9). 
82 
A. 250 
LLN 
~ 
d) 
0 
b 125 
-.. 
~ 
r/) 
i.n-PBS I i.n-FP 9.CS i.n-FP 9.CS i.v-PBS I i.n -FP9.CS i.n-FP9 .CS 
Ln- I i.n- I i.n- LV- I i.v- I i.v-
MVA . S FP9 .CS MVA .CS MVA .CS FP 9.CS MVA .CS 
B. 
800 
* spleen 
600 
~ 
"0 
0 
~ 400 
u 
I.L. 
* 
r/) 
~ • 200 
0 
i.n-PBS I S Ln-F P 9.CS 
in- I i.o- I i.n- Lv- I LV- I i.v-
MVA .CS FP9 .CS MVA . S MVA .CS FP 9.C MVA .CS 
• P va llie < 0.0 I by student t test (2.2) 
Figure 9: Heterologous vaccination with FP9.CS and MY A.CS induces higher responses in the 
lung lymph nodes and spleen than homologous vira l vaccination. Mice were immunised 
intranasally with FP9.CS and 14 days later immunised ei ther intranasa ll y (i .n) or intravenou Iy 
(i.v) with FP9.CS or MY A.CS. 10 days after the second vaccination, spleens and lung lymph 
nodes were removed and assayed for pb9-specific re ponses in IFN-y ELiSPOT. Responses for 
pooled lung lymph nodes (LLN) (A) and individual spleens (8) are shown (n=3). Results are 
representative of two experiments and are expressed as spot forming cells / 106 ce lls (SFCII 06 
+/- SEM). 
Intranasal prime and i.n- boosting vaccinations produced the strongest pb9-specitic T 
cell responses in the LLN (Fig. 9A). Heterologous vaccination with i.n-MY A.CS ! 
i.n-FP9.CS produced a higher response (~3-fold greater) in the LLN than 
homologous vaccination 2x i.n-FP9.CS. 
Intranasal vaccination with FP9.CS was sufficiently immunogenic in the spleen to 
prime a subsequent boosting vaccination with i.v-MY A.CS that was significantly 
higher that vaccination with i.v-MYA.CS alone (P < 0.(1), or 2x i.n-FP9.CS (P < 
0.01) (Fig. 9B). 
Heterologous vaccination produced significantly higher pb9-specific T cell responses 
than homologous regimens in the spleen. This applied to mice given vaccination by 
the purely i.n- route (i.n-FP9.CS / i.n-MY A.CS > 2x i.n-FP9.CS) (P < 0.0\). or mice 
give a priming vaccination i.n- and then boosted i. v- (i.n-FP9.CS ! i. v-MY A.CS > 
i.n-FP9.CS / i.v-FP9.CS) (P < 0.01). 
Table 3.4. Intravenous P. herghei sporozoite challenge of I3ALl3/c 
mice 14 days following vaccination with heterologous viral 
vectors expressing the circumsporozoite gene 
Vaccination a % Survival b 
Challenge I C Naive 0 
2000 sporozoites i.v-FP9.CS I i.v-MY A.CS 50 
i.v-MY A.CS I i.v-FP9.CS 40 
i.n-FP9.CS I i.v-MV A.CS 10 
i.n-MV A.CS I i.v-FP9.CS 0 
Challenge 2 Na'ive 0 
1000 sporozoites i.v-FP9.CS / i.v-MV A.CS RO 
i.v-MYA.CS I i.v-FP9.CS 60 
i.n-FP9.CS I i.n-MY A.CS 0 
i.n-MY A.CS / i.n-FP9.CS 0 
i.n-FP9.CS / i.v-MVA.CS 0 
a Mice (n:::IO) were vaccinated 2 weeks apart and challenge 14 
days post the second vaccination; i.v ::: intravenous immunisation 
of 106 PFU in 1 OO~I: i.n ::: intranasal immunisation of 101> PFU in 
IOOj..ll 
b Survival scored as number of mice that were negative fl.)\' blood 
stage parasitimea 8 days post challenge 
C Mice challenged with sporozoites by intravenous injection in 
IOOj..l1 
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Intranasal administration of MVA.CS / FP9.CS does not afford 
protection from Plasmodium berghei challenge in BALB/c mice 
The protective efficacy of i.n- MVA.CS / i.n-FP9.CS and i.n-MY ACS / i. v-FP9.CS 
vaccination regimens was tested in an i.v- challenge with P. berghei sporozoites. The 
dissections, parasite challenge and subsequent scoring of Geimsa stains slides for 
detection of blood stage parasitaemia were performed by Richard Anderson and 
Carolyn Hannan (NDM, Oxford University). The results are summarised in Table 
3.4. In both experiments, all naIve animals were blood stage positive for malaria at 
day 8 post challenge. The strongest protection observed was afforded by FP9.CS / 
MY A.CS vaccination that produced 50% and 80% protection in experiment I and 2 
respectively. The level of protection reflected the strength of the parasite challenge 
being 2000 and 1000 sporozoites in experiment I and 2 respectively. In experiment 
1, 1 animal vaccinated with i.n-FP9.CS / i.v-MY A.CS was protected but this was not 
reproduced in the subsequent lower dose challenge. Purely i.n- vaccination using 
heterologous viral vectors afforded no protection from disease. 
3.3 Discussion 
The results in this chapter illustrate that in BALB/c mice, the induction of antigen 
specific T cells in secondary lymphoid organs following vaccination with replication 
deficient viruses is highly compartmentalised. The induction of specific T cells in the 
draining LN but not non-draining lymph nodes most likely results from the specific 
migration of antigen-loaded dendritic cells (DCs) from the site of immunisation. A 
previous study has shown that following subcutaneous footpad immunisation, 
labelled antigen loaded murine DCs migrated to the T cell areas of the draining 
popliteal LNs. Very little migration to non-draining LNs, the thymus and spleen was 
detected (274). 
In this study, i.n- vaccination of either MV A.CS or FP9.CS produced strong pb9-
specific T cell responses in the LLNs and concords with the study of Vermaelen el ul 
showing that airway DCs selectively transport antigen to the LLN (245). Intranasal 
vaccination also produced low level responses in the spleen, which may have 
resulted from transport of virus to the circulation from the lung or possibly through 
the gut from reflux during immunisation or low level migration of lung antigen 
X6 
loaded DCs to the spleen. Both i.d- and i. v- immunisation induced high frequencies 
of pb9-specific T cells in the spleen. These routes of immunisation differed in the T 
cell responses in the lymph node compartments. Intradermal vaccination in the ear 
induced strong T cell responses in the draining FLN, low level responses in the LLN 
but no detectable responses in the distal LNs. Intravenous vaccination induced low 
level responses in all lymph node sets, which most likely reflect the deposition of 
virus in organs throughout the body following vaccination. 
The frequency and kinetics of pb9-specific T cells induced by a single vaccination 
with FP9.CS or MVA.CS were comparable. Prime-boost strategies using these 
heterologous viral vectors given i.n- or i.v- were examined. Heterologous viral 
vaccination (FP9/MV A) induced higher numbers of spccific T cells in the LLN than 
homologous vaccination (FP9/MV A>FP9/FP9), when both vaccinations were given 
intranasally. An intranasal vaccination of FP9.CS induced pb9-specific T cells in the 
spleen and when boosted by i.v-MVA.CS produced responses significantly greater 
than i.v- vaccination of MVA.CS alone. These results are in concordance with other 
studies that demonstrate in mice, optimal induction of T cell responses in the 
respiratory compartment is achieved following i.n- vaccination with viral or DNA 
vectors (275). Moreover, the induction of T cell responses in both the lung and 
systemic compartments can be achieved by a combination of systemic and mucosal 
vaccination that is optimised when heterologous vaccine vectors are used (255). 
An i.n- I i.n- or i.n- Ii.v- vaccination regimen with FP9.CS followed by MVA.CS 
failed to protect mice from an intravenous P. berghei sporozoite challenge. These 
vaccination regimens produced significantly lower pb9-specific T cell responses (3-4 
X7 
fold lower) in the spleen than systemic vaccination of FP9.CS / MV A.CS that were 
protective following challenge (270). These results support earlier observations that 
the induction of splenic IFN-y secreting T cells in the spleen is the best known 
correlate of protection against liver stage malaria in mice models (267). 
The induction of specific T cells in the LLN did not correlate with protection against 
malaria that is essentially a disease of the liver and blood. However, the induction of 
T cells in the LLN has been shown to correlate with protection from viral respiratory 
pathogens, like influenza (272). Further studies were undertaken to investigate 
whether the induction of M tuberculosis-specific T cells in the LLN could correlate 
with protection from the tuberculosis. 
4 M. tuberculosis prime-boost 
vaccination regimens - targeting the 
respiratory compartment 
4.1 Background 
xx 
The only licensed vaccine against M. tuberculosis, Bacille-Calmcttc Guerin (BeXi) 
(l0), is an attenuated strain of Mycobacterium bovis. Despite the poor protective 
efficacy afforded by the BeG vaccine against pulmonary tuberculosis, XO(% of 
infants throughout the world receive BeG each year (http://www.who.int/inf .. 
fs/en/factl04.html). This implies that trials of future tuberculosis vaccine candidates 
will likely be performed in BeG vaccinated communities. 
In mice, DNA.85A - MY A.8SA vaccination, whilst inducing high frequencies of 
Ag85A specific splenic IFN-y secreting T cells," did not achieve greater protection 
than BeG following M. tuberculosis challenge (136). The aim of th is part of the 
study was to determine whether in a mouse M. tuberculosis aerosol challenge model, 
BCG-induced protection can be improved by mucosal lung delivery and/or boosting 
with a second dose of BeG or recombinant MVA expressing AgXSA (MVA.8SA). 
4.2 Immunogenicity Studies 
BeG vaccination 
Choice of BCG-sub-strain 
A variety of BCG sub-strains are used in immunogenicity and protection studies in 
animal models (264). In studies performed in this laboratory, both the Pasteur 1173 
P2 and Evan-Medeva BCG protected BALB/c mice equally following infection with 
M. tuberculosis using the aerosol challenge model described in Chapter 2 (compare 
Fig. 5 and (136)). The Pasteur 1173 P2 vaccine strain was chosen for immunogencity 
studies because Pasteur BCG-vaccinated mice induced vcry low levels of non-
specific IFN-y secretion in splenocytes in ELISPOT assays (0- 10 SFC/I O() cells). A 
similar observation has been reported elsewhere (276), In contrast, mice vaccinated 
with Evan-Medeva BCG, produced higher levels of non-specific IFN-y secrction in 
immune assays (100-200 SFC/l 06 cells) (data not shown). 
Antigen 85A is immunodominant following BCG vaccination 
The PPD- and 85A culture filtrate protein- T cell responses induced by parenteral 
(p-) BCG vaccination were compared over the course of a year using IFN-y 
ELISPOT (Fig. 10). PPD is the purified protein derivative from M. tuberculosis 
broth culture. The level of response to 85A protein ranged between 20-60% of the 
overall PPD response. PPD and 85A protein T cell responses were abrogated by 
CD4+ T cell depletion (PPD - 93-98% depletion, 85A - 85-94% depletion of total 
l)() 
response of non-depleted cells in IFN-y ELiSPOT). No morc that 5<% of the total 
response in ELiSPOT was lost following CD8 t T cell depletion showing very low 
levels of CD8! dependent PPD or 85A protein responsive cells induced following 
BCG immunisation. Responses to Ag85A class 1- and 11- restricted cpitopcs (P II 
and PI5 respectively) (277), were also assayed to determine the strength of the 
Ag85A peptide specific response produced by BeG vaccination. T ccll responses 
specific for the major CD4+ epitope in Ag85A, the PI5 peptide, accounted for over 
80% of the T cell response to the whole protein at all time-points and BeG doses 
tested (Fig. to). T cells specific for the CD8+ epitope, PI I were not detected in cither 
ELiSPOT or chromium release assays (data not shown). 
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Figure 10. Antigen 85A is immunodominant following BCG 
immunisation. BALB/c mice (n=3-6) were immuniscd with 5x 10' 
CFU BCG in the footpad. At the time-points indicated. spleens were 
assayed by ex-vivo ELiSPOT for responses to PPD, X5A CFP and 
8SA - C04+ (PIS) and C08+ (PI\) peptides. Responses are 
expressed as IFN-y secreting spot forming cells (SFC) / I Of> cells +/-
SEM. 
o 
i.n- BCG i.n- BeG 
• BCGdeposited in lung iii recovered from llU1g after 5 millS 
Figure II. Mice were vaccinated with 10' or 107 CFU of BCG in a 
100)11 bolus. Within S minutes of vaccination, lungs were removed. 
homogenised and culture for 3 weeks on middlebrook plates. 
Results are expressed as the 10glO[CFUl +/- SEM (n=S) 
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Intranasal BeG immunisation induces strong T cell responses 
in the spleen, lung and lung lymph nodes 
Deposition studies with intranasal delivery of BeG 
BALBlc mice were immunised intranasally (i.n-) (as described in Chapter 3) with 
105 or ]07 CFU of BCG (Pasteur). BCG was cultured from lungs immediately after 
vaccination (Fig. II). Approximately, I % of the bacilli delivered arc recovered from 
the lungs using this technique. 
I mmunogenicity 
The frequency and localisation of IFN-y secreting T cells induced by either 
parenterally or i.n- delivered BCG was compared. The responses to i.n-BCG and r-
BCG produced comparable levels of PPD- and Ag8SA peptide specific CD4 \ T cell 
responses in the spleen (Fig. 12A). In contrast, the frequency of antigen specific T 
cells induced in the lungs 12 weeks after vaccination was significantly higher 
following i.n- vaccination than p- vaccination (Fig. 12B). The cell yields between 
naIve mice and mice receiving BCG either intranasally or in footpad did not 
significantly differ (data not shown). 
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Figure 12. Intranasal BCG (i.n-BCG) immunisation induces higher frequencies of 
specific T cells in the lung compartment than parenteral BCG (p-BCG) 
immunisation. BALB/c mice (n=9) were immunised with 107 CFU of BeG either 
Ln- or p- in the ear. 12 weeks later spleens (A), lungs (8), facial lymph nodes 
(FLN) (D) , and draining lung lymph nodes (LLN) (D) were harvested and assayed 
by ELISPOT, for responses to PPO, and the 85A - C04+ (PI5) and COt{+ (PII) 
epitopes. Spleens and lungs were assayed individually. Results for these organs an: 
the average of two independent experiments, 4 mice per group. For the lymph node 
assays, 9 mice were divided into 3 sub-groups from which nodes were pooled. 
Results are expressed as the mean of the 3 sub-groups +/- SEM. * indicates 
significant differences (P value < 0.05) by Student's t tests in the induction of T 
cell responses by the different routes of vaccination. 
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Parenteral BCG immunisation in the ear produced specific IFN-y secretion in the 
draining FLN whereas intranasal delivery produced responses exclusively in the 
LLN reflecting the pattern of response in the lung (Fig. 12C & D respectively). No 
responses were detected in the distallLN (data not shown). This suggests that similar 
to the observations made with poxviruses, i.n-BCG vaccination induces T cell 
responses that are compartmentalised and dependent on route of vaccination. 
In summary, whilst both i.n-BCG and p-BCG produce strong splenic T cell 
responses, i.n-BCG elicited stronger T cell immunity in the lung and its draining 
lymph nodes. 
MV A.85A boosts both CD4+ and CD8+ T cell responses 
induced by BeG 
MYA can boost both DNA- and FP9- induced T cells, specific to a common 
recombinant antigen (267, 270). Studies were conductcd to dctermine whether 
MY A.85A could also boost BCG-induced Ag85A specific T cell responses. Fourteen 
weeks after }O7 CFU BCG was given parenterally, mice were boosted with IOn PFU 
MYA.85A. This time-point was chosen because the frequency of gSA specific T cell 
responses had plateaued and small standard deviations were observed within groups 
of mice. Parenteral boosting with MY A.85A doubled the PPD response and 
increased the Ag85A specific CD4+ and CD8+ T cell responses 4 and S fold 
respectively in the spleen (Fig. 13A). Immune responses in the FLN showed a similar 
95 
pattern of boosting in PPD and Ag85A CD4 + and CDg t peptide assays (data not 
shown). 
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Figure 13: MYA.8SA specifically boosts both the CD4- and CDSt- 8SA T cell 
responses induced by BCG. BALB/c mice were parenterally immunised with 107 
CFU of BCG. 14 weeks later, mice were boosted (2SIlI/ear) with 106 PFU MY A.8SA 
(A) or 106 PFU MY A.CS (B). MY A or BCG only controls were included. Spleens 
were harvested 10 days post boost and assayed by ELISPOT for responses to PPD 
and 8SA peptides. Results are the mean +/- SEM of two experiments, 3-4 animals per 
group. • indicates significant differences (P value < 0.05) by Student's I tests in the 
induction ofT cell responses by the different vaccine regimens. 
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Parallel experiments were conducted in which mice were immunised with BeG and 
boosted with an irrelevant MYA expressing thc malarial CS protein (MY A.CS), to 
determine whether BCG was specifical1y priming the Ag85A CDS' T cell response 
(Fig. 13B). The frequency of CS-spccific CDS+ T cells was not significantly different 
bctween BCG/MYA.CS and MYA.CS-only groups, suggesting that the AgX5A 
CDS+ restricted T cell response (whilst undetectable following the BCG 
immunisation) is specifically boosted by MY A.8SA. In separate experiments, 
MYA.CS immunisation did not affect the frequency of IFN-'Y secreting T cells 
specific for PPD, PIS and PI} induced by BCG vaccination (Fig. 14A). Conversely, 
prior BCG vaccination did not significantly affect the magnitude of pb9-spccitic 
lysis produced by splenocytes from mice vaccinated with MYA.CS (Fig. 148). 
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• i.n-MVA .CS 
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Figure ]4: PPD, 85A peptide and CS peptide responses in ELISPOT are shown in 
BCG immunised animals boosted with MV A.CS (A). 51Cr release assays were also 
performed on splenocytes from BeG immunised animals boosted with MVACS (8). 
Results for ELiSPOT are expressed as the average (SFC) /106 cells +/- SEM of 
individual spleens from 3-4 mice, assayed in duplicate and in half-fold dilutions. The 
results for 51Cr release assays are expressed as average % CS peptide specific lysis 
minus non-speci fic lysis of P8IS target cells. 
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Histology studies of mIce immunised intradermally with BCG-
MVA.85A 
Ear immunisation of BCG produced a hard lump at the site of immunisation, 
palpable 3 months after vaccination. ZN staining of the ear showed that ZN-positive 
bacilli were retained at the site of immunisation, I month after vaccination 
(Appendix 1). At this time-point, bacilli were also detected in the FLN (Appendix 2). 
MY A.S5A vaccination in the ear of BCG-immunised mice did not exaccrbate 
pathology at the site of immunisation, FLN or the lung (data not shown). 
MV A.85A can significantly boost T cell responses following an 
intranasal vaccination of BeG 
Similar to the wholly parenteral BCG / MV A.85A prime-boost regimen described 
above, parenteral MY A.8SA boosting of i.n-BCG immunised mice also significantly 
increased the level of PPD and AgS5A CD4+ and cost T cell responses in the 
spleen (Fig. 15A). Intranasal MY A.SSA boosting of i.n-BCG immunised mice did 
not significantly increase Ag85A-specific T cell responses in thc splccn (Fig. 15A) or 
the FLN (data not shown) but produced a 3-5 fold increase in the level AgXSA-
specific C04+ T cells in the LLN (Fig. 158). 
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Pigure IS: MY A.85A specifically boosts i.n-BCG induced T eell responses in the 
spleen and lung lymph nodes. Mice were immunised i.n- (JOOIlI) with 107 CFU of 
BCG and after 14 weeks boosted i.n- or i.d- with either Ion PFU MVA.85A or 10(, PFU 
MY A.CS. 10 days later spleens (A) and lung lymph nodes (LLN) (B) were harvested 
and assayed by ELISPOT for responses to PPD, 85A. Results for ELISPOT are 
expressed as the average (SFC) /106 cells +/- SEM of individual spleens or pooled 
lymph nodes from 3-4 mice, assayed in duplicate and in half-fold dilutions. Data 
shown are representative of 2 experiments. * Indicates a P value < 0.05, as determined 
by LRA comparison of all groups. 
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MVA.85A can significantly boost T cell responses following an 
parenteral vaccination of BeG 
Parenteral BeG immunisation, although a poor inducer of specitic T cell responses 
in the LLN, did elicit specific T cell responses in the lung parenchyma. Studies were 
conducted to examine whether the T cells induced in the lung compartment by p-
BeG immunisation could be boosted by i.n-MYA.85A vaccination. Intranasal 
MY A.85A boosting did not significantly increase T cell responses in the splecn (Fig. 
16A). However, i.n-MYA.85A immunisation did increase p-BeG induced R5A CD4' 
T cell responses in both the FLN and the LLN (Fig. 16B & C). 
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figure 16: Ln-MYA.8SA specifically boosts p-BCG induced T cell 
responses in the lung lymph nodes. Mice were immunised p- with 107 
CFU of BCG and atler 14 weeks boosted i.n- or p- with either 106 PFU 
MY A8SA or 106 PFU MY ACS. 10 days later spleens (A), facial lymph 
nodes (B) were harvested and assayed by ELISPOT for responses to PPD, 
8SA. PIS CD4+ dependent responses in the LLN of p-BCG immunised 
mice is shown in (C). Results for ELISPOT are expressed as the average 
(SFC) /106 ceIls +/- SEM of individual spleens or pooled lymph nodes 
from 3-4 mice, assayed in duplicate and in half-fold dilutions. Data shown 
are representative of 2 experiments. * Indicates a P value < 0.05, as 
determined by LRA comparison of all groups. 
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MVA.85A boosting following a low dose i.n-BeG vaccination 
Mice were immunised i.n- with BeG at doses ranging from IO}·/) CFU. Twelve 
weeks later, mice were boosted either i.n- or p- with MY A.X5A (Fig. 17). Lungs 
were homogenised and BCG bacilli recovered (Fig. 17A). Analysis of splenic T ccll 
responses showed that 104 CFU BCG was the lowest dose capable of inducing a 
detectable PPO-specific T cell response in the spleen (Fig. 17B-D). Whilst the KSA 
C04+ T cell response was significantly boosted by MYA.X5A following vaccination 
of 10' and IOn CFU of BCG, no boosting of the PI I-specific COX t T cell response 
was observed (Fig. 17 E-F). These data suggest that lower doses of BeG do not 
induce or inadequately induce 85A specific C08+ T cells that can be expanded by 
subsequent MYA.85A vaccination. 
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Figure 17A: MY A.85A vaccination of BCG immuniscd mice docs not 
affect the recovery of bacilli from mouse lungs 12 weeks aller vaccination. 
BALB/c mice were immunised i.n- with increasing doses of BeG (I x 1O?0 
CFU). 12 weeks later, mice were boosted i.n- or p- with 1011 PFU 
MY A.8SA. 10 days later, lungs were removed. homogcnised and cultured 
to recover residual BCG bacilli. The average eFU +/- SEM are shown for 
each group (n=4) 
Figure 178-1': MY A.8SA vaccination boosts 8SA specific- C04+ but not 
CD8+ T cell responses induced by low dose BCG vaccination. BALB/c mice 
were immunised i.n- with increasing doses of BCG (I X 102-11 CFU) (8)-(E). 
12 weeks later, mice were boosted i.n- or p- with IOn PFU MYA.85A. 10 
days later spleens were harvested and 85A specific T cell responses were 
examined in ELiSPOT. Results are the mean SFC/IO" cells +/- SEM (n=4). * 
indicates significant differences (P value < 0.05) by Student's t tests in the 
induction ofT cell responses by the different vaccine regimens. Bacteriology 
from lungs is shown in FigureI5(A). 
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Table 4.1. MV A.85A" vaccination 8 weeks afler RCG 
immunisation of BALB/c mice does not cxacerhate gross lung 
pathology 
Immunisation Regimen" 
i.n-BCG 102.; 
i.n-BCG 101"1 i.n . 
MVA.85A 
i.n-BCG 101 '1 p-
MVA.85A 
i.n-BCG 106 
i.n -BCG 106; i.n -
MVA.85A 
i.n -BeG 10°; p- MVA.85A 
i.n -BCG 107 
i.n -BCG 107; i.n -
MVA.85A 
i.n -BCG 107; p- MVA.85A 
a MV A.85A dose = I at' PFU 
Lung Pathology 
NAD'.\ 
NAD 
NAD 
Abscess" 
Abscess 
Abscess 
Flecked' 
Flecked 
Flecked 
h i.n = intranasal; p= parenteral (50~1 in footpad) 
" description oflung pathology observed in 4 14 mice 
~ NAD = no abnormality detected 
" Abscess = 2-3 x 3-5 mm white and raised; 5-10 over lungs 
, Flecked describes 2-4 mm flat and off-white and circular 
lesions! > 20 over lungs 
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One mouse in the group that received 104 CFU i.n-BeG then p-MVA.85A produced 
strong T cell responses to P II, P 15 and PPD that increased the mean and the SEM 
within the group (Fig. 17D). In this mouse, the BeG recovery from the lung 8 weeks 
after vaccination was higher than other mice within the group (Fig. 17A). This 
implies that this animal received a much higher dose of BeG at the time of 
vaccination that induced stronger T cell responses that were effectively boosted by p-
MV A.85A vaccination. 
Records were made of the gross pathology induced by vaccination (Table 4.1). 
Intranasal BCG vaccination alone induced pathology at higher doses, but MVA.85A 
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vaccination did not exacerbate gross pathology. No rurther pathology studies were 
performed because in humans, lung immunisation would be more likely given by 
aerosol. Pathology studies following aerosol delivery of BeG in rhesus macaques 
that were given a human dose BCG are described in Chapter 6. 
Intranasal DNA.85A vaccination requires a lipid adjuvant to 
induce T cell responses in the spleen 
In Chapter 3, repeated i.n- immunisation of naked DNA, failed to induce detectable 
T eell responses in the LLN and spleen. In this chapter, intranasal delivery or DNA 
was examined in conjunction with lipid adjuvant and MYA.HSA boosting 
vaccinations. BALB/c mice were immunised with DNA.8SA (DNA.8SA) with or 
without a cationic lipid, GL-67 either i.n- or i.m-. GL-67 (67) is a cationic lipid that 
had been previously shown to significantly increase gene expression of plasmid 
DNA in the murine lung (278). These experiments were performed with Steve Hyde 
(Nuffield Department of Clinical Biochemistry. Oxford University) Two weeks after 
the first vaccination, mice were immunised with a second dose of DNA.HSA +/- 67 
or with MY A.85A given i.n- or i.v-. 10 days later spleens and LLN were removed 
and analysed by IFN-y ELiSPOT (Fig. 18). 
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Figure 18: Lipid GL-67 mixed with naked DNA.8SA adjuvants the induction of 8SA specific- CD4+ and CD8+ T cell responses in the spleen. 
BALB'c mice were immunised with DNA.8SA pCIK8SA) (60)lg) either i.m- or i.n- with or without GL-67. Two weeks later mice with re-
vaccinated with either a second dose ofDNA.8SA with or without GL-67 or i.n- or i.v- with 106 PFU MVA.8SA. 10 days later. spleens (A) and 
lung lymph nodes (LLN) (B) were removed and assayed for 8SA specific CD4+ and CD8+ peptide specific responses in ELISPOT. Results are 
expressed as the average SFC ]06 cells for individual spleens (+- SEM) or pooled LLN (n=4). 
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Yaccination of 2x i.n-DNA.8SA failed to elicit responses in the spleen but low level 
responses were observed following inclusion of lipid 67 (Fig.1 RA). The adjuvant 
effect of 67 on DNA.8SA was clearer in the spleen when mice were boosted with 
MY A.8SA. Interestingly, naked DNA.8SA / MYA.RSA produced responses in the 
LLN equivalent to DNA.8SA+67 / MVA.8SA (Fig.18B). This suggests that naked 
DNA given intranasally can induce low levels of T cells in the LLN but that the 
induction of splenic T cells requires an adjuvant. 
Intranasal DNA.8SA+67 prime followed by systcmic boost with MY A.RSA induced 
the strongest response in the spleen for both CD4+ and CD8+ RSA specilic T cell 
responses (Fig. 18A). This vaccination regimen gave higher levels of response in the 
spleen than the classical i.m-DNA.8SA / i.v-MY A.8SA vaccination regimen. Lipid 
67 did not adjuvant DNA.8SA induced T cell responses when the vaccination was 
given intramuscularly. A mucosal prime and boost using heterologous vaccine 
vectors DNA.8SA/MY A.8SA induced the strongest responses in the LLN. 
4.3 Aerosol M. tuberculosis Challenge 
Acute Aerosol Challenge of Vaccinated BALB/c mice 
Immunogenicity studies using BeG / MYA.85A vaccination regimens had shown 
that the frequency of specific lFN-y secreting T cells induced by BCG could be 
significantly increased. Further, i.n- vaccination with either BCG or MY A.RSA was 
able to induce responses in the LLN. These regimens were chosen as the most 
promising for M tuberculosis challenge studies. Animals were vaccinated with i.n-
III 
BCG. Twenty-two weeks later, mice were given MVA.85A either i.n- or p-. Aftcr I 
month, mice were challenged with M tuherculosis given as an aerosol. Lungs and 
spleens were harvested and cultured for the presence of M tuherculosis colonies 6 
weeks after challenge (Fig. 19A & B). There was no significant dit1erence in the 
number of mycobacterial colonies on plates with or without TCH indicating no 
detectable BCG in the lungs or spleens, six weeks after challenge (data not shown). 
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Figure 19: Protection of BALB/c mice against aerosol M. tuberculosis challenge by 
BCG boosting regimens. Mice were immunised with BCG given either i.n- (I0~ 
CFU) or p- in the footpad (5xIO~CFU). 22 weeks later groups were boosted either 
i.n- or p- (footpad) with BCG or MY A.85A (106 PFU). Four weeks following the 
second immunisation mice (n = 9-12) were challenged and approximately 250 CFU 
M. tuberculosis H37rv was deposited into the lung. After six weeks, lungs and 
spleens were harvested and plated out in serial dilutions on Middlebrook agar plates 
containing TCH (5Ilglml). Results are shown for lung and spleens in (A) and (8) 
respectively. Results are expressed as the mean (1oglO[CFU j) of either the lung or 
spleen +1- SEM. • indicates significant differences (P value < 0.05) by Student's I 
tests in bacterial load between the various groups clustered by arrows. The origin of 
the arrow (circle) designates the reference group to which statistical comparisons 
were made. 
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Two doses of BeG afforded greater protection than one in BALB/c mice 
Compared to the naive controls, significant protection was conferred in the lung but 
not the spleen by a single parenteral dose of BeG administered 22 weeks before 
challenge in BALB/c mice (lung: P<O.OI, spleen: P=0.84). In previous studies, Bee; 
immunisation 4 weeks prior to aerosol challenge yielded highly significant 
protection in both the spleen and lungs (Fig. 5, Chapter 2), indicating that the 
protective effect of BeG in the spleen diminishes with time (265). When mice were 
immunised with a second dose of BeG, protection in both the lungs and spleens was 
highly significant when compared to naive controls (lung: P<O.OO I, spleen: 
P=O.OO I) and to the I x p-BCG group (lung: P=O.022, spleen: P=O.OO I). 
Intranasal BeG offers greater protection than p-BCG in 13AL13/c mice 
A single i.n-BCG immunisation (0.5 log CFU lower than the parenteral dose) 
resulted in significant protection in the lung compared to the na·ive control group 
(P<O.OOI), but this was not significantly different from the p-BCG group (P=O.065) 
(Fig. 19A). Numbers of bacilli in the spleen were similar between the i.n-BeG, p-
BCG and naive control group (all comparisons: P>O.5) (Fig. 1(8). When a second 
i.n-BCG immunisation was given, protection in both the lung and spleen was 
significantly improved when compared to the naive, Ix i.n-BCG and Ix p-BCG 
groups (all comparisons - lung: P<O.OO I, spleen: P<O.OO I). Two doses of i. n-BCG 
also showed significantly greater protection in the lung than immunisation with 2x p-
BCG (P<O.OOl). 
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MY A.85A boosting of BCG provides comparable protection to two 
BCG immunisations & 2.5 log protection over naives 
Boosting i.n-BCG, either i.n- or p- with MVA.85A produced significantly higher 
levels of protection compared with the Ix i.n-BCG group against challenge (Fig. 19). 
Protection in the i.n-MVA.8SA boosted group was striking, showing the same levels 
of protection as the 2xi.n-BCG group (lung: 2.S logs and spleen: I.S logs lower than 
the na"ive group). When compared to the i.n-BCG group, the mice boosted 
parenterally with MV A.8SA did not show increased protection in the lung (P=--0.494) 
(Fig. 19A). However, the level of protection in the spleen was significantly more 
than the i.n-BCG group (P<O.05) and comparable to the 2xi.n-BCG and i.n-BCG ! 
i.n-MVA.8SA groups (Fig. 19B). 
Protection in the lung correlates with T cell responses in the LLN 
On the day of challenge (4 weeks post 2nd immunisation), four mice from each group 
were sacrificed for immunogenicity studies. Only mice in the 2xi.n-BCG and i.n-
BCG / i.n-MVA.85A groups produced detectable T cell responses to the PIS Ag85A 
CD4+ T cell epitope in their LLN at the time of challenge (Fig. 20A). These groups 
showed the highest levels of protection in both the lungs and spleen following 
challenge, which indicates that Ag8SA specific T cell responses in the LLN correlate 
better with protection in the lung than splenic responses. No T cell response was 
detected in the LLN to the 8SA CD8+ PI I peptide in any group, most likely because 
the BCG dose used in the challenge experiment was too low to induce a specific 
CD8+ T cell response. 
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Figure 20: Protection in the lung against aerosol challenge with M tuherculosis 
correlates with the presence of 85A specific- IFN-y secreting CD4+ T cells in the 
lung lymph nodes (LLN). LLN from mice were pooled and examined for 
responses to PPD and the 85A peptides PI5 and Pll by ELISPOT(A). 
Splenocytes were examined using ELISPOT for responses to PPD (B), 85A 
protein (C), Pl5 (0), PI 1 (E). Specific lysis of PI 1 pulsed P815 target cells are 
examined in (F). Results are expressed as the mean SFU/lOb cells. * indicates 
significant differences (P value < 0.05) by Student's t tests in the induction of T 
cell responses from BCG or MY A.85A only vaccine regimens. 
II:" 
~ 
Ill-lilt! Ill-Ill'(, P' 
111- \·1 \A S"I.\ 
M\".\ S".'\ 
* 
* ~ 
III-Hl'(, Ill-lit.'ii p-
111- M\,-\ "A 
M VA "A 
__ p-lin) tp-IH li 
~llI-Bl'(i 
-.-1 II-Bel; 111-
Ul'lj 
___ 1.u-Bl'{i, LII-
MVA)o\(," 
....... I.II-IWCi Ip. 
MVA K'A 
116 
Some differences were observed between groups in the splenic assays. Whilst all 
groups produced comparable responses in IFN-'Y ELISPOT to PPO and 8SA proteins 
(Fig. 20B & C respectively), the Ag8SA C04+ T cell response to PIS in the i.n-BeG 
/ i.n-MV A.85A and i.n-BCG / p-MVA.85A groups were increased two- and three-
fold respectively over the Ixi.n-BCG group (Fig. 20D). Responses to the PII COX' 
T cell epitope were detectable at low levels in the i.n-BCG / p-MVA.XSA group in 
ELISPOT (Fig. 20£). In chromium release assays performed on culturcd 
splenocytes, only this group produced significantly highcr levels of spccilic lysis 
(30%) of PI I-pulsed targets compared with control cells (Fig. 20F). Again, because 
of the lower BCG dose used in the challenge experimcnt, the detection of 85A-
specific C08+ T cells in the spleen was most likely induced by MVA.8SA 
vaccination alone. 
4.4 Discussion 
Recombinant MVA effectively induces both CD4+ and C08" IFN-'Y secreting T cells 
to foreign antigens, including Ag85A and is particularly effective as a boosting 
vector (136,267,279). MVA.85A immunisation boosted AgX5A specific C04 r and 
CD8+ T cell pools induced by BCG, demonstrating that a recombinant virus can also 
boost T cell responses induced by a bacterial prime. 
The protective efficacy of the BCG .~ MV A.85A prime-boost regimen was tested in 
aerosol M tuberculosis challenge. This regimen was compared to single and double 
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vaccinations with BCG given either parenterally or intranasally. In BALB/c mice, 
irrespective of route of delivery, two BCG immunisations were more protective than 
one in the lungs and spleens. In humans, repeated intradermal BCG immunisation 
did not provide any greater protection against pulmonary tuberculosis irrespective of 
age at time of boost or time between BeG immunisations in Malawi (I H9). 
However, in the region examined, a single BCG immunisation conferred no 
protection against pulmonary tuberculosis. Multiple BCG doses or indeed boosting 
with MVA.85A may still provide some benefit in a population where a single BeG 
immunisation is partially protective. Repeated BeG immunisation has been found to 
increase protection from leprosy by about 50% (191). The antigen 85A protein 
derived from Mycobacterium leprae-Ag85A shares 90% amino acid identity with M. 
tuberculosis-Ag85A, is protective in mice models, and can induce specitic T cell 
responses in infected humans (280, 281). In addition, Mycohaclerium leprae (M. 
leprae) specific cytolytic CD8+ T cells have been identified in leprosy patients (282, 
283). Future clinical trials could also assess whether a BCG-MVA.85A regimen 
could boost M. leprae specific- CD4+ and CD8+ T cell populations and what impact 
this could have on protection from leprosy. 
The protective effect of eliciting lung-localised T cell populations through mucosal 
delivery of tuberculosis vaccines was also examined. Intranasal BCG was as 
effective as p-BCG in inducing peripheral T cell responses but induction of 
responses in lymph nodes was highly dependent on the route of immunisation. 
Intranasal delivery of BCG elicited robust responses in the LLN that could be further 
IIX 
boosted by i.n- immunisation with MYA.8SA (284). A single dosc of i.n-BeG gave 
the same level of protection as p-BCG following a M. tuherculosis challenge. In 
mice that were immunised intranasally with BeG and again boosted intranasally 
with either a second BCG dose or MY A.8SA, the levels of protection in thc lungs 
and spleens were both significantly higher than a single BCG immunisatiun. This 
level of protection (2.5 logs) has not previously been reported in murine vaccination 
studies. 
At the time of challenge (4 weeks after the last vaccination), only the i.n-prime / i.n.-
boost vaccination regimens produced detectable responses in LLN and the highest 
levels of protection. The frequency of specific T responses in the spleen did not 
correlate with the strong protection observed in these groups. These data suggest that 
the frequency of antigen specific IFN-y secreting CD4+ T cells in the LLN may 
constitute a better indicator of protection in the lung than systemic responses against 
pulmonary tuberculosis. Two explanations exist for this observation. Firstly, in mice 
that have been infected aerogenical\y with M. tuherculosis, bacilli disseminate tirst 
to the LLN, possibly via dendritic cells, and then to periphery (285, 286). The 
induction of M. tuherculosis specific T cells follows dissemination of bacilli. The 
responses are induced first in the LLN (but not other LN compartments) and later in 
the spleen (285). The strong protection observed in both the lungs and spleens in the 
i.n-prime / i.n-boosted groups may have resulted from the microcidal actions of 
resident M. tuberculosis specific T cells in the LLN limiting disseminatiun of bacilli 
back to the lungs and periphery. Whether M. tuberculosis dissemination from the 
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lung parenchyma to the lung lymph nodes also occurs in humans is unknown but in 
both symptomatic and asymptomatic individuals pathology is often found in the hilar 
lymph nodes (6). Alternatively, antigen specific T cells in LLN may renect 
lymphatic drainage of protective T cell populations resident in the lung (271, 2H4, 
287). Several murine studies have shown a correlation between an influx of IFN-y 
secreting CD4+ and CD8+ T cells into the lung during acute infection and protection 
from tuberculosis (253, 288-290). In humans, Condos et at show that the broncheo-
alveolar lavage (BAL) of patients with less clinically advanced pulmonary 
tuberculosis contained higher levels of IFN-y secreting lymphocytes than patients 
with advanced tuberculosis who conversely had increased numbers of neutrophils in 
their BAL (291). 
The acute M. tuherculosis challenge model used here did not in itself distinguish 
between the utility of BCG and MVA.85A as boosting agents after BeG priming. 
Previous studies have shown that BCG is still recoverable from the lung, albeit in 
very low numbers one month after lung immunisation (86, 2(2). Histological 
analysis showed an ongoing inflammatory response in the lungs and numbers of 
macrophages, neutrophils, NK cells and anti-microbial mediators such as IL-12 and 
TNF-a in lung lavage were still elevated (292, 293). The level of protection 
observed following challenge of 2x i.n-BCG immunised mice, could in part be due 
to ongoing innate immune reactions induced by the residual BCG bacilli in the lungs. 
In contrast, it is unlikely that innate immune mechanisms contributed to the 
protection observed in the i.n-BCG / i.n-MVA.85A group. Unlike BCG, the MVA 
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virus does not persist in rodent lungs (294). In cotton rats that arc highly susccptible 
to vaccinia virus infection, MY A could not be detected in lungs fivc days after 
intranasal immunisation and no pathology was observed. Similarly, intranasal 
immunisation of BALB/c mice with 5x I 07 PFU (1.5 logs greater that the vaccination 
dose in this study) of non-recombinant MY A did not provide any protcction from 
challenge with the lung pathogens, respiratory syncytial virus (RSV) or 
parainfluenza virus (PlY) (295, 296). In those studies, groups of mice vaccinated 
with recombinant MYA expressing RSY or PlY proteins were protectcd following 
intranasal challenge a month after vaccination. 
Whilst the i.n-prime I i.n-boost vaccination regimen was highly protective In this 
study, was intranasal delivery of the vaccines necessary for both the prime and the 
boost? In this study, a single BeG vaccination, whether parenteral or intranasal, 
afforded equivalent protection in lungs and spleens. A similar observation was 
recently reported by Palendira el at (182). These results conflict with carlier studies 
in other animal models in which showed aerosolised BeG atTorded better protection 
than parenterally delivered BeG (256, 297). In these early studies, the time bctween 
vaccination and challenge was relatively short, and as described above any ongoing 
inflammatory reaction in the lung may have contributed to increascd levcls of 
protection. In this study and that of Palendira el aI, BeG was eliminated from the 
lung by either resting the animals after BeG vaccination (22 weeks) or by antibiotic 
treatment. Palendira et at also showed that irrespective of the route of BeG 
vaccination, the recruitment of IFN-y secreting eD4+ T cells to the lung tollowing 
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aerogenic M. tuherculosis challenge was similar. This suggests, in this model at 
least, that following a single immunisation of BeCi, protection is independent of 
route of vaccination. Previous studies in viral systems have similarly suggested that 
following a single intranasal immunisation, T cell responses first develop in the 
LLN, then extravasate stochastically from the blood to organs like spleens and lungs 
(255, 273, 287). When the animals were challenged intranasally, the presence of 
antigen drew T cells back to the lung (182, 255, 287, 298). Applying these 
observations to the prime-boost regimen in this study, an intranasal MY AJ55A boost 
of BCG-immunised mice, will express Ag85A in the lung and not only expand 
Ag8SA specific T cells resident in the respiratory compartment but also pull in 
memory T cells from the periphery. This is supported by the observation that 
intranasal boosting with MYA.85A of parenterally BCG-immuniscd micc also 
significantly increased PPD and Ag85A CD4+ T cell responses in the LLN (see also 
(255». This view is not in conflict with the wealth of vaccinology publications 
showing that mucosal vaccination affords longer lasting and greater protection than 
parenteral vaccination from mucosal pathogens (reviewed in (299». In the majority 
of these studies, vaccination regimens have involved repeated mucosal vaccination, 
each time not only boosting but also targeting memory T cells to the mucosal tissue. 
These data suggest that in mice the induction of T cell responses in the respiratory 
compartment is important in protection from pulmonary disease. Even so, strong 
peripheral T cell responses remain central to protection in the spleen. Following M. 
tuberculosis challenge, i.n-MY A.8SA boosting gave greater protection in both the 
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lung and spleen than i.n-BCG immunisation alone. Parenteral MY A.XSA boosting of 
miee immunised with BCG intranasally improved the level of protection in the 
spleen but not the lung. No Ag85A specific immune responses were detected in the 
i.n-BCG / p-MYA.85A group in the LLN. However, splenic immune responses in 
this group were significantly higher than other groups. Parenteral immunisation or 
MY A has been previously reported to elicit strong lytic T cells responses in the 
periphery but not the mucosa (255). Together this suggests that parenteral boosting 
of BCG-immunised mice with MY A.85A expanded peripheral T cell populations 
that, following challenge controlled better the levels of M luherculosis bacilli that 
had disseminated from the LLN. In humans, parental BCG vaccination is protective 
against systemic forms of disease and parenteral BCG vaccination in rhesus 
macaques appears to protect from haematogenous spread of bacilli (12, 207). In 
summary, whilst lung lymph node T cell responses may correlate with protection in 
the lung, specitic T cell responses in the spleen may constitute a good indicator of 
protection from systemic forms of disease. 
In this chapter, BCG-mediated protection against an aerosol M. tuherculosis 
challenge was significantly increased by MY A.85A boosting of BCG immunised 
mice and/or intranasal vaccine delivery. The induction of specific IFN-y secreting 
cells in the LLN appears to be predictive of protection in the lung, although in the 
present study the contribution of innate immune responses to the protection observed 
in the 2xi.n-BCG group cannot be excluded. The potential of lung delivery of 
vaccines to increased protection from pulmonary tuberculosis is further investigated 
in the rhesus macaque model in the following chapters. 
In the clinic, irrespective of route of delivery, MY A.8SA boosting may be of more 
benefit than multiple BCG vaccination for several reasons. Increasing evidence 
suggests that exposure to environmental mycobacteria have a negativc effect on 
BCG-induced protection (193). Unlike BCG and as outlined above, the strong 
immunogenicity and protective capacity of MYA.gSA occurs without any viral 
replication and therefore is unlikely to be compromised by exposure to 
environmental mycobacteria (222). In addition, MY A has been given without 
adverse effects to severely immunocompromised primates suggesting it would carry 
less risk in HIV positive individuals than subsequent vaccinations with live Bl 'C; 
(300). Increasing evidence suggests that C08+ T cells arc also necessary for 
protection from disease, particularly against reactivation of latent tuberculosis 
infection (137). MVA.8SA expanded low-level BCG induced Ag8SA specific COg t 
T cell response as wel1 as C04+ T cel1 responses. However, COR T cell boosting was 
only observed following high dose BCG vaccination and would not have contributed 
strongly to the protection observed in BCG / MYAJ~SA vaccinated groups following 
challenge. The ability to boost C08+ T cell responses with recombinant viruses 
should provide an advantage, particularly for long-term protection, over multiple 
BCG immunisations and possibly over other subunit vaccination regimens that 
induce T cell responses that are predominately CD4-t dependent. In this Chapter and 
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Chapter 2, DNA plasmids and poxvirus vectors (FP and MV A) were shown to 
effectively combine to induce high levels of specific CDS" T cell responses. 
As such, studies in monkeys sought to further augment 85A specific COX t T cell 
responses by including fowlpox expressing Ag85A vaccination to BCe; MV A.K5A 
vaccination regimens (Chapters 6 & 7). 
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5 Intranasal vaccination with, 
and/or MVA.85A boosting of BeG does 
not improve BCG-mediated protection 
of C57BL/6 mice 
5.t Background to Chapter: 
Host genetic heterogeneity in humans and animal models directly impacts on the 
type and strength of the immune response to intracellular pathogens (30 I). The 
promising levels of protection achieved with BCG / MVA.85A vaccination of 
BALB/c mice warranted repeat of these experiments in a second mouse strain, 
C57BLl6 mice. Several 85A specific- CD4+ but no CD8+ restricted T cell epitopes 
have been identified following vaccination with BeG, MV A.85A or D.XSA in 
C57BII6 mice (302,303). 
5.2 Results 
Intranasal vaccination with, and/or MY A.8SA boosting of BeG does not 
improve BCG-mediated protection of CS7BLl6 mice 
C57BLl6 mice were vaccinated parenterally in the footpad (p-) or i.n- with 105 CFU 
of BCG. 36 weeks later, mice were given a second vaccination of BeG or MV A.HSA 
(106 PFU) given i.n- or p-. Four weeks after the last vaccination, mice were 
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challenged with M. tuherculosis given as an aerosol. Bacterial burdens were 
determined from lungs and spleens harvested 6 weeks after challenge. 
All vaccinated groups were significantly protected in both the lung (average - 0.7 
log) and spleen (average 1.1 log) compared to na"ive controls (lung - P < 0.00 I, 
spleen - P < 0.00 I) (Table 5.1). Boosting of BeG immunised mice with either a 
second dose of BeG or MY A.85A did not significantly increase the level of 
protection in either organ. 
Table 5.1: Bacillary load (IoglO (CFU» in organs 6 weeks after aerosol M. 
tuherculosis challen~e ofC57BU6 mice 
Group" Lung SEM Spleen SEM 
NAIVES 5.86 h.< 0.07d 4.44 h.' 0.15 
pC-BCG 5.03 0.06 3.20 0.16 
p-BCGI p-BCG 5.22 0.11 3.46 0.17 
p-BCGI p-MV A.8SA 5.10 0.\0 3.21 0.17 
i.n-BCG1 5.14 0.12 3.51 0.16 
i.n-BCGI i.n-BCG 5.15 0.09 3.38 0.16 
i.n-BCGI i.n- 5.22 0.04 3.39 0.16 MVA.85A 
i.n-BeG/ p- 5.14 0.05 3.37 0.14 MVA.8SA 
a in each group n=IO 
b value is geometric mean of the loglO(CFU) in the lung 
< comparison of naives to all other groups by Student's t test produced P < 0.0 I 
d +/_ SEM 
C p.= footpad immunisation of Sx I 05 CFU BCG or I O~ PFU MY A.8SA 
f i.n = intranasal immunisation of 105 CFU BeG or 106 PFU MY A.8SA 
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Figure 21: p-MYA.85A vaccination of p-BCG immunised C57BU6 mice induces signilicantly 
higher 85A specific- IFN-y secreting splenic T cells. At the time of challenge (4 weeks post 
second immunisation), spleens (n = 4) from vaccinated mice were assayed for PPD (A) and 85A 
culture filtrate protein (B) and 85A peptide specific (C) responses in IFN-y ELISPOT (SFCIIO° 
cells +/- SEM) (A) * indicates significant differences (P value < 0.05) by Student's t tests in the 
induction ofT cell responses to BCG and MY A.85A only vaccine regimens. 
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FIGURE 22: p-M.8SA vaccination of p-BCG imrnunised CS7BLl6 mice induces significantly higher 
8SA specific- proliferation. At the time of challenge (4 weeks post second immunisation), spleens (n = 4) 
from vaccinated mice were assayed for PPD and 8SA protein specific proliferation. 
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Immunogenicity Results in C57BLl6 mice 
Four mice from each group were sacrificed at time of challenge (4 wecks following 
the second immunisation) for immunogenicity studies. Additional groups, PBS/p-
MVA.8SA, PBS/p-BCG, PBSIi.n-MV A.8SA and PBSI i.n-BeG were included as 
controls. Splenic T cell responses to PPD, Ag8SA protein, Ag8SA peptide pools or 
individual epitopes were tested in IFN-y ELISPOT and proliferation assays (Fig. 21 
& 22 respectively). 
There was no significant difference In the frequency of the PPD specific IFN-y 
secreting T cells in ELISPOT between BeG vaccinated mice whether given BCG 
parenterally or intranasally or vaccinated once or twice (Fig. 2IA). In contrast, the p-
BCG/p-MVA.8SA vaccinated mice showed significantly higher 8SA protein and 
peptide specific responses than other groups (Fig. 21B & C). This group also 
produced significantly higher proliferation to the 85 protein than mice vaccinated 
with BCG and MVA.8SA alone (Fig. 22). Intranasal delivery of BeG induccd 
specific IFN-y and proliferative responses comparable to p-BCG (Fig. 21 & 22) but 
unlike BALB/c mice. i.n-BCGI p-MV A.8SA vaccination did not induce PPD- and 
8SA- specific T cell responses greater than in-BCG alone (Fig. 2IA&B). 
5.3 Discussion 
In this chapter, vaccination regimens that produced protection greater than 
parenterally delivered BCG in BALB/c mice failed to increase protection 111 
CS7BLl6 mice. Failure to improve on BCG-mediated protection occurred even in a 
group (p-BCG/p-MVA.8SA) that at the time of challenge, exhibited significantly 
130 
higher specific IFN-y secretion and proliferative T cell responses than that induced 
by BCG vaccination alone. These data contrast with the results from BALB/c mice 
studies where increases in splenic 85A specific IFN-y secreting (,04+ T cells 
correlated with increased in protection in the spleen. 
Both C57BLl6 and BALB/c mice strains are described as resistant to M. tuhercu/osis 
infection (204). C57BLl6 mice live slightly longer following i.v- challenge (204). In 
this study, bacterial loads in the lung and spleen did not differ significantly betwecn 
strains 6 weeks after challenge. Whilst C57BLl6 and BALB/c mice are similarly 
resistant to M tuherculosis infection, differences have been reported in the immune 
responses of these strains following BCG vaccination and resistance to infection 
with other bacteria. Following intratracheal BCG vaccination, C57BLl6 mice secrete 
higher levels IL-12 and IFN-y into lung lavage than BALB/c mice (292) and also 
clear a second BCG infection more rapidly than BALB/c mice (304). BAL13/c mice 
are also strikingly more susceptible than C57BLl6 mice to other infectious pathogens 
like Leishmania major, Yersinia enterocolitica and Chlamydia trachomatis 
infections (305-307). In each case, the increased susceptibility of BALB/c compared 
to C57BLl6 mice has been associated with lower IL-12 and IFN-y but higher levels 
of TH2-type cytokine secretion following infection (305-307). Shibuya el a/ 
suggested that the mechanism for strain differences may related responsiveness to 
IL-12 and demonstrated that optimal induction of IL-12 in BALB/c mice needed IL-
Ia and TNF-a as cofactors which were not required for C57BLl6 mice (308). 
Therefore, despite significant increases in specific IFN-y secreting CD4 t T cells by 
MVA.85A boosting BCG vaccinated C57BLl6 mice this may have been insufficient 
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to significantly improve the strong protective effect afforded by BeG from M. 
tuherculosis challenge. So far, no other vaccination regimen has afforded greater 
protection than BeG in this mouse strain, which may be because the a~ (,04+ T cell 
responses induced by BCG vaccination affords maximal protection from a M. 
tuherculosis challenge in C57BLl6 mice. Alternatively, the induction of other arms 
of immune response like C08+ T cells (induced in BALB/c but not CS7BLl6 mice 
following MV A.8SA vaccination) may be necessary to increase BCG-mediated 
protection in this strain. 
This study demonstrates that MVA.85A vaccination can signilkantly increase HSA 
specific T cell responses induced by BCG in C57BLl6 mice but also highlights the 
strong protective effect of BCG in this strain and the genetic differences between 
BALB/c and C57BLl6 mice. Such divergent protection results in inbred mice strains 
both classified as resistant to M. tuherculosis strains, prompted investigation of BCG 
I MV A.85A vaccination regimens in outbred non-human primates, which are 
described in the subsequent chapters. 
1~2 
6 Prime-boost vaccination 
regimens in rhesus macaques 
6.1 Outline 
A 2 year study using the rhesus macaque (Macaca mulal/a) model was conducted to 
directly compare aerosol and intradermal BeG delivery. Animals were also boosted 
with MVA.85A and different recombinant virus, Fowlpox (F) expressing X5A 
(FP9.85A) to determine whether the significant boosting of T cell responses 
observed in the murine model could be replicated in non-human primates. This study 
involved the development of several immune assays that are described in detail In 
the Materials and Methods section. 
[£I OIJ [ill [illCill ~ 
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Figure 23: Vaccination schedule. Each arrow indicates the week of and type of 
immunisation given. The animals (1 to 6) immunised at each time point are shown in boxes 
above the time line. I =Glyn; 2=Hector; 3=Golf; 4=Gulp; 5=Hal; 6=Harry. The asterisk 
indicates the week of autopsy of animals I to 4. The following abbreviations are used: i.d-
BCG. intradermal BCG (4x I 05 CFU) given into the upper right arm; aero-BCG. aerosolised 
BCG (4x 105 CFU) delivered by a Halolite nebulizer: MV A.85A (5 x I 08 PFU); FP9.R5A 
(5 x108 PFU). Both poxvirus vaccinations were given intradermally into the upper left and 
right arms 
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6.2 Results 
Induction of T cell responses in peripheral blood mononuclear 
cells 
BeG delivered intradermally or by aerosol elicits similar kinetics and T 
cell responses in the blood compartment. 
Antigen specific T cell responses to PPO, 85 culture filtrate protein and X5A peptides 
were compared fortnightly in the tirst 12 weeks following either intradermal or 
aerosol vaccination of 4x I 05 CFU BCG in 4 macaques. The schedule of vaccination 
is shown in Fig. 23. Prior to vaccination, animals produced no T cell response to 
either PPO or 85 protein in ELISPOT but a high frequency of IFN-y secreting cells 
were observed in all animals following non-specific mitogenic stimulation with 
conconavalin A (conA) (> 1000 SFCII 06 cells) (Sigma-Aldrich, Dorset. England) 
(data not shown). Responses to PPO and Ag85A were first detected 3 weeks after 
vaccination in both BeG intradermally (Fig. 24A&B) and acrosol immunised 
animals (Fig. 24C&D). The frequency of response increased until weeks H-12 
reaching comparable levels in all 4 animals regardless of route of vaccination. No 
PPD- or 85A protein- specific T cell responses were detected over the same period in 
the non-vaccinated macaques, Hal and Harry (data not shown). In summary, BeG 
vaccination either intradermally or via aerosol induced a high frequency of PPD- and 
85 protein- specific T cell responses. Similar to the observations made in BALB/c 
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and C57BI/6 mice, Ag85A was immunodominant to rhesus macaques lollowing 
BCG vaccination. 
ELiSPOT perfonned on short-tenn cel11ines 
Cultured EUSPOT performed on short-term cells lines (STCLs) were optimised by 
week 10 of the study. Cells were stimulated with BCG- infected autologous 
macrophages and cultured for 14 days to expand any low frequency 85A-specilic T 
cell pools. Subsequent ELISPOTS on these cell lines detected strong PPD- and 85A 
protein- specific responses in Glyn, Golf, Gulp and Hector at week 12. liolf also 
produced a response to the P25-33 (Table 6.1). STCLs specific for the Ag85A CFP 
were detected in Harry. No antigen specific STCLs were derivcd from Hal, although 
strong IFN-y secretion to mitogenic stimulation with Con A was observed. 
Table 6.]: Antigen specific responses of STCLs perfomled between week 10-29" 
Antigen 
PPD 
85 protein 
1-20 
23 
31 
Glyn 
+ 
Hector 
+ 
+ 
+ 
+ 
Golf 
+ 
+ 
+ 
Gulp 
+ 
+ 
Hal HaIry 
+ 
con A + + + + + + 
U STCL generated by stimulation with BCG-infected autologous macrophages. Cells were fed every ~ 
days with 10 units / well of Iymphocult-T for 2 weeks. STCLs were stimulated for 1l{-20 hours with 
the antigen indicated in the presence of equal numbers of y-irradiated autologous fresh PRMCs 
h + designates a positive ELiSPOT response produced by stimulation of ST( 'Ls. A response was 
designated positive for the response was > 50 SFC / 10' cells greater that control wells which were I) 
non-stimulated STCLs 2) y-irradiated autologous fresh PBMCs plus antigen 
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MV A.85A vaccination of rhesus macaques with or without prevIous 
BeG vaccination 
Between week 12-16, all macaques were immunised with Sx I OX PFU of MV A.XSA 
(Fig. 24A-D). Bloods were taken 2 weeks after vaccination and fortnightly thereafter. 
The dose of vaccine given was deduced from previous studies and was predicted to 
both induce T cells specific to the recombinant antigen and be well tolerated (225, 
309). 
Ex-vivo ELlS POT 
The frequency of BCG induced T cells responses between weeks 12-16 were strong 
but fluctuating from bleed to bleed in all 4 animals (Fig. 24A-D). There is no clear 
data that MVA.85A boosted the frequency of PPD or Ag85 specilic IFN-y secreting 
T cells in BCG immunised animals (Fig. 24A-D). No IFN-y secretion to either PPD 
or the 85 protein was detected two weeks after vaccination in the two animals that 
received MV A.8SA alone (data not shown). A second MVA.8SA immunisation was 
given 5-9 weeks later (Fig. 24A-D). Again, there was no evidence that T cell 
responses were boosted following the second vaccination. 
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Figure 24: Induction of T cell responses following i.d- or aero-BCG 
vaccination and subsequent MY A,85A boosting. Animals were immunised 
intradermally (A & B) or by aerosol administration (C & D) with 4x\O~ CFll 
of BCG (Danish strain 1331). All 4 macaques were given two doses of 
MY A,8SA i.d- at the time-points indicated. The frequency of IFN-y secreting 
T cells specitic for PPD and 8SA culture filtrate protein in the blood. are 
shown. The x-axis shows the week of the study where the week of BCG 
vaccination is week O. Responses are the average of duplicate wells minus 
background and are expressed as spot forming cells/l06 cells (SFCII06 cells). 
Figure 25: FP9.85A vaccination significantly boosts pre-existing 8SA specific 
T cell responses. Each macaque was immunised with two doses of FP9.8SA 
given intradermally at the weeks 42 and 47, as indicated by the arrows below 
the x-axis. The x-axis itself shows the week of the study The left panel (A, C. E, 
G, I & K) shows the frequency of IFN-y secreting T cells specific for PPO and 
85A culture filtrate protein and r85B protein in the blood. The right panel (8. D, 
F, H & J) shows the frequency of IFN-y secreting T cells specific for 8SA 
peptides split into pools of pep tides 1-8. 9-16, 17-24 and 25-33. Responses are 
the average of duplicate wells minus background and are expressed as spot 
forming ceIlslI 0° cells (SFCII06 cells). 
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Animals produce responses to 8SA peptides 
Pools of 20mer peptides overlapping by 10 amino acids spannmg Ag85A and 
recombinant 8S8 (r8S8) were included in assays from week 33 (Fig. 25). 
Re.\ponses in BCG-MVA.85A vaccinated animals: 
Whilst all BCG vaccinated animals produced responses to R5A protein, strong rR58 
responses were also detected in Glyn (80 SFC/\O° PBMCs) and Golf (145 SFCII06 
PBMCs) (Fig. 2SA&E). Low level 85A peptide specific responses were also detected 
in Golf to PI-8 (12.5 SFC/I06 P8MCs), P9-15 (IS SFC/IO° PBMCs) and 1>25-3.\ (25 
SFCII 0° P8MCs), all of which produced responses over 100 SFCII 06 P13MCs in 
subsequent bleeds (Fig. 25F). 
For the first time, low frequency responses were detected to 85A culture-liltrate 
protein (30 SFC/lO° P8MCs) in Harry's blood (Fig. 25.1). Stronger responses to 
r85B protein (65 SFCII06 PBMCs) and 85A P9-15 (85 SFC/IO° PBMCs) were also 
detected showing that MV A.8SA vaccination alone did induce T cell responses (Fig. 
25./). It is unclear why responses to MVA.85A were not detected earlier in this 
animal but the response identified at week 33 was maintained at week 42 showing 
that these responses were real and specific and induced by vaccination. The 8SA 
peptide pool responses in Harry were CD8+ T cell restricted which may explain the 
prior failure to detect a response following stimulation of cells with 85A protein 
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alone (see Table 6.2). No responses to PPD, 85A protein, r85B (Fig. 25K) or the X5A 
peptides (data not shown) were detected in Hal at week 42. 
ELISPOT perfonned on short-tenn cell lines after MVA.85A boosting 
Cultured ELISPOTs were perfonned between weeks 14 and 27. All Bee; vaccinated 
animals produced PPO- and 85A protein- specific STCLs (Table 6.1). A STCL 
specific for 85A protein was also derived from Harry, which reinforced the 
observations in ex-vivo assays showing that MV A.R5A vaccination or Harry had 
induced a de novo T cell response. 
In addition, Glyn, Hector and Golf produced peptide specific responses at multiple 
time-points to P31. Hector also produced a response to P23 (Table 6. I ). 
FP9.85A vaccination of MV A.85A immunised macaques with or 
without BCG vaccination induce both CDS+ and CD4 1 T cell responses 
All macaques were immunised with 5xlOx PFU of FP9.85A at weeks 42 and 47. 
Bloods were taken on the day of vaccination, 7 days post vaccination and 21 days 
post vaccination. The FP9.85A had been previously tested in BALB/c mice and like 
MYA.85A induced specific C08+ and CD4+ T cell responses to the Ag85A peptides 
Piland P 15 respectively (data not shown). 
Glyn (i.d-BCG / MY A.85A I FP9.85A) 
Glyn who had a strong BCG-induced Immune response prior to FP9.85A 
vaccination, did not exhibit any appreciable increase in protein response clearly 
attributable to poxvirus vaccination (Fig. 25A). The response to P25-33 increased 
slightly as did the response peptide 31 (P31) found within this pool (Fig. 25B). 
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Hector (i.d-BCG I MYA.85A I FP9.85A) 
Hector did not exhibit any increase in protein-specific response to FP9.X5A 
vaccination (Fig. 25C). At week 42, a low-level response to P25-33 (22.5 SFCI I<t 
PBMCs) was detected. At week 43, 7 days after the first FP9.85A vaccination, the 
P25-33 responses doubled and a response to P16-24 (37.5 SFClIO fl P13MCs) was 
also detected. The peptide pool responses dropped to background levels by 21 days 
then rose again (~S-fold increase), 7 days after the second vaccination. These two 
peptide pools contained P31 and P23 that induced a positive response in cultured 
ELISPOT after MY A.85A vaccination. Responses to individual peptidcs were also 
examined. No response to P31 was detectable at week 42 but FP9.85A vaccination 
induced a response of ISO SFC/I06 PBMCs at week 43, dropping to less than 50 
SFCIl06 PBMCs at week 45 and then doubling in response to the second FP9.85A 
vaccination (data not shown) (Fig. 2SD). Low level responses to P23 (25 SFClI06 
cells) were also detected 7 days after each FP9.8SA vaccination that then dropped 
back to background levels. 
Golf(aero-BCG I MYA.8SA I FP9.85A) 
The effects of FP9.85A vaccination were much stronger in the remaining animals. 
Golf showed a significantly increased in response to PPD, 8SA protein following the 
first vaccination (Fig. 2SE). The second vaccination did not appear to boost protein 
responses. Responses to PI-8 and P2S-33 were boosted significantly at week 43. 
Pool 1-8 responses increased over ten-fold and responses to P2S-33 from 160 
SFCIIO/l PBMCs to greater than 400 SFC/IO° PBMCs (Fig. 25£). The response to 
P31 doubled but did not account for level of boosting observed in P25-33, which was 
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later attributed to P29 (Table 6.2). The second FP9.RSA vaccination did not boost but 
rather maintained the level of protein or peptide responses at weck 4H. 
Gulp (aero-BCG / MYA.8SA / FP9.8SA) 
Gulp's protein specific T cell responses did not appreciably increasc attcr FP9.H5A 
vaccination (Fig. 2SG). The T cell response to P 1-8 increascd ten-fold to ~500 
SFCIl06 PBMCs and to P16-24 increased from undetectable levels to over HOO 
SFCII Of> PBMCs (Fig. 25H). Here the second FP9.85A vaccination had an effect, 
boosting the peptide pool response to P16-24 (from 100 to --400 SFClIOh PBMCs), 
though not to the same levels as the first vaccination. 
Harry (MY A.8SA / FP9.8SA) 
After the first FP9.8SA vaccination, responses to both PPO and R5A protein 
increased from less than 50 SFCIlOf> PBMCs to several hundred in Harry (Fig. 25/). 
These responses were maintained tor S weeks. Responses to peptide pools 9-15 and 
16-24 were impressive. Peptide pool 9-15 T cell responses were less than ]00 
SFCIlOf> PBMCs at week 42 (Fig. 25J). Responses were boosted to 1200 SFC/IO° 
PBMCs after the first FP9.85A vaccination. Responses to P16-24 were boosted from 
undetectable levels to over 500 SFCIlOf> PBMCs at week 43. These responses 
decreased by week 47 (although were higher than pre-FP9.8SA vaccination levels) 
and were again boosted by the second vaccination. As observed in Gulp, the level of 
boost to the second homologous FP9.8SA vaccination was not as great as the first. 
Hal (MVA.8SA / FP9.8SA) 
MVA.8SA vaccination did not induce detectable T cell responses in Hal in ('.r-vivo or 
cultured ELiSPOT assays despite production of IFN-y to non-specitic mitogenic 
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stimulation at all time points. Following FP9.8SA vaccination responses to pro, 
8SA protein and r8SB were clearly induced (Fig. 2SK). Interestingly, in contrast to 
the other animals for which the peak of response to FP9.RSA vaccination was day 7, 
for Hal the response peaked later, at 3 weeks. These responses dropped back down to 
background levels at week 47 and were not boosted by the second FP9X5A 
vaccination. No responses were produced to the 8SA-peptide pools following 
FP9.85A vaccination (data not shown). 
Characterisation of T cell responses 
PPD and 8SA protein T cell responses were CD4 + dependent 
Depletions were performed using human dynabeads. Flow cytometry showed that 
the dynabeads were less efficient in depleting CD4+ T cells than CDS' T cells in 
rhesus macaque PBMCs. This was reflected in the quality of the results in the 
ELISPOT assays performed on the depleted cells (Table 6.2 and 6.3). Even so, the 
ELISPOT results following C04+ and cmt T cell depletions showed responses to 
PPD and 8SA protein were predominately CD4+ dependent (Table 6.2). 
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Figure 26: Peptide 31 from the 85A aa sequence 
contains a putative MAMU-DR supemlotif to which 3 
of the macaques responded following BeG vaccination 
41. The boxed residues fit the predicted anchor residues 
ofMAMU-DR supermotif. 
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8SA peptide specific responses 
Responses to peptide pools (data not shown) and individual peptides were COX' 
dependent with the exception of P3I (Table 6.3). Peptide 31 was recognised by 
C04+ T cells in 3 of the 4 BCG immunised animals (Glyn, Hector and Golt), first 
detected by cultured ELISPOT and then confirmed in ex-vivo assays. At the time of 
necropsy (14 weeks after the last FP9.8SA vaccination) a P31-specific T cell 
response was clearly detectable in these animals in ('x-vivo ELISPOT (Glyn 57, 
Hector ~ 342, Golf -214 SFCI 106 cells). The p31 sequence tits a predicted MAMU 
OR supermotif for macaques (Fig. 26) (310). It is unclear why the AgXSA peptides 
did not detect more C04+ T cell responses, despite strong C04' T cells response to 
8SA protein in all macaques. In other studies performed in this group these same 
peptides have been used and detected C04+ T cell responses in BALB/c (Chapter 3) 
and C57B1I6 mice (Chapter 4), cattle (E. Taracha, personal communication) and 
humans (311). Together these observations suggest that there may be some 
impairment in the presentation or recognition of C04' peptide epitopes by macaque 
antigen presenting cells or specific C04+ T cells respectively. Further studies are 
needed to investigate these observations. 
In summary, FP9.85A vaccination significantly boosted C04' and COX' 85A 
specific T cell responses in BCG-MVA.85A and MVA.85A immunised macaques. 
Overall, the second FP9.85A vaccination whilst capable of boosting T cell responses 
was not as effective as the first (312). 
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Vaccination with MV A.85A / FP9.85A induces responses to rX5B 
protein 
Ag85A shares significant homology at the amino acid level with R513 (HO%) also 
expressed in the 85 complex. Not surprisingly, vaccination with recombinant virus 
expressing 8SA induced strong responses to stimulation with r8513, which generally 
followed the kinetics of responses induced following 8SA protein stimulation and 
were predominately CD4+ dependent (Fig. 251 & 25.1, Table 6.2). 
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Table 6.2: PPD, 85A and r85B Erotein resEonses are Eredominatel~ CD4' deEendent 
Animals PPD 85A X5H 
"Week "CD4 (% CDR 01<) CD4 o/c) CDS (% CD4 (~/f) ('[)X {!Jo 
depletion depletion depiction depletion depIction depiction 
Glyn 27 72 0 74 25 
50 85 0 100 0 
Hector 27 93 0 71 0 
48 84 12 
Golf 27 100 61 94 0 
48 96 8 72 6 82 
Gulp 27 82 40 
48 100 0 70 0 74 14 
Harry 48 88 0 75 15 88 18 
82 95 6 88 4 
Hal 82 78 2 84 0 
"Week bead depletions were performed 
h % depletion = 100-«number of IFN-'Y specific responses in ELISPOT in depleted cells / number of 
IFN-'Y specific responses in ELISPOT in non-depleted cells) x 100) 
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Table 6.3: 85A peptide specific responses are predominately CD8+ dependent" 
Animals P 1-8 P 9-15 P 16- 24 P 25-33 
peptide %CD4 %CD8 peptide %CD4 %CD8 peptide %CD4 %CD8 peptide %CD4 %CD8 
depletion depletion depletion depletion depletion depletion depletion depletion 
-----~ 
Glyo P3I* 90 0 
Hector P23* 40 100 P3I* 100 30 
Golf P2 2 92 P28 6 8R 
P29 9 96 
P3I* 78 5 
Gulp PI 9 100 P19 12 94 
Hal 
Harry P13 0 100 PH 8 96 
P14 4 100 
"Week bead depletions were performed 
b % depletion = 100 --((number ofIFN-y specific responses in EllS POT in depleted cells number ofIFN-y specific responses in EllS POT in non-depleted 
cells) x 100) 
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Tuberculin Skin Testing 
Intradennal BCG vaccination produces a stronger tuberculin skin test 
(TST) than aerosol BCG vaccination 
Intrademlal or subcutaneous BCG vaccination or infection with M. Ilihercu/osis 
induces a strong DTH reaction to tuberculin PPD in humans. Rhesus macaques also 
produce a positive tuberculin skin test (TST) following M. tuhercli/osis infection or 
intradermal BCG vaccination. The routine TST for macaques is intradermal injection 
of 1250 units of M. havis tuberculin into the eyelid (S Wolfensohn, Veterinary 
Services Oxford University, personal communication). In order to align the macaque 
TST with studies in humans, the animals were injected with M. Ilihercli/osis 
tuberculin in increasing doses (10, 100 and 1000 units). The rhesus macaques were 
tested for TST responses at week 53 (Table 6.4). Tuberculin doses at 10 and 100 
units lacked the sensitivity to detect differences within the group. In response to 
injection of 1000 tuberculin units, the animals intradermally vaccinated with BeG 
produced a positive TST of 3-4 whereas the animals immunised by aerosol produced 
negative response 0-1. 
MY A.8SA / FP9.8SA vaccination alone can induce a strongly positive 
TST. 
Harry and Hal were also given a TST after MV A.85A-FP9.85A vaccination (Table 
6.4). Hal was negative but Harry produced a very positive TST of 4-5 showing 
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recombinant 85A viral vaccinations alone can induce a strong delayed type 
hypersensitivity to tuberculin. 
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Table 6.4: Tuberculin Skin Te&1ins (TST) Results U 
Animal Vaccination Regimen" Tuberculin Dose Weeks post last TST Cumments 
(units) vaccination Grading' 
----~--~-."-
Glyn i.d-BeG / 2xMV A.8SA / 10 1 6 (5) h 0 
FP9.8SA 
102 0 
101 )-4 
Hector i.d-BCG /2xMV A.85A / 101 6 (53) 0 + 
FP9.8SA IO l 0 
101 3-4 
Golf Aero-BCG I 2xMV A.8SAI 101 6(S3) 0 
FP9.8SA 102 0 
10.1 
Gulp Aero-BCG / 2xMV A.8SAI 101 6(53) 0 
FP85A 102 0 
IOJ 2 
Hal 2xMV A.85A12xFP9.85A 10 1 6(S) () 
102 0 
IOJ 0 
103 23 (70) 1-2 
2xMV A.8SAl2xFP9.85A I 103 12 (82) 0 
i.d-BeG 
Harry 2xMVA.8SAl2xFP9.8SA 101 6(S3) 0 
102 0 
101 4-5 + 
2xMV A.8SAl2xFP9.85A I 103 12 (82) 0 
i.d-BCG 
a TST - 1000 units tuberculin given intradermally into right eyelid. Reactions were scored 48 hours 
later 
b Vaccination regimen detailed further in Fig. 23 
C Number in brackets is reference week number described in time line in fig. 23 
TST eyelid grading 0= no reaction (-); I =bruise (-); 2=erythema of palpebrum, no swelling (-); 
3=Erythema of palpebrum and slight swelling (-1+); 4=Swelling of palpebrum, drooped eyelid and 
erythema (+); 5=Swelling and/or necrosis, eyelid closed (+). 
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Induction of T cell responses In secondary lymphoid organs 
and respiratory compartment 
The CD4 t /CD8+ subset ofT cell responses induced by vaccination is the 
same in blood, spleen, lymph nodes and broncheo-Iavage compartments. 
The BCG-MVA.85A-FP9.85A vaccinated macaques were necropsied at week 67. 
Sections of spleen and various lymph nodes were removed lor immunc analysis. Ccll 
preparations were arbitrarily considered viable if conA stimulation produced a 
response in ELiSPOT > 1000 SFC/ 106 cells. Two observations were made from the 
successful assays. The character of T cell responses was maintained between the 
blood and secondary lymphoid tissue (Fig. 27A & B; Table 6.5). Secondly, the 
immunisation with BCG whether given intradermally or by aerosol lollowed by 
intradermal poxvirus boosting, elicited 85A specific T cell responses in the majority 
of lymph node compartments tested (Table 6.4). 
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Figure 27: The restriction of 85A peptide specific T ce ll respon es 
observed in the blood are conserved in the spleen and lymph node sets of 
rhesus macaques. No specific homing of T cell responses was observed. 
The BCG immunised macaques were necrop ied at week 67 . Blood, spleens 
and lymph nodes (LN) sets were removed and 8SA specific T ce ll responses 
were assayed by EllS POT. Compari sons of T cell responses are shown 
between blood and other compartments. Gulp: blood vs. spleen (A); Hector: 
blood vs. LNs (8); Harry: Blood vs. BAL (C). Resul ts shown are the 
average of duplicate wells minus background and are expressed as spot 
forming cellsl l06 cells (SFC/l 06 cells). Assay results for spleens and lymph 
nodes were only accepted ifthe Con A respon es was > 1000 SFC/ I 06 ce lls. 
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Table 6.5: BCG vaccination delivered intradermally or as an aerosol induces specific T cell responses 
in lymph nodes both di stal and prox.imal to the site of injection . 
Lymph Nodes' Glyn Hector Golf Gulp 
~;. 
Hi lar x x 
J 
Axill iary xb,c x x x 
i 
• 
Inguinal x x x x 
lIIiac I x x c' ~ 
1 ';, ,I 
Cervical x x 
',' 
Submandibular x x x 
..: 
i 
Tonsil >< 
a lFN-y ELISPOT assays performed on lymph nodes harvested from macaques at week 67 of study 
b The 'x ' indicates a positive antigen specific response to either 8SA protein or peptide pools. A 
positive response is taken as greater than 20 SFC/ l06 cells over background. Responses in media only 
wells were < 5 SF 1106 cells for all lymph node assays. 
C The shaded cell indicates assays where the frequency of cells responding to con A stimulation was > 
1000 SFCI 106 cells. 
The BCG vaccinated anjmals were also repeatedly bronchoscoped and lung lavage 
conta.ining lung lymphocytes were collected. No erythrocyte contamination was 
observed in the broncheoalveolar lavage fluid (BALF). Responses of BALF T cells 
to PPD and 8SA protein and peptide antigens exhibited the same T cell restriction as 
observed in the blood but were 1-2 logs higher than the blood compartment (Fig. 
27C; Table 6.6). BALF was also taken from Hal and Harry following MV A.8SA-
FP9.85A vaccination. Similarly, strong 8SA-specific T cell responses were detected 
showing that intradermal vaccination with poxviruses alone is sufficient to induce 
specific and strong T cell responses in the macaque lung (Fig. 27C; Table 6.6). 
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Table 6.6: Com£arison ofIFN-yres£onses in Broncheo-alveolar lava~e fluid (BALF) and blood 
Animal Vaccination II Time PPD 85A 
Blood BALF Blood BALF 
Glyn i.d-BCG/2xMV A.85N2xFP9.85A 6 (53) b 180d 2186 
Hector i.d-BCG/2xMV A.85N2xFP9.85A 6 (53) 50 1697 
Golf aero-BCG/2xMV A.85N2xFP9.85A 6 (53) 130 11455 
Gulp aero-BCG/2xMVA.85N2xFP9.85A 6 (53) 67.5 4100 
Hal 2xMV A.85N2xFP9.85A 6 (53) 22.5 1097 0 1192 
20 (67) 175 2300 187 1100 
Harry 2xMV A.85N2xFP9.85A 6 (53) 400 6485 325 8243 
20 (67) 255 800 140 1300 
a Vaccinations received at time oflavage 
b Weeks since last immunisation. Number in brackets refers to week of study outlined in Fig. 23. 
C PPD or 85A protein specific responses expressed as SFC ' 106 cells in ex vivo ELISPOT 
1:'i7 
BALF samples produced a similar cytokine profile regardless of 
vaccination regimen. 
The luminex system enables the simultaneous detection of cytokines within in a 
single sample. This assay was used to analyse BALF samples taken from the 
macaques to determine whether aerosol BeG vaccination had induced a ditkrcnt 
cytokine milieu in the lung. The concentration of cytokines differcd betwecn 
animals. This was probably a reflection of the quality of the sample. All animals 
produced very similar cytokine profiles even from different time-points (Fig. 2H). 
Both type I and 2 cytokincs, IFN-y, IL-4 and IL-13 were detected in all animals (Fig. 
28A-F) and the pro-inflammatory cytokine, IL-8 was detected in three animals, Hal, 
Harry and Golf (Fig. 28A,B & E). 
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Figure 28: Aerosol BCG vaccination does not produce a different cytokine profile 
in broncheo-alveolar lavage supernatant from intradermally vaccinated animals, 
30 weeks after vaccination. Concentrated BALF fluid was obtained at the time-
points indicated and assayed for the presence of cytokines using the luminex 
system. Results are shown for each animal: Glyn (A), Hector (B), Golf (C), Gulp 
(D), Hal (E), Harry (F). Results are expressed as the average pg/ml for lO x BALF 
concentrate for duplicates. 
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Necropsies of BeG vaccinated animals 
Pathology 
Glyn, Hector, Golf and Gulp were necropsied at week 67. In the mice studied in 
Chapter 4, high dose intranasal BCG immunisation produced severe pathology in the 
lung. A major question in this section of the study was whether aerosol delivery of 
human doses of BeG to non-human primates also induced pathology in the lung. 
Thorough gross and histological examination was performed on all organs including 
the lungs for any evidence of vaccine induced pathology (G. Hall, C AMR; Rest 
Associates, Cambridge UK). No abnormalities or ZN positive bacilli were detected 
(detailed pathology reports comprise Appendices 3-7). 
Culture of ZN -positive mycobacteria. 
Lungs, spleen and secondary lymphoid tissue including the hilar lymph nodes were 
cultured for viable mycobacteria. One acid-fast colony was grown from the 
homogenised lung of Hector (i.d-BCG). Following biochemical testing it was 
identified as Mycohacterium Jortuitum (M. jortuitum), which is a fast, growing 
bacterium that is found in water, soil and dust that can transiently colonise the 
respiratory tract in humans (313, 314). 
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BCG vaccination of MV A.85A/FP9.85A vaccinated macaques 
induces a recall response to PPD- and 85A- specific CD4+ T 
cells 
Background 
At week 70, Hal and Harry were both producing strong T cell responses, in response 
to either PPD or 85A-protein stimulation. Both animals wcre vaccinated 
intradermally with 4x lOs CFU BCG. 
BeG vaccination induced lesions at the site of previous MY A.XSA and 
FP9.85A vaccination. 
BCG vaccination induced lesions at the site of prior poxvirus vaccination in both 
macaques (Table 6.7). The lesions did not occur at the sitc of BeG vaccination but 
appeared to correspond with the site of prior poxvirus vaccination. Notably. no skin 
reaction had been observed following vaccination with MV A.R5A and FP9.85A in 
these animals which suggests that the lesions were induced by BCG vaccination. The 
lesions may have been caused by 8SA-specific T cells induced by BeG vaccination 
responding to residual live virus or virally encoded antigen persisting at the site of 
poxvirus immunisation. Whilst each poxvirus immunisation was given over 5 sites. 
only two lesions were produced following BCG vaccination and may be explained 
by viral antigen persisting at only some injection sites. 
Table 6.7: BeG vaccination of animals previously immunised with MV A.85A / FP9.85A induces 
lesions at the site of nor ox\irus immunisation 
Animal a 
Hal 
2xMV A.85A12xFP9.S5A1 
BeG 
Harry 
2xMV A.85A12xFP9.S5A/ 
BeG 
weeks post 
BeG 
3 
Description of pathology 
2 small lesions on right upper arm 
I small red lump (no scah) on righl upper arm. 
2 small lesions on right upper arm 
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3 2 small lesions - both red. one with scab al the top of 
wound. 
4 2 raised plaques of 5-Smm diameter. Well demarcated. 
crusty lesions. Axillary lymph nodes slightly enlarged. 
a MVA.85A and FP9.85A vaccinations given in 5 sites between upper lell and right arms 
h BeG vaccination given in I site in upper right am 
" Pathology descriptions for week I and 3 made by an animal technician and week 4 by an Oxford 
University Veterinary Officer. 
d at all time-points animals were described as being in good health 
Ex-vivo responses post vaccination 
Animals exhibited a classical memory T cell response following BeG vaccination to 
PPO and 8SA protein stimulation 
BeG immunisation induced increased in the frequency of T cells specific for gSA 
and PPO protein in both Hal and Harry (Fig. 29A&B). T cell responses were detected 
a 7 days post BeG vaccination and appeared to peak at week 3. This was earlier than 
in the other BeG vaccinated animals for which responses peaked between 8-12 
weeks post vaccination (inserts Fig. 29A&B). Responses in Hal and Harry declined 
over the next 4 weeks and then plateaued at a steady state level. The peak of 
response was not any greater than the peak observed in the other BeG immunised 
16.1 
animals. This data shows boosting of specific T cell responses by BCG but also 
illustrates a memory recall response in which antigen specific T cells induced by 
poxvirus vaccination expand faster in response to BCG immunisation than na"ive 
cells. CD4+ and CD8+ bead depletions again showed T cell responses to the PPD and 
85A protein to be CD4+ dependent (Table 6.2), 
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Figure 29: BCG vaccination of MY A.85A-FP9,.85A vaccinated macaqUl.'S induces a 
PPO and 85A specific C04+ T cell recall response to but does not boost pre-existing 
8SA specific C08+ T cells. The MY A.85A-FP9.85A vaccinated macaques were 
intradermally BCG vaccinated at week 70 as indicated by the arrows. PPD (A) and 
85A (B) specific IFN-y secretion was assayed over the following 12 weeks and are 
shown in bold. Responses of Glyn and Hector after intradermal RCG vaccination 
from the earlier part of the study are shown in dashed lines to highlight the 
differences in the kinetics of T cell responses between the animals. Weeks are shown 
on the x-axis where the week of BCG vaccination is week O. 
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Figure 30: Tht: arrows designate the week and type of vaccination. The inset shows 
the individual 8SA peptide response assayed over the same period. Responses are 
the average of duplicate wells minus background and are expressed as spot tlHming 
cellsl106 cells (SFC /1011 cells). 
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BCG vaccination does not boost 85A specific C08' responses 
The C08+ restricted peptide responses to P22 and PI4 in Harry were unchanged by 
BCG vaccination showing clearly that BCG vaccination did not boost 8SA spccilic-
C08+ T cell responses (Fig. 30). 
MVA.85A / FP985A vaccination induces C08+ T cell responses lasting lor over a 
year in rhesus macaques. 
At week 112 of the study, 42 weeks after BeG vaccination PPO and 85A T ccll 
responses were still strong. COS+ T cell responses to PI4 (43 SFCIIO() PBMCs) and 
P22 (43 SFC/106 PBMCs) induced by MVA.85A / FP9.85A vaccination wcre still 
detectable in Harry 65 weeks after the last FP9.85A vaccination (Fig. 30). 
Increases in T cell responses with time in the absence of vaccination 
The T cell response to FP9.85A vaccination induced low level PPO and 85A protein 
specific T cell responses at week 43 and 45 in Hal. These responses dropped down to 
undetectable levels by seek 48. At week 67, Hal produced responses to PPD and 85A 
in the order of hundreds of SFCI 101> cells that were maintained bctwcen weeks 67, 
70 and 71 (compare Fig. 25K and Fig. 30). 
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Figure 31:: Analysis of frozen PBMCs shows that the 
MY A.85A/FP9.85A- induced T cell responses specific for 85A culture 
filtrate protein were detectable at weeks 50 and 71 in Hal. Antigen 
specific T cell responses in frozen PBMCs from different time points 
were compared in ELISPOT (A) and 5 day proliferation assays (B). 
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16X 
The mechanism of the apparent increase in Hal's 8SA-specific T cell response was 
unclear. To investigate this observation, EllS POTs were performed on frozen cells 
from bleeds taken at week 39 through to week 76 (Fig. 31). The magnitude of the 
response of frozen cells were similar to that observed in ex-vivo assays and like the 
assays on the fresh cells, showed the clear induction of a memory recall response to 
both 8SA and PPD at weeks 74 and 76. However, in contrast to ex vivo assays where 
no specific T cell responses were detected at week 50 (despite strong IFN-y 
production to ConA) (Fig. 25K), frozen cells from this time point produced specific 
85A- and PPD- T cell responses (140 SFC and 80 SFC/\06 cells rcspectively) (Fig. 
3IA). This suggests that low level T cell responses were not detected in the original 
ex-vivo assays, rather than an increase in the frequency of 85A-specific T cells 
between weeks SO and 67. This observation was supported by proliferation assays 
performed in parallel on the frozen cells in which a positive stimulation index was 
recorded in Ag8SA stimulated cells (SI = 7.6) (Fig.3IB). Assay parameters such as 
the quality of antigen used at weeks 50 and 67 (4 months apart) may explain the 
differences in the frequency of T cell responses observed in the ex vivo assays. 
MV A.8SA and FP9.85A vaccination induces 85A-specific 
antibodies. 
Plasma samples were screened for Ag8SA specitic immunoglobulin, induced 
following the various vaccination regimens (Fig. 32). All 6 macaques had pre-
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existing 8SA specific antibodies (endpoint titrcs were between 4-16) (Fig. 32 and 
data not shown). Non-vaccinated rhesus macaques have been reported to have 
antibodies to M. tuherculosis culture filtrate proteins (315). The H5A specific 
antibodies may have been induced by exposure of the macaques to environmental 
mycobacteria, most of which express the 85 complex of proteins; like thc M. 
Jortuitum cultured from Hector's lung (316). No 8SA specific antibodies were 
induced following intradermal or aerosol BeG vaccination. In 3 of the 6 macaques, 
MVA.85A vaccination boosted antibody titres (Fig. 32). Rcsponses were strongest 
following the second vaccination in 2 animals (Fig. 328&C). A similar observation 
following 2 recombinant MVA vaccinations has been made previollsly in monkeys 
(317). 8SA-specific antibody levels also increased after FP9.8SA vaccination, but 
were modest despite significant increases in specific CD4+ and CDS' T cclls 
observed in the peripheral blood at these time points (Fig. 32 B&C). 
170 
A. 
12s 
Glyn 
I 
I'd'flu; 121t 
O~~-~-~~-~'-~.'~."" •..... '-r.'.' " .. ,' .....• 
(l 2 4 \I l' 
,., ~ " .' ~ " ". 
I ("9l'1"'\ I lot/ X~:, 
B. 
yt, 
~ 
f-
5 M Jv. t-~ '2 
-
" \ 4 (. , , " " • + . ~ 2\ " " ,., \I " 'J ,., + .' .'~. " '" 
c. MVA.S5A MY.\ X5.\ 
12. 
Gulp 
% 
. 
~ 
f-
5 M 
t-
og 
UJ 
'2 
Figure 32: MY A,85A and FP9.85A but not BeG vaccination induce X5A spccitic 
antibody responses detectable in plasma. 85A specific antibody titres in plasma samples 
were assayed over the course of the study. The week of the study is shown on the x-axis 
and the arrows denote the time and type of vaccination received by the animal. A 
response was deemed positive if the average Abs405nm from duplicate wells was> 2 x 
mean (control wells). 
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6.3 Discussion 
This study was conducted to examine the immune responscs induced in a non-human 
primate model by aerosol administration of BeG and also by subsequent boosting 
with recombinant MVA and FP9 viruses expressing the BCG immunodominant 
antigen, 8SA. 
Deposition of BeG into the lungs as an aerosol induced comparable kinetil:s and 
frequencies of T cell responses in the blood as intradermal BeG vaccination. PPD 
and 8SA specific IFN-y secreting T cells were detected 3-4 weeks attcr vaccination. 
The frequency of response rose and peaked between 8-12 weeks post vaccination. T 
cell responses to proteins were CD4+ dependent. Similar responses (slow induction 
of response, gradual rise and CD4+ T cell dominated) had been observcd in 
splenocytes when comparing intranasal (given as a 100111 bolus) and parenteral BCll 
vaccination in BALB/c (Chapter 3). 
At the time of necropsy, Hector had a M. jortuitum infection providing some 
evidence of prior exposure to environmental mycobacteria in these animals and most 
likely explains the pre-BCG vaccination 8SA specific antibody responses detected. 
Black and colleagues have hypothesized that exposure to environmental 
mycobacteria interferes with the induction of IFN-y secreting BeG induced T cells 
(200). Many mycobacteria express the 8SA protein including M. fortuitum (although 
the degree of amino acid homology is not known) (3\6). Brandt and colleagues 
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showed in mice, that certain isolates of environmental mycobacteria (but not M. 
fortuitum) could inhibit BeG replication and diminish BeG-induced IFN-y secretion 
(199). In this study in macaques, prior exposure to environmental mycobacteria 
whilst sufficient to induce antibody responses did not induce PPD or gSA specific T 
cell responses detectable in IFN-y ELISPOT. BeG vaccination of these animals 
induced sustained numbers IFN-y secreting T cells. However, it is not possible to 
exclude that the frequency of IFN-y secreting T cells induced by B( '(J vaccination 
may have been higher in naive macaques. 
In humans, T cell responses against M. tuberculosis in the respiratory compartment 
are important in protection from pulmonary disease (291). In this study no evidence 
was found of specific mucosal homing to either the regional lymph nodes or HALF 
produced by aerosol administration of BeG. Rather, the results from analysis of 
BALF and necropsy lymphoid samples suggests that intradermal vaccination in non-
human primates induces high frequency T cell responses in the respiratory 
compartment and in secondary lymphoid compartments distal and proximal to the 
site of injection. The strong T cell responses induced in the BALF of Hal and Harry 
after intradermal MVA.8SA-FP9.8SA vaccination contrasts with studies in mouse 
models, which show high levels of compartmentalisation of immune responses 
following different routes of viral infection (Chapter 3 see also (275). The homing 
patterns of T cells are not fully characterised in man but it is possible that the T cell 
responses induced in macaques following vaccination are more comparable to man 
than the observations made in inbred mice. As such, the implication of these data is 
that in humans, intradermal vaccination of live bacterial vaccines or attenuated 
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recombinant viruses are sufficient to induce high frequencies of antigen specific cells 
in the lung. In addition, the characterisation T cell responses in the peripheral blood 
(the compartment most available for human studies), appears to be a good surrogate 
for profile of T cell responses in the lung compartment and secondary lymphoid 
tissue, including the spleen. 
To my knowledge, this is the first study, albeit preliminary, to perform multi-
cytokine profiling of the macaque BALF. As such the cytokine profile of a healthy 
lung is not known. All 6 macaques irrespective of vaccination regimens harboured 
similar cytokine profiles in their BALF including both TH I (IFN-y), TH2 cytokines 
(IL-4 and IL-13) and the chemokine, IL-8. To date no studies have been published 
describing cytokine profiles using the luminex system in humans. However, cytokinc 
ELISAS in man and animal models have detected each of these cytokincs in lung 
lavages or secreted by lung cells. A wide literature exists showing increased or 
depressed levels of these cytokines associated with susceptibility or rcsistance to 
pulmonary diseases. For example, IL-13 has anti-inflammatory effects by acting on 
TNF-a and IFN-y in sarcoidosis (318). IL-8 is elevated in HIV -I t patients with 
(319). IFN-y is depressed and IL-4 elevated in lungs of patients with pulmonary TO 
(99, 291). In the present study, cytokines were detected in the HALF in the absence 
of abnormal lung pathology, which suggests that the profi les observed retlect 
cytokines present in healthy lungs including the two macaques receiving BeCl as an 
aerosol. Further confirmation of this observation could be provided by cytokine 
profiling of lung lavages of non-vaccinated healthy macaques. 
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One difference between aerosol and intradermal BeG administration was obscrved 
in the TST response of the macaques. Here, aerosol delivery of BeG was as 
immunogenic as intradermal BeG but produced a lower response to tuberculin 
(320). These observations may reflect ditTerent homing patterns of immune cells to 
the skin following the different routes of immunisation, although since TST is not 
predictive of immunity the relevance this may have to protection from disease is 
unclear (196, 321). This observation may have benefits to tuberculosis diagnostics. 
The TST is an important tool in the deternlination of recent M. tuhaculosis exposure 
but displays poor specificity in people previously intradermally vaccinated with 
BeG. Further studies are needed, but delivery of BeG as an aerosol may help avoid 
issues of specificity in the use of the TST for M. tuherculosi.\· contact tracing. 
The hand-held aerosol device engineered for humans enabled delivery of a deli ned 
BeG dose without adverse effect to infant macaques through a paediatric mask and 
suggests that widespread human aerosol BeG vaccination is tenable. Aerosol 
delivery of vaccines provides several advantages over intradern1al delivery. Aerosol 
vaccination is non-invasive and therefore avoids risks associated with parenteral 
injections like issues of safe disposal of syringes, particularly relevant in HIV 
endemic areas. There is some experience of aerosol delivery of vaccines in man. The 
measles vaccine, which is an attenuated strain of the airborne measles virus has been 
delivered successfully as an aerosol to over 1.5 million people including children for 
over a decade in Mexico (322, 323). A theoretical risk associated with any nasal 
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route of immunisation is vaccine-induced encephalitis, produced by infection of the 
CNS via the olofactory lobe that is also accessible via the respiratory compartmcnt. 
Necropsies of macaques in this study detected no AFB or histological abnormality in 
the nasal turbinates or olfactory bulb nor any inflammation of the meninges. No 
clinical features of tuberculosis-like disease such as coughing, lethargy or weight 
loss in the macaques were recorded during in the year following vaccination. 13('( I 
has been given previously as an aerosol to adults and children and repeatedly and 
very high doses to metastatic cancer patients (324, 325). Respiratory function tests 
and post-mortem examination of the cancer patients who received aerosolised BeG 
showed no pulmonary dysfunction or disseminated BeG infection. Household 
contacts and relatives remained PPO skin test negative throughout the study period, 
suggesting vaccinees were not infectious after aerosol BeG administration (325). 
Prima facie, BCG vaccination by aerosol is safe and well tolerated however further 
testing is required, particularly toxicology studies at earlier time points following 
vaccination. In summary, we show that delivery with BeG is possible and safe and 
that it induces comparable levels of responses as intradermal immunisation. 
The six macaques were twice immunised intrademally with MV A.8SA (5-9 weeks 
apart) then 21 weeks later received two FP9.85A vaccinations (5 weeks apart). 
MVA.85A vaccination induced no 8SA specific CD4+ T cell responses in ELISPOT 
in the naIve macaques. No C04+ restricted T cell responses by MV A.8SA 
vaccination was recorded in the 4 BeG immunised animals but a small but bona fide 
increase in 8SA antibody titre was recorded in 3 animals. It is unclear why 
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MYA.8SA did not boost 85A specific C04+ T cell responses induced by BeG as 
was observed in BALB/c and C57BLl6 mice. It is possible T cell boosting in 
response to MY A.85A vaccination may have been missed because the BeG induced 
T cell response was still strong and fluctuating between weeks 12-16 or because of 
technical issues. 
The inclusion of peptides spanning 8SA-protein sequence in EllS POT assays 
identified T cell responses produced by MY A.8SA vaccination in Harry and Golf. In 
BALB/c mice, MY A.85A vaccination was able to boost low level COg t T cell 
responses induced by BCG. In this study we observed no evidence MYA.HSA 
boosting of BCG induced C08+ T cell responses. The differences between these 
studies may be a function of dose. Boosting of BeG induced CD8+ T cells in mice 
was only observed following high dose BCG vaccination (I07CFU) and lost at lower 
doses. Here, the macaques received the human BeG dose, which can induce H5 
specific C08+ T cell responses in man, but at low frequencies (133). 
The macaques were further vaccinated with FP9.85A, which has been shown to 
significantly boost C08+ T cell responses following a DNA or poxvirus prime (326). 
FP9.85A vaccination either induced or significantly boosted existing CD4 t and 
CD8+ T cell responses in all 4/6 macaques. Responses peaked at day 7 with the 
exception of Hal, in which responses peaked 3 weeks after vaccination. A second 
FP9.85A vaccination further boosted responses in several animals but not as strongly 
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as the first vaccination. Peptide pool responses were C08' whilst PPO and AgX5A 
protein responses were almost wholly C04+ dependent. 
Hal and Harry that had both received two vaccinations each of MY A.8SA and 
FP9.85A were intradermally vaccinated with BCG at week 70. At this time both 
animals were producing strong C04+ restricted T cell responses to both PPO and 
85A protein and CD8+ restricted T cell response to p22 and p 14 were clearly 
detectable in Harry. Following BCG vaccination both animals exhibited a recall 
response to C04+ T cell PPO and 85A protein. Responses peaked at 3-4 weeks post 
vaccination rather than 8-12 weeks as had been observed in the study. The peak or 
response was no greater than earlier observed. BeG failed to boost the COX' 
dependent T cell responses in Harry. 
Animals were given TST to determine whether MY A.85A-FP9.85A vaccination had 
any effect of BeG induced TST. Prior to BeG vaccination but after MYA.XSA-
FP9.85A vaccination, Harry was strongly positive demonstrating that vaccination 
with recombinant viruses expressing just 8SA is sufficient to produce positive skin 
test to tuberculin. In people, OTH to TST has been shown to peak 2-3 months after 
BCG vaccination (327). Animals were skin tested 12 weeks and again 40 weeks after 
intradermal BCG vaccination. At both time-points, the animals failed to produce a 
positive skin test. Losses of TST reactivity have been reported in both primates and 
humans. Prior BCG vaccination can render M tuherculosis infected macaques 
unresponsive to tuberculin (256, 320). In humans, Hoft and co-workers showed that 
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a TST response was no longer detectable in intradem1ally vaccinated humans when 
they have been previously primed with oral BCG vaccination (321). Together this 
suggests that vaccination with MY A.85A I FP9.R5A may render macaques, anergic 
to subsequent DTH reaction to tuberculin. The mechanism of this inhibition is 
unclear but could result from differences in the phenotype of the T cells induced by 
MY A.85A/FP9.85A or BCG vaccination. Whilst both vaccination rcgimens wcre 
given intradermally and induced IFN-y secreting T cclls, differences in cytokine 
production or expression of integrins that mediate traflicking of the T cells to and 
from the skin may exist. Furthcr characterisation using flow cytomctry and multi-
cytokine secretion assays of the T cells induced by MYA.85A1FP9.85A vaccination 
compared with BeG vaccination will help to elucidate the differences in TST 
responses observed. 
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7 BCG-MVA.85A-FP9.85A 
vaccination of cynomolgus macaques 
7.1 Results 
Challenge 
Cynomolgus macaques (Macaca fascicularis) were intradermally vaccinated with 
4x lO5CFU of BCG (BCG Copenhagen, SSI). 12 weeks later, the animals wcrc 
immunised with MY A.8SA (Sx lOx PFU) and after S weeks vaccinated with FP9.85A 
(5 x lOx PFU) (Fig. 33). Both poxvirus vaccines were given intradermally to both 
upper left and right arms. Three control animals were included that had received an 
adjuvant preparation that had been shown previously to afford no protection from 
tuberculosis disease (J. Langermans, personal communication). The third group in 
the study received 4x 105CFU of BCG alone. Animals were challenged 
intratracheally with 1000 CFU M. tuherculosis (Erdman strain) 5 weeks allcr their 
last vaccination and monitored for 6 months. The challenge was supervised by Jan 
Langermans (BPRC, Rotterdam. Holland). The challenge perameters were designed 
following consultation between Jan Langermans, Adrian Hill and myself. A 
summary of challenge results presented in Table 7.1 but is not part of this thesis. All 
animals in the control (no BCG) group had caseating granulomas in their bronchial 
lymph nodes. In the BCG only group, one animal showed no abnormalities following 
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gross examination whereas the remaining two animals had involvement 10 the 
bronchial lymph nodes though to a lesser extent than the control animals. In the 
BeG-MV A.85A-FP9.85A group, two of the three animals were normal on gross 
examination but the third had open cavitatory tuberculosis with lesions in the spleen 
and lung. The results from the challenge were promising and suggested that the 
BeG/MV A.85A1FP9.85A vaccination regimen may increase BCG-mediated 
protection in cynomolgus macaques. Further, studies are underway to understand to 
explain the severe disease pathology (worse than control animals) observed in one of 
the BeGIMV A.85AIFP9.85A vaccinated animals. All macaques in this study were 
outbred and this animal may have been particularly susceptible to mycobacterial 
disease. The immunogeneity data presented was performed in Oxford in an effort of 
optimise immunogenicity assays in this species of macaque. 
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Figure 33: Vaccination schedule for cynomologous macaques. Each 
arrow indicates the week of and type of immunisation given. All animals 
were challenged with M. tuherc:u/o.l'i.l' at week 27. The following 
abbreviations are used: i.d-BeG, intradermal BeG (4 x IO~ CFU) given 
into the upper right arm; MVA85A (5 x 1OR PFU); FP9.R5A (5 x IOX PFU), 
i.t - intratracheal. Both poxvirus vaccinations were given intradcrmally 
into the upper left and right amlS. 
lX2 
Table 7.1 Gross pathology results following M. fuherclI/O.l'i,I' challenge of BCli-MVA.X5A-FPQ,X5A 
vaccinated cynomolgus macaques 
Reference Vaccination Description of Gross Pathology at necropsy' 
---------.-
J-455 MPUDDA adjuvant Involvement of RLN d granuloma & caseation / 
some lesions 
J-462 MPUODA adjuvant Involvement of RLN granuloma & caseatioll / 
some lesions 
J-466 MPUDDA adjuvant Involvement of BLN granuloma & caseation I 
some lesions 
J-450 BeGh Normal 
J-460 BeG Limited involvement RLN 
J-463 BeG Limited involvement RLN 
J-457 BeG-MY A.85A- Normal 
FP9.85A 
J-458 BeG-MY A.85A- Normal 
FP9.85A 
J-459 BeG-MY A.85A- Open TB large lesion lower left lobe of lung, 
FP9.85A lesions in liver & spleen 
- --- - -- -- - --------_.- -~--- _. 
a macaques were challenged intratracheally with 1000 CFU M. fuhl'rClI/Il.l'i.l' (Erdman strain) 5 weeks 
after the last vaccination. Necropsies were conducted 6 months after challenge. 
h 4x 105 CFU BeG (Danish 1331) given intradermally 
'5 x 10' PFU MYA.85A or FP9.85A given intradermally 
d BLN=bronchiallymph nodes 
Optimisation of immunogenicity assays III cynomolgus 
macaques 
ELiSPOT assays 
Frozen PBMCs from a non-vaccinated cynomolgus macaque were assayed by IFN-y 
ELiSPOT using the same protocol described in rhesus macaques (Fig, 34). Cells 
were stimulated for 20 hours with PPD, 85A protein, 5J.1g/ml streptokinase: 
streptodornase (SKSD) and the non-specific mitogen, ConA. The response from non-
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stimulated cells was about to 10 SFC/JO° at a concentration of 2x 105 cells/well. 
PPO stimulation did not produce a response above control wells. Low level 
responses were observed at the 2x J05 cell/well concentration to 85 protein « 10 SFC 
/ 10° cells) and SKSO (~IO SFC / 106 cells) (Fig. 34A). ConA stimulation 
demonstrated that cynomolgus PBMCs could produce strong IFN-y secretion (> II 00 
SFC / J00 cells) in this assay stimulation (Fig. 34B). The frequency of ConA-specific 
responses decreased with cell concentration. 
Immunogenicity results from vaccinated cynomolgus macaques 
PBMCs frozen at different time-points following vaccination were then tested in 
ELISPOT (Fig. 35). Cells from control animals (adjuvant only) were also included in 
the assays. Responses to conA were consistent and strong (>600SFCI I Ot> cells) in all 
samples tested. Non-stimulated cells produced low background «20 SFC / IOn cells) 
in two of the four animals (Fig. 35A&C) and higher non-specific responses (~50 SFC 
/ 106 cells) in the others (Fig. 35B&D). The level of background was consistent 
between all the time-points tested. No 8SA peptide-specific T cell responses were 
detected at any time-point. Following stimulation with PPO, a response of ~ 200 
SFC / J00 cells was detected on a naive macaque (adjuvant only) but not to any of 
the BCG-MVA.85A-FP9.85A vaccinated animals. 85A protein responses were 
consistently above background (100-500 SFC / 106 cells), including pre-vaccination 
time-points and in the control animal. 
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Figure 34: PBMCs of non-vaccinated cynomologous macaques prod uce IFN-y 
in response to stimulation with Conconavalin A ( onA). PBM from a na'ive 
ma.caque were timulated with several antigens a well a onA in different 
cell concentrations in an ELISPOT well . Di fferent ca les for the y-axi are 
shown in (A) & (B). Respon es are shown as the average pot-forming cell 
from duplicate wells. 
Figure 35: BCG vaccination of cynomologous macaque does not induce PPD, 
85A culture filtrate protein or 85A peptide specific- IFN-y secreting T cell in 
ELISPOT. Assays were performed on PBM s from an animal from the ontrol 
group (A) and on macaques from the B -MY A.85A-FP9.85A vaccinated 
groups (B)-(D). Re ponses are shown as the average spot-forming ce lls per 
million PBMCs (SFC/ I06 cells) from duplicate we ll from diFFerent time-
points. The time of the bleed is expres ed as the la t vaccination plu a 
numeral , where the numeral represents the number of week post-vaccination . 
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Proliferation Assays 
Previous studies in rhesus macaques had shown that the level of proliferation 
following incubation of J H in either 3 or 5 day old cultures was similar (data not 
shown). Cells from a non-vaccinated cynomolgus macaque were tested to conlirm 
whether the assay also worked in this species. A stimulation index (SI) of > 10 to 
con A was observed (Fig. 36A). In the single sample provided from a non-vaccinated 
cynomolgus macaque, strong proliferation to 8SA protein but not to PPD was 
observed. 
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Pigure 36: BCG vaccination does not induce proliferation to PPO or 8SA culture filtrate protein 
in cynomologous macaques. Proliferation assays were perfonned following timulated with 
PPD, 8SA cu lture filtrate protein or Conconavalin A ( onA) a nai've macaque (A), on 
macaques from the BCG-MY A.8SA-FP9 .. 8SA vaccinated groups (8), ( ), (D) and an animal 
from the control group (E). The I index i expressed as the fold increa e in proliferation of 
cells stimulated with antigen over non-stimulated cells. 
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Proliferation assays performed on cells from the animals in the study (control and 
BCG-MY A.85A-FP9.85A vaccinated) did not proliferate in response to PPD but 
proliferated strongly to the 85A protein (Fig. 36 B-E). The pattern of 85A-specific 
proliferation over the various time-points in the 3, LKG-MY A.X5A-FP9.X5A 
vaccinated animals reflected the con A responses. This, together with the positive 
proliferation to 85A protein in non-vaccinated animals suggests cells were 
responding to non-specific mitogenic component in 8SA culture-filtrate and not H5A 
antigen itself. 
7.2 Discussion 
In humans, a hallmark of BCG vaccination is the induction of IFN-y following PPD 
stimulation of PBMCs (200). Failure to produce IFN-y in response to BeG 
vaccination can lead to uncontrolled growth of BCG within patients (65). In this 
study, the ELISPOT and proliferation assays developed in cynomolgus macaques 
demonstrated that BCG vaccination despite affording significant protection against 
M. tuberculosis challenge, did not induce PPO-specific IFN-y secreting T cells. 
These data are supported by a previous study showing PPO stimulation of PBMCs 
from BCG vaccinated cynomolgus macaques produce 3 fold less IFN-y in ELISA 
compared with BCG-vaccinated rhesus macaques (207). In either the absence of T 
cell derived IFN-y or very low levels of IFN-y (below the limit of detection of the 
ELiSPOT assay), it is unclear by what mechanism BCG induced protection in these 
animals. 
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An alternative explanation for these results is that BeG vaccination did induce IFN-y 
secreting T cells but that the in vitro immune assays failed to detect the speci fic cells. 
It is possible that either the assay lacked sensitivity generally or the frequency of 
IFN-y secreting T cells was below the limit of detection of the assay. The former is 
less likely as ex vivo cells did produce strong IFN-y and proliferative responses to 
non-specific mitogen stimulation and these animals. The latter point could be 
examined by the culture of cells to expand the mycobacterial specific T cell pools. 
Cynomolgus PBMCs can produce IFN-y to PPD and R5A protein in ELISA and 
ELISPOT after M tuberculosis challenge when lungs contain very high numbers of 
replicating bacilli (J. Langernlans. personal communication). This suggesL" that that 
BCG vaccination is not sutliciently virulent to induce IFN-y secretion in this species 
and that the protection from disease observed in this study was afforded by immune 
responses other than IFN-y production. 
Identification of the immune mechanisms induced by BeG in cynomolgus macaques 
will be important to understanding the broader host immune response that may be 
involved in protection from tuberculosis disease in humans. Until such time, the 
contribution of this macaque model to testing T cell vaccines is limited because the 
lack of informative immunogenicity data prevents determination of correlates of 
protection from disease. Development of a wider array of immune assays examining 
the production of other cytokines such as TNF-a and characterising other 
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lymphocyte subsets induced by BeG vaccination In cynomolgus macaques IS 
warranted. 
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8 Concluding Remarks 
8.1 Summary of results 
In humans, the protection afforded by the BCG vaccine is primarily mediated by the 
induction of IFN-y secreting T cells, predominately of a CD4+ T cell phenotype, that 
cross-react with M tuberculosis proteins (200). Despite the induction of spccific 
IFN-y secreting T cells in most BCG vaccinees, protection from BeG is variable and 
wanes with time ( I I). 
In this thesis, strategies to Increase the protective efficacy of BCG have bcen 
investigated in animal models of tuberculosis disease. These include, I) boosting 
BCG-induced, IFN-y secreting CD4+ T cells 2) the de novo induction or the boosting 
of Ag85A specific CD8+ T cells and the 4) induction of higher frequencies of CD4' 
and CD8+ T cells in the lung mucosa by intranasal or aerosol delivery of BCG or 
recombinant poxvirus vaccines. 
BeG vaccination 
BCG vaccination induced long-lived T cells in both BALB/e and C57BLl6 mice. In 
BALB/c mice, PPD- and 85A- specific CD4+ T cell responses were detcctable 1 year 
after vaccination, although there is some evidence of waning of the BCG-mediated 
protective response following M tuberculosis challenge. PPD- specific T cells were 
also detectable in C57BLl6 mice 9 months after vaccination at which time BeG 
conferred significant protection from challenge. 
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In BALB/c, CS7BLl6 and rhesus macaques 8SA specific T cells were strongly 
induced in the lungs and spleen following BCG vaccination. At all time-points tested 
in BALB/c, C57BLl6 and rhesus macaques, 8SA-specific protein or pcptide 
responses constituted 20-80% of total PPO response, suggesting that Ag8SA is an 
immunodominant following BCG vaccination. 
In cynomolgus macaques, although BCG vaccination afforded significant protection 
from M. tuberculosis challenge, no PPO- or 8SA- specitic T cell responses response 
were detected following BCG vaccination. 
Poxvirus vaccination 
The kinetics of the frequency of T cells induced by recombinant MY A or FP 
vaccination differed greatly from BCG vaccination. In mice, responses in the spleen 
or LN peaked at 5 days post vaccination and decreased by a log, 10 days following 
MY A.CS vaccination. Similar kinetics were observed in FP9.8SA vaccinated 
macaques in which 8SA peptide specific T cell responses peaked at day 7 post 
vaccination dropping down - 3-fold by 3 weeks post vaccination. 8SA-specific CD4+ 
T cell restricted responses were detectable 6 months after vaccination (last time-
point available before BCG vaccination) in Hal and Harry. C08+ T cell responses 
were detectable 15 months after FP9.85A vaccination. 
Heterologous Poxvirus boosting 
Some work was performed on heterologous poxvirus boosting (without BCG) using 
malaria antigens in BALB/c mice and using 85A antigen in rhesus macaques. The 
results show in mice that heterologous prime-boost induces higher frequencies of T 
cells in the LLN than homologous vaccination. Further testing is needed to compare 
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MY A-FP9 or FP9-MY A directly against BCG-MY A-FP9 and other prime-boost 
strategies like DNA-MY A in mouse and macaque models. 
Boosting R5A .\pecific CD4+ T cells 
In BALB/c, C57BLl6 mice and rhesus macaques significant increases in either the 
frequency of BCG-induced 85A specific IFN-y secreting CD4+ T cells or HSA 
specific proliferation was observed following poxvirus boosting with either 
MYA.85A or FP9.85A. Recombinant poxviruses have been shown previously to 
boost DNA and protein induced T cells but this is the first demonstration of boosting 
of bacterial prime with a virus in mice and non-human primates. Conversely, 13C<.i 
immunisation of rhesus macaques previously immunised with MYA.HSA and 
FP9.85A induced a recall T cell response to 8SA. 
The induction of 85A specific CD8+ T cells 
Poxvirus boosting of BCG-induced CD8+ T cells was dependent on the BeG dose. 
The human dose of BCG given to the rhesus macaques did not induce CDH' T cells 
in ex vivo assays and did not appear sufficient to prime a CD8+ T cell response after 
MYA.85A vaccination. The induction of 85A specific T cells was demonstrated 
using DNA.85A / MY A.8SA vaccination in mice or MY A.85A / FP9.85A 
vaccination in macaques. Together this suggests that in humans a single vaccination 
with either MY A.85A or FP9.85A may be insufficient to significantly expand 
specific CD8+ T cell responses. Heterologous vaccination regimens such as 
DNA/MY A or MY AIFP9 may be required to induce CD8+ T cells, independent of 
BCG vaccination. 
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The induction of CD4+ and CD8+ T cells in the lung mucosa hy intranasal or aerosol 
delivery afvaccines 
There was a clear difference between murine and non-human primate models in the 
induction of T cells in secondary lymphoid tissue following vaccination. The studies 
in BALB/c mice demonstrated that the induction of specific T cell responses \0 
regional lymph nodes is highly compartmentalised and dependent on route of 
vaccination. Vaccination with poxviruses or BeG induced responses in thc LN 
draining the site of injection but not in distal LN. As such, in BALB/c Illlce. 
intranasal immunisation was the best route of immunisation for the induction of 
specific T cells in the respiratory compartment. In rhesus macaques, parenteral 
vaccination induced very high numbers of specific T cells in the lung compartment 
and T cell responses in most lymph node sets. In terms of induction of T cells in the 
lung, there was not clear benefit of aerosol administration compared with parenteral 
vaccination of BCG. 
Intranasal hoosting increases specific T cell responses in the rl'spiratOlY 
compartment 
The impact of intranasal boosting by BCG or MV A.85A significantly increased 
protection from aerosol M tuherculosis challenge in BALB/c mice in both the lungs 
and spleen. This correlated with the detection of 8SA-speeific CD4 t T cells in the 
LLN at the time of challenge and provided a correlate of protection from lung 
disease in this mouse strain. These same vaccination strategies failed to increase 
protection in CS7BLl6 mice highlighting the impact of genetic heterogeneity in 
protection from tuberculosis disease. 
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8.2 Future Directions 
Overall, these data provide promise that BCG-induced specific T cell responses can 
be boosted with recombinant poxviruses expressing Ag8SA in humans. The question 
remains whether the boosting of a BeG immunodominant antigen that is also 
expressed by M. tuherculosis is sufficient to increase protective efficacy against 
human tuberculosis. This question is further complicated by the many clinical 
manifestations of tuberculosis disease (primary Ireactivation I fe-infection discasc 
and/or pulmonary I systemic disease) against which poxviral boosting Of mucosal 
vaccination may have variable success. In addition, factors like HIV-I infection, thc 
variability of BCG protective efficacy, exposure to environmental mycobacteria and 
anti-poxvirus vector immunity may all impact on the success of these vaccine 
regimens in man. These questions can only be answered by Phase III field trials that 
in the past have run over decades and involved thousands of patients ( 196). As such, 
the development of animal models mimicking factors such as latent infection, 
environmental exposure and HIY -I will be beneticial to further test the cfficacy of 
poxvirus boosting and/or mucosal vaccination regimens and expedite the whole 
process. 
Protection against reactivation disea~e 
The aerosol mouse challenge developed early in this project is a model of primary or 
acute disseminated disease. Extrapolating to humans, the protection results and 
significant increases in specific CD4+ T cells produced by intranasal vaccination 
with BCG I MY A.8SA in BALB/c mice are promising for protection against 
childhood and systemic disease. Collaborative studies in guinea pigs have shown that 
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BCG / MV A.85A / FP9.85A afforded significantly greater protection than Beli alier 
M. tuherculosis challenge. The guinea pig model is also an example of post-primary 
disease where the read-out of protection is survival following lung infection with M. 
tuherculosis. 
These studies are not infom13tive as to whether these vaccine regimens will afford 
any protection from reactivation of disease that often manifests in adulthood 
following years of latent M. tuberculosis infection. Models of latent M. tuberculosis 
infection have been developed in mice models where tuberculosis is reactivated 
spontaneously or by immunosuppression (328, 329). Experiments are planned to test 
the efficacy of BCG boosting and! or mucosal vaccination regimens in this model to 
determine whether vaccination can prevent reactivation of disease. 
Antigens other than Ag85A may be more effective to prevent reactivation of disease. 
During latent infection, M. tuberculosis bacilli are believed to persist in a non-
replicating state that no longer expresses high levels of the 85 complex (170). The 
16kDA antigen, like the 85 complex is a secreted protein by M. tuherculosis and 
BeG but is also expressed in vivo and in vitro in persistent non-replicating 
mycobacteria; and is also being investigated as a target antigen for the prevention of 
reactivation (170). 
Protection from re-infection 
The rate of tuberculosis, arising from re-infection increases in tuberculosis endemic 
regions and increases against in HIV-l positive individuals. No animal models of re-
infection have been reported, most likely because guinea pigs, mice and rhesus 
macaques are highly susceptible to M. tuherculosis infection and cannot contain the 
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primary infection without antibiotic treatment. Cynomolgus macaques are more 
resistant to M. tuberculosis infection and can contain infection at a sub-clinical state 
(208). However, the lack of specific IFN-y secretion following mycobactcrial 
infection and poor TST responses produced in this animal suggests it would be 
difficult to identify latent infection for which the test is specific IFN-y secretion to 
ESAT -6 antigen or a positive TST. Future clinical trials will have to include 
extensive characterisation of M tuberculosis sub-strains to distinguish between re-
infection and reactivation of disease. 
Protection in HIV-I infected individuals 
The progressive loss of C04+ T cells caused by HIV -I infection signilicantly 
increases progression to tuberculosis disease (117). It is unknown whether a 
tuberculosis T cell vaccine will be successful in preventing tuberculosis in HIV-I / 
M. tuberculosis co-infected in the absence of either effective anti-retroviral therapy 
to maintain C04+ T cell levels and/or an effective HIV-l vaccine. 
Several studies have been published in rhesus macaques modelling co-infection with 
M. tuberculosis and SIV or SHIV (SIV / HIV chimeric virus) (119). To date, none 
have tested vaccines beyond BCG. These models would be highly informative to 
determine the contribution of C08+ T eell mediated protection against tuberculosis 
disease in CD4+ T cell depleted animals. This model would also enable the 
examination of combinations of M tuberculosis vaccines with anti-rctroviral 
therapies or HIV -I vaccines. 
The demonstration that BCG can be delivered as an aerosol will be of particular use 
in HIV -I endemic areas to minimise usage of syringes and decrease reliance on 
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expertise In vaccine delivery. However, studies cxamining the aerosol delivery of 
BeG to SIY+ macaques are necessary to exclude questions arising of increased 
toxicity of the vaccine delivered by this route. 
Protection against pre-existing environmental mycohacterial injection 
Studies in both mice and guinea pigs have shown that exposure to certain types of 
environmental mycobacteria inhibit BeG replication and protective efficacy. 
Recently, Brandt and colleagues have published that immune responses induced by a 
subunit vaccine expressing 8SB- and ESA T -6- fusion protein were not inhibited by 
prior exposure to environmental mycobacteria (199). Similar studies need to be 
performed to test the protective efficacy of poxviruses expressing RSA. It is unclear 
whether aerosol delivery of BeG or poxviruses will be more or less inhibited by 
prior exposure to environmental mycobacteria than parenteral vaccination. Most 
environmental mycobacteria are found in soil and drinking water and would infect 
via the gut. 
No studies have been published in macaques on the effects of environmental 
mycobacterial exposure to BeG-mediated protection. The strong induction of PPO 
specific IFN-y in BeG vaccinated rhesus macaques like that observed in humans 
suggests that parallel studies such as by Black et at could be conducted in macaques 
looking at effects of environmental mycobacteria on BeG IFN-y production (200). 
These studies could be taken further and examine the effects of exposure to 
environmental mycobacteria on the immunogencity and protective efficacy of 
MVA.8SA and FP9.8SA without BeG priming. 
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MVA.85A / FP9.85A as a post-exposure vaccine 
BCG is ineffective as a post M. tuherculosis exposure vaccine (262). Indeed 
pathology worsened following BeG infection of animals chronically infected with 
M. tuherculosis. This is referred to as the Koch phenomena and is believed to result 
from exacerbation of the immune response produced by BeG infection. 
It is possible that MV A.8SA or FP9.8SA may work as a post-exposure vaccine 
because neither vaccine is dependent on replication for expression of its recombinant 
antigen. Immunisation with recombinant poxviruses, in M. tuhercu/osis infected 
though healthy individuals, has two implications. The issue is the timing of poxviral 
boosting of BeG immunised children. In the developing world, the high levels of M. 
tuberculosis exposure mean that whilst children are BeG vaccinated at birth, it is 
likely that many will become M. tuberculosis infected during childhood. Prior M. 
tuberculosis exposure will have an impact on when children should be boosted ie 
early in infancy before M. tuherculosis infection or perhaps 10-IS years later when 
BCG protective efficacy is thought to wane. The second issue is whether MV A.XSA 
or FP9.8SA vaccination of M. tuherculosi\' infected individuals will exacerbate 
pathology and can be investigated using histological analysis. 
U\'ing poxviruses as vaccine vectors for other diseases 
The reintroduction of the vaccinia virus vaccine and the use of MV A as vaccines in 
the study of other infectious diseases (most notably, HlV-I, hepatitis and malaria) 
may induce cell-mediated responses against the viral vector. It is unknown whether 
anti-vector immunity will inhibit the induction of 85A specific T cells produced by 
MV A.8SA vaccination, although studies are ongoing. Other groups are invcstigating 
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the use of different viral vectors (examples include - Semliki Forest virus and 
Sindbis virus) that do not cross-react with vaccinia virus to circumvent this problem. 
Identifying correlates of protection 
There is clear evidence in humans that IFN-y signalling and C04 t T cclls arc 
essential to host immunity and protection from mycobacterial disease. Accordingly, 
in BALB/c mice, the induction of 8SA specific IFN-y secreting C04 t T cells in the 
LLN correlated with protection. However, unlike disease such a mcasles whcrc 
antibody titres clearly correlate with protection, T cell vaccines may require the 
analysis of susceptible and resistant phenotypes that is using more than I assay and I 
cytokine. Both TNF-a and Th2 cytokines have been implicated in resistance and 
susceptibility to disease. In this study muIti-cytokine analysis was used successfully 
and this and similar techniques hold promise for broader characterisation of disease 
resistant and susceptible phenotypes. 
How have these studies contributed to vaccine development again-a tuherculosis 
disea<;e? 
M. tuherculosis is a patient and insidious pathogen. However, in many countries the 
incidence of tuberculosis disease has decreased from epidemic proportions to low 
levels though the use of effective contact tracing, chemotherapy and improved living 
conditions. The degree of contribution of BeG vaccination to this decrease is 
controversial. 
In the developing world, despite the efforts of the DOTS programme, tuberculosis 
disease continues to rise. This is due to sub-optimal levels of case detection, non-
compliance with chemotherapy, HIV-l infection and poorer standards of living like 
201 
overcrowding and malnutrition and the low protective emcacy of 1K'(i from 
pulmonary disease. It is in this population that an improved BeG vaccine will have 
the greatest impact. 
These studies have advanced the use of poxviral vectors as tuberculosis vaccines and 
have also strengthened the case for lung delivery of vaccines for the induction of 
mucosal immunity and as an alternate and safe route of vaccination. Poxviral 
vaccines and mucosal delivery of vaccines are approaches to tuberculosis vaccine 
development that are immunogenic, inexpensive and prima facie are safe. As such, 
further studies are justified to develop these regimens as realistic tuberculosis 
vaccines for the developing world. 
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9 Materials & Methods 
9.1 Vaccines 
DNA Plasmids 
The vectors, pSG2.CS were constructed by Sarah Gilbert (NDM. Oxford 
University). pSG2.CS contains entire coding region of P. berghei circum porozoite 
protein. pCIK85A was constructed by Deborah Gill (NDCS Oxford Univer ity) by 
sub-cloning the 85A coding region from PSG28SA (136). P IK85A contains aa 1-
323 of Ag85A from the H37Rv M tuberculosis strain. Eighteen aa from the -
terminus end of Ag85A were deleted (5'-ALGATPNTGPAQGA-3') during the 
cloning process of PSG2.85A and replaced with S'-GSIPNPLLGLD-3'. The 
highlighted sequence i an epitope called a Pk tag that i recognised by the 
monoclonal antibody MCA136 (Serotec, Oxford UK) and wa used to confirm 
expression of the recombinant protein 
Recombinant Viral Vectors 
The con truction of MY A.85A and FP9.85A ha been de cribed previously (136, 
330). Both vectors express aa 1-323 of the 85A coding sequence under the control 
of the vaccinia virus P7.S early/late promoter. 
Briefly, chicken embryo fibroblasts (CEFs) were infected with wild-type MV A and 
transfected with the vaccinia virus shuttle vector containing the 85A or S coding 
sequence. Plaques containing recombinants expressed ~-galactosidase that produce 
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a blue precipitate in the presence of its substrate, X-galactosidase. This property 
enabled the recombinants to be picked and purified. 
Construction of FP9.R5A involved infection of primary CEFs with wild-type 
fowlpox and transfection with a shuttle vector containing the 85A sequence (cax' 1-
323) and green-fluorescence protein (GFP) as the selection marker. GFP expressing 
recombinants were sorted separately from non-recombinant CEFs by usc of a 
fluorescence-activated cell sorter. Recombinants were further purified by plaque 
picking and virus stocks were grown in primary CEFs and purified through a sucrose 
cushion by ultracentrifugation and diluted in endotoxin free PBS for injection. 
Preparation for Vaccination 
DNA plasmid purification 
DNA plasm ids were stored at -20°C until use. Vials were thawed and diluted in 
endotoxin free PBS within 2 hours of use. 
Viruses 
Virus stocks were stored at -BO°C until use. Vials were thawed on ice, sonicated 
(3 x 15 seconds bursts) then diluted in endotoxin free PBS (Sigma, Dorset.UK). The 
virus was kept on ice until vaccination. 
BCG 
The Pasteur vaccine strain (PI I 72D2) (Micheline Lagranderie. Pasteur Institute. 
Paris) used in mouse studies was stored at -80°C until usc. Stock vials (J-2x J 09 
CFU/ml) were thawed on ice, sonicated (2 x 15 seconds bursts) then diluted in 
endotoxin free PBS (Sigma, Dorset.UK). The BCG was kept on icc until vaccination. 
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Mice were immunised within 1.5 hours of thawing of the BeG. The stock solution of 
BCG was vortexed (-15 seconds) just prior to vaccination. 
The Copenhagen strain (Batch # 10012: Statens Serum Institut. Copenhagen S 
Denmark) used to vaccinate the rhesus and cynomolgus macaques, was stored as a 
Iyophilised powder -80°C until use. The BCG was diluted in the recommended 
diluent, briefly vortexed and maintained on ice until vaccination. Macaques were 
vaccinated within I hour of reconstitution of BCG. 
Mycobacterium tuberculosis H37R v 
The M. tuberculosis strain H37Rv (Trudeau Mycobacterial Culture Collection # I (2) 
was grown in Dubos medium at 37°C for 21-28 days. The broth culture was 
centrifuged, suspended in a tryptic soy broth-glycerol and stored at -70°C alter 
titration. Stock solutions were sonicated before use. 
Ziehl-Neelson Stain 
The bacterial culture was smeared on a glass slide and dried. Thc culture was lixcd 
in absolute methanol for 1 minute, then covered with 1% carbol fuchsin 
(concentration), heated to steaming and then allowed to stand for 5 minutes. The 
slides were rinsed gently with water and the excess drained from the slide. The slide 
was decolourised with 3% acid - 70% alcohol solution until the colour no longer ran 
from the slide then counter-stained with 0.1 % methylene blue for 30 seconds. The 
slide was rinsed gently and excess fluid drained. The slide was air dried and 
examined with a 1000x light microscope. 
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9.2 Animal Welfare 
All procedures were performed by myself (personal license PPL 30/50 II ), veterinary 
officers or licensed technicians in accordance with the Home Office {iuidance and 
Codes of Practice (on the Housing and Care of Animals used in Scientific 
Procedures, the Housing and Care of Animals in Designated Breeding and Supplying 
Establishments) and the Humane Killing of Animals under Schedule I to the Animals 
(Scientific Procedures) Act (986). 
9.3 Murine Studies 
Mouse Strains 
8- IO week old female BALB/c (H_2d) and C57BLl6 (H-i') mice (Harlan Orlac, 
Blackthorn, UK) were used for the studies described. Mice were hOllscd in an animal 
breeding facility in conventional conditions. 
Immunisations 
Intranasal Immunisation 
Intranasal vaccinations were performed in a Class I hood. Animals were anaesethised 
with halothane (vaporising within a glass container) (Merial Animal Health, Harlow 
UK). Mice were deemed fully aneasethised when body movement was no longer 
observed and breathing patterns changed to a visible, rapid movement or the rib 
cage. 7- IO seconds later, mice were removed from the container and the vaccine 
given drop-wise using a pipette to the nares over 3-5 seconds. 
Intravenolls Immunisation 
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Mice were warmed for ~5 minutes at 37°C or until vasodilation of the lateral tail vein 
was visible. Mice were restrained and immunised with 50pl or lOOp I in the lateral 
tail vain using aU-I 00 29G needle (BD Consumer Hcalthcare, Le Pont de Cluix. 
France). 
Intradennal Ear Immunisation 
Mice were anacsethised intraperitoneally with 50- 100111 Midazolan (Antigen 
Phannaceuticals Tipperary. Ireland): Hypnovel (Merial Animal Health Harlow. 
Essex. England): water (I: I :2), then vaccinated with 25,.J\/ear lIsing u- 100 2YU 
needle (BD Consumer Healthcare, Le Pont de Uaix. France) 
Footpad immunisation 
Mice were restrained and SOpl bolus was injected using a U-lOO 29(1 needle (BD 
Consumer HeaIthcare, Le Pont de Claix Franee) beneath the skin of the left- hind 
footpad. 
Intramuscular Injection 
Mice were anaesethised intraperitoneally with 50 - lOOp I Midazolan: Hypnovel: 
water (I: 1 :2). Fur was removed using dilipatatory cream and 50p I was injected into 
the lower tibialis of each leg using a 26 G needle (Becton Dickinson. Oxford). The 
needle had been sheathed to ensure it did not penetrate beyond the muscle. 
Immune Assays 
Preparation of single cell suspensions 
Splenocyte.\· 
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Splenocytes were removed aseptically and kept at room temperature (RT) in PBS 
until use. A single cell suspension was produced by crushing the spleen with the butt 
of a 10m I syringe and straining cells through a 70).lm cell strainer (Becton Dickinson 
Le Pont De Claix France). Cells were pelleted (7minutes, 300g with brake) and 
residual erythrocytes lysed by incubation in ACK lysis butTer (0.15M NH4CI. I 111M 
KCO" 0.1 mM Na2EDTA) for 5 minutes, during which cells were gently mixed. 
Lysis was stopped after diluting the cell suspension I in 5 with PBS. Cells were 
spun, suspended and counted either by crystal violet staining or using a easy I TT 
(settings 5.47 - 15).lm) (Scharfe System. Reutlingen. Germany). This method yielded 
over 98% cell viability and negligible erythrocyte contamination. 
Lymph Node Cells 
Lymphocytes were removed aseptically and kept at RT in PBS until usc. Residual fat 
was removed prior to crushing of LN through a wet cell strainer. Cells were washed 
twice in PBS, suspended in CTL media and counted. Cells showed over '>XU,;, 
viability. 
Lung cells 
Isolation of lymphocytes from murine lungs was adapted from a protocol by 
Gonzales-Juarrerro et al (331). Lungs were perfused with 10 ml of PBS / heparin 
following the insertion of an l8G needle 2-3mm into the apex of the heart (left 
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ventricle}. Lungs were diced intol mm cubes with razor blades in 2 ml of RPMI. An 
equal volume of 1.4 mg/ml collagenase XI (Sigma C7657) and 60Ilg/ml Dnase IV 
(Sigma D5025) in RPMI was added. The tissue was incubated for 30 minutes at 
37°C with occasional mixing. The reaction was stopped with 5% FCS in RPMI. The 
resulting slurry was mixed thoroughly and pushed through a 70J.1m cell strainer. 
Cells were spun for 5 minutes at 300g. Residual erythrocytes were lysed with ACK 
lysis buffer. Cells were suspended in RIO (RPMI, 10% foctal bovine serum) and 
counted using trypan blue exclusion. Cells typically showed RO-90% viability. 
Cell Culture and Peptides 
All cells were cultured in CTL media comprising a-MEM (Gibco13RL, Paisley UK) 
supplemented with 10% foetal bovine serum (FBS) (Sigma, Watford UK), O.OSmM 
~-mercaptoethanol (GibcoBRL, Rockville USA), IOIlM HEPES buffer (GibeoBRL), 
20mM L-glutamine (GibcoBRL) and IOOJ..lglml penicillin/streptomycin 
(GibcoBRL). 
The panel of 20'mer 8SA peptides from Ag8SA protein from M. luherculosis H37Rv 
(Genbank Accession Number: P 17944) used in these studies are shown in Table 9. I. 
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Table 9.1. Antigen 85A peptides from H37Rv M tliherClilosi~ strain 
# Sequence a # Sequence # Sequence 
mqlvdrvrga vtgmsrrlvv 12 vrnpvggqssf ysdwyqpacr 23 mwgpkedpaw qll1dpllnvg 
2 vtgrnsrrlvv gavarlvsgl I3 ysdwyqpacr kagcqtykwe 24 qmdpllnvg klianntrvw 
3 gavarlvsgl vgavggtata 14 kagcqtykwe tfltselpgw 25 klianntrvw vycgngkpsd 
4 vgavggtata gafsrpglpv 15 tfltselpgw Iqanrhvkpt 26 vycgngkpsd Iggnnlpakf 
5 gafsrpglpv eylqvpspsm 16 Iqanrhvkpt gsavvglsma 27 Iggnnlpakf legfvrtsni 
6 eylqvpspsm grdikvqfqs 17 gsavvglsma assaltlaiy 28 legfvrtsni kfqdaynagg 
7 grdikvqfqs gganspalyl 18 assaltlaiy hpqqfvyaga 29 kfqdaynagg rhngvfdfpd 
8 gganspalylldglraqddf 19 hpqqfvyaga msglldpsqa 30 rhngvfdfpd sgthsweywg 
9 Idglraqddf sgwdintpaf 20 msglldpsqa mgptIiglam 31 sgthsweywg aqlnamkpdl 
10 sgwdintpaf ewydqsglsv 21 mgptliglam gdaggykasd 32 aqlnamkpdl qrhwvprptp 
II ewydqsglsv vrnpvggqssf 22 gdaggykasd mwgpkedpaw 33 qrhwvprptp gppqga 
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Other peptides used in assays include pb9 -- SYIPSAEKI (amino acids: 372-XO) from 
circumsporozoite protein from P. herghei (Genbank Accession Number: 
AAA29541) (Research Genetics, Huntsville USA); NP pcptidc- TYQRTRAL V 
(amino acids: 147-155) from nucleoprotein expressed by intluenza A virus (tienbank 
Accession Number: CAA36234). 
Ex vivo IFN-y Elispot 
Specific IFN-y secretion by spleen or lymph node cell suspensions was assayed by 
ELlSPOT. MAHA plates (Millipore, Bedford. MA USA) were coatcd overnight at 
4°C in 50~1 of 10llgimi of IFN-y coating antibody (MABTE(,H Nacka Swcden) in 
PBS. Plates were blocked in 10% FBS in RPMI overnight at 4°(". Cells were 
incubated for 18-20 hours with antigen cultured in CTL media (267). Following 
incubation, cells were discarded and the plate washed 2x with PBS, followed by a 5 
minute incubation with distilled water to lyse any residual cells. The plates were 
washed a further 3x with PBS and then incubated overnight at 4°(, with lJ.tglml of 
biotinylated anti-IFN-y antibody (MABTECH Nacka Sweden). Plates were then 
washed 5 times in PBS and incubated with 50~1 of lllgimi of streptavidin alkaline 
phosphatase (MABTECH Nacka Sweden) either overnight at 4°(, or at room 
temperature for 2-4 hours. Plates were developed by eye using a BioRad ALP Kit 
according to the manufacturer's instructions. The colour reaction was stopped using 
tap water. Well images were captured with an AID ELiSPOT Reader System ami 
spots enumerated using the companion software (Autoimmun Dignostika (imBH, 
Strapberg. Germany). The final concentration of antigens used in the assays was 
PPD at 10~g/ml, individual peptides at 2~giml and Ag85A protein at IOllgiml. 
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Results are expressed as the mean spot-forming cellsll 06 cells (SFClmillion) +/-
SEM. 
51Chromium Release Assays 
Cells were stimulated with 211g/ml of peptide P 11 and cultured for 7 days. Cells were 
fed with 10 units/ml of Lymphocult-T (Biotest, Dreieich Germany) on day 3. ('ells 
were harvested then incubated for 4 hours with slChromium-loaded P815 cells 
(ATCC: TIB-64). Specific lysis was calculated as follows: 100x [(experimental 
radioactivity - spontaneous radioactivity) / (total radioactivity - spontaneous 
radioactivity)]. Results are expressed as the mean percentage (%) specific lysis t/-
SEM. 
Proliferation Assays 
Cells (1-2xI05cells/well) were stimulated with 111g/ml of pcptidcs, IOI1g/ml PPD or 
Ag85A protein or ConA in a final volume of 200111 for 3 days. Wells werc pulsed 
with II1Ci I 20111 RO (RPMI) of 3H-Thymidine. Plates were frozen 12-18 hours later. 
The proliferation response or stimulation index (Sl), was calculated as the fold 
increase in incorporation of eH] thymidine by cells stimulated with antigen over 
cells cultured in media alone. A SI equal to or greater than 2 was reckoned as a 
positive proliferative response to antigen. All cell samples produced a SI > \0 to 
ConA. 
M. tuberculosis Challenge 
Aerosol Challenge 
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Four weeks after the second immunisation, mice were challenged by aerosol with M. 
tuherculosis using a modified Henderson Apparatus, which was enclosed within a 
Category III isolator (258). Mice were individually restrained to allow exposure or 
only the nose during challenge (ADG Developments, Hertfordshire, UK). Deposition 
in the lungs was estimated 24-48 hours after challenge. 
Enumeration of bacterial load 
Bacterial load in organs was calculated by plating lO-fold serial dilutions of organ 
homogenates on both Middlebrook 7H II agar and thiophene-2-carboxylic acid 
Hydrazide (TCH) (5Ilglml) supplemented Middlebrook 7H II plates. TCH (Sigma-
Aldrich, Dorset, UK) at this concentration prevents BeG growth (39). Organs were 
fully homogenised in Iml PBS in screw cap tubes containing glass beads (O.Hmm) 
using a Mini-Bead Beater (Stratech Scientific Soham UK) for 60-100 seconds at 50 
revolutions per minute (rpm) and then left to settle for 10 minutes. Plates were 
examined at 1 week to ensure no contamination with rapidly growing mycobacteria. 
Protection results are expressed as logto (mean (CFU» +/- SEM (n=9-12). 
9.4 Macaque Studies 
Housing and behaviour 
Six infant rhesus male macaques (12-22 months) weighing between 2.0-2.7 kg were 
used in this study. The schedule for vaccination is described in Fig. 23. 
Animals were housed in troupes of 20-30 juvenile males and were monitored daily 
for signs of distress or any changes in behaviour in their interactions with other 
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macaques and animal technicians. All observations were recorded and dated. No 
adverse behaviour was reported during the study. Body weight was recorded 
monthly. All animals showed a 45-60 % gain in body weight in the year lol\owing 
BeG vaccination (Fig. 37). 
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BeG immunisations 
Intradermal Vaccination 
Animals were intradermally immunised with BeG (Danish strain 1331, SSI, 
Copenhagen, Denmark) as a single injection of 4x lOs CFU in a IOOIJ I bolus to the 
upper left arm. 
Aerosol Delivery of BCG 
Two animals were given 4x 105 CFU BCG (Danish strain 1331, SSI, Copenhagen, 
Denmark) by aerosol. This vaccine dose has been reported to be well tolerated in 
macaques (256). Prior to vaccination, macaques were screened with an emulator to 
mimic the breathing pattern of eaeh animal and to calculate the time required for the 
specified dose of aerosolised BCG to be administered to the lungs. A HaloLite I \1 
nebulizer (Profile Therapeutics, Bognor Regis, UK) was used to generate aerosols of 
between 1-5 IJm based on previous estimates to achieve optimal deposition in the 
lower lung. Aerosols expelled by the HaloLite™ were delivered to an anaesthetised 
macaque via a paediatric mask with an outlet valve connected to a filter (0.22IJlll, 
Pall). Light pressure on the mask created a seal that also blocked the nasal passage 
ensuring the macaque breathed only through the oral cavity. The mask was held in 
position for 12 minutes during which the macaques breathed with no apparent 
discomfort. Macaques were monitored for several hours following the procedure. No 
visible signs of respiratory discomfort or coughing were observed imlllediately alier 
vaccination or during the course of the study (67 weeks). 
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MVA.85A and FP9.85A vaccinations 
MVA.85A and FP9.85A vaccinations were given intradermally. Immediately before 
vaccination, viruses were vortexed for I minute. The maximum volume injected into 
anyone site was I 001l I. Animals typically received 5 injections divided between the 
left and right upper arms. 
Tuberculin Skin Testing 
Animals were anaesthetised and 10, 100 or 1000 tuberculin units (TU) of Tuberculin 
Purified Protein Derivative (Evans VACCINES, Liverpool. UK) diluted in 100pl of 
water was injected in the upper left or right eyelid, between the medial and lateral 
canthi. 48 hours later, any local reaction was read and scored on a scale of 0-5 by a 
qualified veterinarian. 0= no reaction (-); 1= bruise (-); 2= erythema of palpebrum, 
no swelling (-); 3= erythema of palpebrum and slight swelling (+/-); 4= swelling of 
palpebrum, drooped eyelid and erythema (+); 5= swelling and/or necrosis (t); 5 . 
eyelid closed (+). The + or - symbols in parenthesis indicate whether the tuberculin 
skin test (TST) is deemed positive or negative respectively. This scale was 
developed by S. Wolfensohn (Oxford University, Senior Veterinary Officer). 
Necropsies 
The aerosol and intradermally BCG-immunised animals were necropsied at week 67. 
A full autopsy was performed recording gross appearance of external condition and 
all major internal organs of each animal. Organs either whole or in part were lixed, 
sectioned and heamatoxylin / eosin stained, then examined and scored for evidence 
of pathology (Rest Associates, Cambridge. UK). Other sections were stained by the 
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ZN method to detect the presence of acid-fast mycobactcria (AFB) (Rest Associates. 
Cambridge. UK). No AFB were detected by this method. 
Bacteriology 
Sections of the right apical and left caudal lung lobes, spleen and lymph nodes not 
used for histological examination, were homogenised and cultured for 4 weeh at 
37°C on middlebrook plates to detect viable mycobacteria. One ZN positive colony 
grew from a right caudal lung homogenate from Hector. The colony was identified 
as Mfortuitum (Public Health Laboratory Service, Dulwich Hospital. UK). 
Broncheo-alveolar Lavage 
Animals were lavaged several times during the study to sample cells in the lung 
compartment. Repeated lung lavage is well tolerated by macaques (332). None of the 
animals in this study displayed any adverse effects following lavage. The procedures 
were performed by animal technicians (Harlan. LoughbofOugh UK) 
Animals were anaesthetised and tubing (5mm ID I 8.0 mm OD) (Portcx. Hythe. 
Kent, England) was inserted past the level of the third bifurcation of the bronchus. 
Warm sterile Hank's solution (~ body temperature) (Sigma-Aldrich. Dorset. 
England) was introduced into the lung through the tube. The fluid was left in the 
lung for I minute and then withdrawn under suction (not exceeding 40mm/hg) uver 
several minutes. Typically a 20ml volume was introduced into the lung and 10-151111 
was recovered. Broncheo-alveolar lavage tluid (BALF) was stored on icc unti I 
processing. 
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Preparation of single cell suspensions 
Peripheral Blood Mononuclear Cells 
Blood was diluted 1 in 2 with RPMI (GibcoBRL, Strathclyde. UK) and then isolated 
using a Lymphoprep gradient (Axis-Shield, Oslo. Norway). Cells were spun for 45 
minutes at 950g with no brake. Macaque peripheral blood mononuclear cells 
(PBMCs) did not form a clean interface between the Lymphoprep and plasma layer. 
As such, the majority (around 15mls) of the interface and ficoll gradient was 
removed with a Pasteur pipette and diluted into SOmIs RPMI. Cells were then 
washed twice (no brake during centrifugation). Cells fonned a loose pellct with 
significant erythrocyte contamination, which produced high levels of background in 
IFN-"( ELISPOT. Residual contaminating erythrocytes were hypotonically lysed with 
5-7 ml ACK buffer for 5 minutes. Cells were then washed and pelletcd. If 
erythrocyte contamination was still observed, cells were again lysed. The degree of 
erythrocyte contamination appeared to be a function of the animal not protocol. 
Golfs blood was typically lysed 2-3 times to achieve a pure lymphocyte pellet. The 
plasma (50%) layer was frozen for antibody studies. Cells were washed and 
suspended in RPMl, 10% foetal bovine serum (R 10). Cells were either immediately 
used for proliferation and cultured ELISPOT, frozen in 10% DMSO/FBS lor later 
analysis or cultured overnight without antigen at 37°C degrees in RIO medium 
(RPMI, 10% FBS, 20mM L-glutamine, IOOJlglml penicillin/streptomycin) at a 
concentration of 2-4 106 cells/ml for use indirect EllS POT assays. 
Following PBMC isolation, cells were diluted 1/1000 and counted lIsing a easy 1 TT 
(Scharfe System. Reutlingen Gern1any) on settings 5.7 - 12 ~m. Cells showed 9Xo o 
:!Il} 
viability and at every time point produced a strongly positive response to ConA 
stimulation. 
Lymph Nodes 
Lymph nodes were maintained in PBS at RT until preparation for immune assays. 
All manipulations were then carried out under aseptic conditions. Fat was removed 
and LN were then crushed with the butt of a 10mi syringe and put through a 70~ m 
cell strainer. Cells were washed and left overnight at RT without antigen for analysis 
in indirect ELISPOT assays. 
Splenocytes 
Spleens were maintained in PBS until cell preparation. Spleens were roughly cut 
with sterile scissors then crushed with the butt of a 10mi syringe into a metal 
strainer. 25% of cell suspension was removed for bacteriology. The remainder was 
then strained over 5, 70~m cell strainers and washed twice with PBS. Three rounds 
of lysis with ACK buffer were required, to achieve complete lysis of erythrocytes. 
The cells were suspended in 100ml of RIO and left overnight. Both thc splcen and 
LN cell suspensions congealed overnight yielding far lower cells than predicted for a 
lymphoid organ of that size. Further optimisation of these cell-isolation techniques is 
needed. 
Broncheo-alveolar lavage cells 
All manipulations of BAL cells were conducted under aseptic conditions. All 
reagents and instruments were firstly cooled to 4°C. BALF was strained thollgh a 70 
~m filter to remove mucus then spun (10 minutes, 950g) with no brake. Cells were 
counted by trypan exclusion and cell morphology recorded. Lung lavage yielded 2-4 
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x IOn cells. 55-60% of BALF cells had a lymphocyte morphology bcing small. round 
and highly refractive. Cell viability ranged from 50-90%. The majority of dead cells 
did not appear to be lymphocytes being larger with a fibroblast or endothelial cell 
morphology. 
Lymph Nodes and Splenocyte." 
Cell concentration and percentage viability were determined by trypan hlue 
exclusion. Cell viability for lymph nodes and splenocytes prior to usc in immune 
assays ranged between 90-98%. Cells were small, round and highly refractive and in 
culture responded strongly to the mitogen, con A by fonning budding colonies and 
secreting IFN-y. 
Thawing of Frozen Cells 
Frozen cells that had been stored in 90% FBS 110% dimethyl Sulfoxide in liquid N, 
were thawed in a 37°C water-bath. A solution of 60IJg DNase I (type IV) / RPMI 
(Sigma-Aldrich, Dorset UK) (RT) was added drop-wise to the thawed vial and the 
frozen cells gently mixed with the diluent. The cells were then added to a tube 
containing 10m I DNase I / RPMI, centrifuged for 5 minutes at 300g. The cell pellct 
was suspended and another 3 m1 of DNase I / RPM! added for 2-3 mins. 10 rnls of 
RIO was added, cells were spun then suspended in 5mls RIO. Cells were left at 37 C 
for 45-60 mins, then spun, suspended and counted using trypan blue exclusion. 70-
85% of cells frozen were recovered with this technique. Thawing of cells without 
adding DNase !, recovered -20% fewer cells. 
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Indirect Elispot 
The Monkey I Human IFN-y kit (MABTECH, Nacka. Sweden) was used in all 
ELISPOT assays. MAIP plates (Millipore, Bedford. MA USA) were coated with 
IOpglml of IFN-y antibody (clone 7-B6-1) diluted in 100pM Carbonate ButTer, pH 
9.6 (Sigma-Aldrich, Dorset UK) overnight at 4°C. Plates were blocked with 2°0 
BSAlH20 and incubated overnight at 4°C. Cells were aliquoted into wel1s at a tinal 
concentration of 2-4 x lOs cells/well for PBMCs. Splenocytes and lymphocytes were 
used at 2-8 xI05cells/well and BALF cells at 1.25xl04 10~ cel1s/well. All samples 
were assayed in duplicate and lor with titrations of cells. Antigens were diluted in 
RIO and added to wells to achieve a final volume of lOOp I. Cells were stimulated 
with antigens at the fol1owing final concentrations - PPD - lOf.lglml (SSI. 
Copenhagen Denmark), 85A protein -5 f.lglml (K. Huygen, Institut Pastcur), X5B 5 
Jlg/ml (Lionex GmbH, Braunschweig Germany), 20'mer peptides spanning AgX5A-
25 f.lglml (Research Genetics, Huntsville US), concanavalin A-IO Jlglml (Sigma-
Aldrich Dorset UK). Cells were left at 37°C for 18-22 hours then washed OX with 
PBSI 0.05% Tween. lOOp I of biotinylatcd anti-IFN-y antibody (clone GZ-4) at 
I ).lglml was added to each well and incubated overnight at 4°C, Plates were washed 
and streptavidin-ALP (1/1000 dilution) was added and incubated either overnight at 
4°C or at RT 2-4 hours. Plates were washed 6 times then developed using an AP 
Conjugate Substrate Kit (BioRad Laboratories, Hercules, CA USA) according to 
manufacturer's instructions. Well images were captured with an AID ELISPOT 
Reader System and spots enumerated using the companion softwarc (Autoilllll1un 
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Dignostika GmBH, Strapberg. Germany). Background responses in non-antigen 
stimulated wells were typically <25 SFC / \00 cells and responses to the non-specific 
mitogen, ConA > \000 SFC I \00 cells. Table 9.2 compares the percentage of 
lymphocytes before and after ACK lysis and after overnight culture without antigen. 
The results show that the percentage of B, T and NK cells did not differ between the 
ACK lysis stage and overnight culture. Overnight culture of cells did significantly 
deplete large, granular cells in the monocyte gate most likely reflecting the 
adherence of cultured monocytes to the tissue culture dishes (46-50% to < 22-33°0 in 
3 independent samples) (Fig. 38). 
Flow cytometry 
PBMCs were stained with a series of human antibodies. Cross-reactivity with rhesus 
macaque PBMCs was confirmed for the antibodies listed (data not shown). The 
following volumes/stain were used: aCD3-PE (SP34) - 20fll; aCD4-FITC (M-T477) 
20JlI; CD8-FITC, bCD8-TC 5fll (RPA-T8) Sfll; bCDI4-TC (M5E2) Sill; aCDI6-
FITC (3G8) 20fll; bCD20-FITC (2H7) Sf.!I; aCD45RA-PE (SH9) 20fll; IgGI-TC; 
aIgG2a-FITC, 3IgG3-PE, 3IgG3-APC. 3= Becton-Dickinson. Oxford UK; h= Caltag-
MedSystems, Silverstone UK. 
106 PBMCs were washed with PBS then 2x with F ACS buffer (2% FBS/ O.OSmM 
EDT A / PBS). Cells were incubated with antibodies for 20 minutes at 4 0(' then 
washed twice with 0.5ml F ACs butTer. Cells were pelleted then tixed with 2% FBS I 
1% PF A / O.OSmM EDT A / PBS for analysis the following day. 
Table 9.2 Percentage (average of 3 samples) of lymphocyte 
subsets during PBMC isolation 
within lymphocyte I NK gate LP" LP+ Next Day' 
ACKh 
CD3+ ICD4+ICDS- 67.24 72.65 74.5 
CD3+ ICD4-/CDS+ 20.4 15.6 15.95 
CD3+ ICD4+/CD8+ 2.23 1.64 2.43 
CD3+ ICD4-/CDS- 10.12 10.12 7.13 
dCD3- /CD8+/CDl6+ 16.8 30.7 27.8 
CD20+ /CD3-/CDI4- 24.8 13.74 17.3 
a LP= PBMCs purified from Iymphoprep gradient 
hLP + ACK = PBMCs after ACK hypotonic lysis ofresidual erythrocytes 
'Next Day = non-adherent PBMCs after overnight culture in RIO, no 
antigen 
d cells first gated on the population in bold 
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Figure 38: Overnight incubation of macaque P8M s decrca es 
cells in the monocyte gate by about 50%. FOlward vs Side catter 
density plots were generated of PM8Cs after isolation from whole 
blood subsequent ACK buffer lysis (A) and after overnight 
incubation in RlO (8). The monocyte gate (boxed) shows that the 
density of monocytes, decrease following overnight incubation. 
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CD4 t / CD8+ T cell depletions 
The restriction of peptide specific T cell responses was determined by using ELlSP< n 
following depletion of cells CD4+ (M-450) and COX' (M-450) human Dynaheads 
(DYNAL, Wirral, Merseyside. UK) used in accordance with the manufacturcr's 
instructions. The efficacy of depletions (ranging between CD4 bcads: XO-94°u; CDS 
beads: 95.4- 99.8%) was confimled using flow cytomctry. 
Cultured Elispot-
PBMCs were left OIN in round bottom 96 well plates at 4 x lOll cells / Illl without 
antigen. The following day, non-adherent cells were harvested. The remaining adherent 
cells were infected with 2x 104 CFU BCG/well (SSI, Denmark Copenhagen) for 2-4 
hours in RPMI (no additives). Cells were washed and non-adherent cclls added back at 
a concentration of 2 x 105 cells/ well. Cells were fed with 10 units Lymphocuh-T every 
3 days. After 14 days culture, non-adherent cells harvested and washed. 10' cultured 
cells were added with equal numbers of y-irradiated (12 minutes, 3000 rads in Iml 51) 01 
FBS/RPMI) autologous cells (freshly separated PBMCs from subsequent hleed). <. ·ells 
were stimulated with 1OJ..l glm I PPD, SJ..lglml 85A protein or 25J.1g1ml X5A pcptidcs for 
18-20 hours. Control wells contained y-irradiated autologous cells plus antigen and did 
not produce IFN-y « 20 SFC / 101> cells). The development of the cultured ELISPOT 
was the same as described for the indirect ELISPOT. 
Proliferation Assays 
Quadruplicate wells each containing I x 105 cells were seeded in 96-wcll RB plates \\el"'~ 
stimulated for 3 or 5 days with antigen at the following concentrations (PPD - 1()~lg!lll. 
8SA protein -Ilg/ml. peptide pools- \0 Ilg/ml, Conconavalin A-5 Ilg/Illl). 
The proliferation response or stimulation index (SI). was calculated as the fold increase 
in incorporation of ['H] thymidine by cells stimulated with antigen uver cells cultured in 
media alone. A SI equal to or greater than 4 was reckoned as a positive proliferative 
response to antigen. All cell samples produced a SI > 10 to ConA. 
Antibody ELISA 
Preliminary experiments were performed to determine saturating concentrations of 
coating antigen and peroxidase conjugated antisera. 
Nunc-Immuno Polysorp plates (Fisher Scientific U.K. Ltd. l.uughbofOugh. 
Leicestershire UK) were coated overnight at 4°C with 501111well of 5~Ig/ml llf !o\SA-
culture filtrate protein diluted in carbonate buffer. Plates were washed 6 times with 
0.05% Tween 20 / PBS and then blocked with 2%BSA/water for I hour at 37"( '. This 
and all subsequent incubations at 3rC were performed in a humidilicd chamber. The 
50% plasmaslRPMI were thawed, centrifuged for 3 minutes at 670g to remove any 
precipitate and then added to plates in a final volume of 50llllweli. Scrial half fold 
dilutions were made (1 - 1/1024) with I%BSAlO.05% Tween 20/PBS (diluent butTer). 
Each plate contained duplicate blank wells (no plasma) and half fold dilutions of a 
reference rhesus macaque serum (11100 - 1/3200) (NMonS from Nordic 
Irnmunologicals. Tilberg Netherlands) that was positive for X5A antibodies at titres of 
400 -800. Plates were incubated for 2 hours at 37°(" washed and 50111 of peroxIdase 
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conjugated rhesus macaque immunoglobulin antisera (containing Ig(i, IgA. IgM. Fe. 
Fab) was added to each well at a dilution of 1/250 with diluent butTer (iAMON-lg 
from Nordic Immunological Laboratories Tilberg. Netherlands). Plates werc incuhatcd 
for a further hour at 37°C and then developed using the ABTS Microwell Peroxidase 
Substrate System (KPL Gaithersburg, Maryland US) according to manufacturer's 
instructions. The reaction was stopped after 10 minutes incubation with an equal 
volume of 1% SDS. A single absorbance reading was made at 405 nm using an endpoint 
or multi-plate titration protocol on a Model 550 Microplate Reader (BIO-RAD Ilcmel-
Hempstead, Hert UK) 
Multi-cytokine analysis of BALF 
The BALF supernatants were concentrated 5 - 25 times by centrifugation using a .~kDa 
Centriprep device (Millipore, Bedford USA). The BALF was then analysed for the 
presence of \3 cytokines using a Lincoplex Multiplex Immunoassay Kits Human 
Cytokine Panel as per manufacturer's instructions (Lincoplex. St ('harles. USA). Assays 
were performed in duplicate. Briefly, 25 ~I of concentrated HALF was mixed with 
Luminex beads and incubated on a blocked MABV plate for I hour at RT with shaking. 
Secondary and tertiary antibodies were then added and incubated for 30 minutes with 
shaking. The samples were read using a Luminex-IOO machine (1000 events in total i 
minimum of 50 events per cytokine). Positive controls (provided with the kit) fell 
within the forecast range and standard curves were acceptable for a\1 cytokincs. 
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Appendix 
Animal models are important in the development of novel vaccines not only for testing 
the immunogenicity and protective efficacy of vaccine regimens but also for toxicology 
studies. At various stages in the immunology studies described in this thesis, organs 
were examined for evidence of vaccine-induced pathology. Whilst further pathology 
studies are warranted, from the studies conducted there was no evidence of adverse 
pathology produced in the animal models from aerosol delivered BeG, MY A.HSA or 
FP9.8SA. The reports from the pathology studies are tabled below and have been 
referenced in the text. 
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Appendix] : Summary of HIE staining and ZN pathology in Ear 
Vaccination 
Regimen 
I 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Sex Features" Intell1retation 
I 17 - accompanying mild acanthosis :; 
4 6 
2n :; 
I 17 - dilatation of infundibulum of follical within inflammation 6 
with keratin. both have mild lymphatic dilatation 
4 :; 
117 
mild dilatation of both 
217 
I - lymphatic dilatation of both 
4 
117 
6 
6 
6 
5 
both have mild diffuse expansion of demlis by mixed. 6 
degenerating inflammatory cells and lymphatic dilatation. 
7 - both have focal t diffuse expansion of dermis by mixed. 6 
degenerating inflammatory cells and lymphatic dilatation. 
1/7 6 
7 - both have diffuse expansion of dennis by mixed. 6 
degenerating inflammatory cells and lymphatic dilatation. 
7 - one has focal fibrosis and the other focal inflammation of the 6 
dermis with lymphatic dilatation of dermis by mixed 
inflammatory cells. the second main piece has lymphatic 
dilatation 
I 13 17 -the second main piece has lymphatic dilatation 
1/3/7 
1/317 
2 17 - both have lymphatic dilatation 
6 
6 
6 
• I. one piece has focal expansion of dermis by mixed. degenerating inflammatory cells I 2 both have 
focal expansion of dermis by mixed. degenerating inflammatory cells I 3 the second has lymphatic 
dilatation 1 4 normal range apart from mild lymphatic dilatation 1 5 focal subacute dermatitis as.o;lx:iah:d 
with mycobacteria 16. oedema 1 7. ZN +ve long beaded organisms seen 
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Appendix 2: Summary of HIE staining and ZN pathology in Facial Lymph nodes 
Mouse Sex Features a Intcrpr-
dation h 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
15 
16 
17 
18 
19 
20 
I 12 - foci of large, pale macrophages in central area 
I 12 - foci of large, pale macrophages in medulJary cord areas 
2 - foci of large, pale macrophages in various areas 
6 
6 
I 12 I 3 - foci of large, pale macrophages and plasma celJs in medullary 6 
cords 
2 / 3 I 4 - Scattered foci of large, pale macrophages and plasma cells 6 
mainly in medullary cords 
2 I 3 14 -large, pale macrophages and plasma cells mainly in medullary 6 
cords 
3/5 6 
2 I 3 / 4 -scattered foci of large, pale macrophages and plasma cells 6 
mainly in medullary cords 
3/5 
3/5 
I /2/5 
I /2 I 5 
I /2/5 
I /2/5 
I /2/5 
2/4/5 
112 / 5 
2 /5 
2/4/5 
I /2/5 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
a I some pale centred active follicles / 2 ZN +ve long beaded organisms seen / 3 LN structure ch:an:r i 4 
foci small and inactive / 5 foci of large, pale macrophages in various areas 
h 6 microgranulmata associated with mycobacteria 
27X 
Al!l!endix 3. Re20rt on ~TOSS 2atholo~:i of macagues at time of necT02s:i 
Ghn Hector Golf Gull! 
External Condition Skin NAD ~ Good NAD Good NAD NAD hour loss 
condition condition trulll b""k 
Eyes NAD NAD NAD NAD 
Orifices No discharges Nu discharges- No discharges No dlschargt·s 
slight faecal 
staining at base of 
tail 
Body Condition Lean NAD ~ Lean Lean Lean 
Digestive system Li\er NAD NAD - hepatic NAD ~ hepattc Small area ofmdd 
LN undetectable LN undetectable ditlilse capsular 
fibrosis 
Gall NAD NAD NAD NAD 
bladder bileduct p 
ancreas 
Mouth,tongue NAD NAD NAD NAD 
Pharynx.'tonslls NAD NAD NAD NAD 
Oesophagus NAD NAD NAD NAD 
Stomach NAD Slight reddening NAD NAD 
or the gastric 
mucosa in the 
fundus 
Small in test ine NAD NAD NAD NAD 
Caecum NAD NAD NAD NA[) 
Caecal LN NAD 
Colon· rectum NAD NAD NAD NAD 
MLN NAD Anterior MLN NAD NAD 
englarged 
Respiratory System Nares NAD NAD NAD NAD 
Larynx. trachea Blood stained Blood stained NAD Blood sliltll ..... i 
fro th at trae heal froth at tracheal froth attra.:heul 
bifun;ation bi furcation bifurcation 
Thyroids'par.lthyr NAD NAD NAD NAD 
oids:thymus 
lungs 'X X NAD X 
pleura NAD NAD NAD NAD 
Tracheo~bronchial NAD NAD NAD NAD 
LN 
Urinary System Kidneys/adrenals NAD NAD NAD NAD 
Ureters NAD NAD NAD NAD 
Bladder NAD NAD NAD NAD 
Urethra NAD NAD NAD NAD 
Reproductive Testes NAD - immature NAD~ immature NAD ~. immature NAD Ullmature 
System 
Seminal vesicles NAD - immature NAD - immature NAD - immature NAD - Illltllllture 
Prostate NAD - immature NAD - immature NAD~- Immature NAD - nnmature 
penis NAD NAD NAD NAD 
• NAD - no abnormality detected 
'Bright red mottling - attrIbuted to hypostatic congestion 
Appendix 4 - Summary of H/E staining following rhesus macaque necropsies at week 67 
Glyn - Organs 
L Inguinal LN 
R Axillary LN 
L Cervical LN 
R Cervical LN 
R Submandibular LN 
L Tonsil 
L Turbinates 
R Turbinates 
Nasal Septum 
HilarLN 
Spleen 
Liver 
L Lungx2 
Brain 
Features Interpretation 
Normal range 
Active follicles Normal range 
Very large and secondary active follicles. Paracortical expansion, sinus Hyperplasia, Band T 
compression. 
Few small but active follicles only. 
Large and secondary active follicles. Paracortical expansion. 
Large and secondary active follicles. Paracortical expansion. 
Foci of fibrosis with a few neutrophils 
Foci of eosinophils 
Normal range 
Hyperplasia, Band T 
Hyperplasia, B and T 
Subacute rhinitis, focal and minimal 
Eosinophilic rhinitis, focal and minimal 
Nodules of lymphocytes and a few histiocytes. 
neutrophils in the submucosa 
eosinophils and Subacute rhinitis with mixed inflammation. 
mild 
Few active follicles, oedema of sinuses 
Follicles active. T cell areas less active. Red pulp contains significant 
number of eosinophils and neutrophils .. 
Staining ofperiacinar hepatocytes less dense (glycogen) 
Terminal congestion and oedema, peribronchial .' perivascular lymphocyte 
nodules 
Normal range 
Hyperplasia B white pulp with neutrophilic 
eosinophilic infiltrates of red pulp 
Normal range 
Previous antigenic stimulation. agonal oedema 
Normal Range 
279 
ZN 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-\'e 
Appendix 5 - Summary of HIE staining following rhesus macaque necropsies 
Hector - Organs 
R Internal Iliac LN 
L Inguinal LN 
L Axillary LN 
R Retropharangeal LN 
R Submandibular LN 
R Tonsil 
Features Interpretation 
Normal range 
Sinus histiocytosis. Few eosinophils in sinuses. Artefact one are Sinus histiocytosis 
Secondary active follicles. Paracortical expansion. Sinus histiocytosis Sinus histiocytosis, haemosiderosis 
with haemosiderosis. 
Secondary active follicles. Paracortical expansion. Hyperplasia, Band T 
Secondary active follicles. Paracortical expansion. Hyperplasia, Band T 
Active follicles, neutrophil and eosinophil exocytosis Hyperplasia with mild acute tonsillitis 
L Turbinates 
septum 
nasal Lymphocytes and a few histiocytes, eosinophils and neutrophils in the 
submucosa. Focal cartilaginous proliferation 
Subacute rhinitis with mixed inflanlmation. 
mild 
R Turbinates / nasal 
septum 
Hilar LN 
Spleen 
Liver 
Lung x 2 
Brain 
Lymphocytes and a few histiocytes, eosinophils and neutrophils in the 
submucosa and focally with exocytosis. 
Follicles active, T cell areas less active. Red pulp contains significant 
number of neutrophils. 
Subacute rhinitis with mixed inflammation. 
mild 
Normal range 
Hyperplastic white pulp with neutrophil 
infiltrates of red pulp 
Normal range 
T enninal congestion and oedema. peribronchial: perivascu lar lymphocyte Previous antigenic stimulation. agonal oedema 
nodules 
Nonnal range 
2XO 
ZN 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
Appendix 6 - Summary of HIE staining following rhesus macaque necropsies 
Golf - Organs 
R Internal Iliac LN 
L Inguinal LN 
L AxiUary LN 
L Retropharangeal LN 
R Submandibular LN 
R Tonsil 
L Turbinates 
septum 
R Turbinates 
septum 
HilarLN 
Spleen 
Liver 
Lung x 2 
Brain 
Nasal 
Nasal 
Features 
Some secondary foUicles 
Sinus histiocytosis 
Expanded paracortex, focal histiocytosis 
Expanded paracortex 
Few secondary follicles 
Active follicles, neutrophil exocytosis 
Lymphocyte foUicles, few plasma cells, histiocytes. eosinophils and 
neutrophils in the submucosa with eosinophil exocytosis. 
Lymphocyte follicles and a few histiocytes, eosinophils and neutrophils in 
the submucosa. 
Expanded paracortex 
Interpretation 
Mild hyperplasia, B 
Sinus histiocytosis 
T-cell hyperplasia 
T -cell hyperplasia 
Mild hyperplasia, B 
Hyperplasia with mild acute tonsillitis 
Subacute rhinitis with mixed inflammation. 
mild 
Subacute rhinitis with mixed inflammation. 
mild 
T-cell hyperplasia 
Follicles and T cell areas active, Red pulp contains significant number of Hyperplastic white pulp with neutrophil 
neutrophils and eosinophils. Macroscopic nodule structure identical. infiltrates of red pulp 
Normal range 
Terminal congestion and oedema, peribronchial; perivascular lymphocyte Previous antigenic stimulation, agonal oedema 
nodules 
Normal range 
21'1 
ZN 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
Appendix 7 - SummaI)' ofRlE staining following rhesus macaque necropsies 
Gulp - Organs 
L inguinal LN 
R Axillary LN 
R Cervical LN 
L Retropharangeal LN 
R Submandibular LN 
L Tonsil 
L Turbinates 
L Nasal Septum 
R Turbinates 
Septum 
HilarLN 
Spleen 
Liver 
Lung x 2 
Brain 
Nasal 
Features 
Expanded paracortex 
Expanded paracortex, one with brown pigment (probably melanin) 
Secondary active follicles. ParacorticaI expansion. 
Secondary active follicles. ParacorticaI expansion. 
Secondary active follicles. Paracortical expansion. 
Active follicles 
Few histiocytes, eosinophils and neutrophils in the submucosa. 
Lymphocytes, histiocytes, eosinophils and neutrophils in the submucosa. 
Nodules of lymphocytes, histiocytes. eosinophils and neutrophils in the 
submucosa with exocytosis 
Paracortical expansion. Sinus histiocytosis 
Interpretation 
T -cell hyperplasia 
T -cell hyperplasia 
Hyperplasia, B and T 
Thymus normal range 
Mild hyperplasia, Band T 
Mild hyperplasia, Band T 
Mild hyperplasia 
Subacute rhinitis with mixed inflammation, mild 
Subacute rhinitis with mixed inflammation, 
locally moderate 
Subacute rhinitis with mixed inflammation. 
locally moderate 
Mild T-cell hyperplasia and sinus histiocytosis 
Follicles and T cell areas active. Red pulp contains significant number of Hyperplastic white pulp with neutrophil 
neutrophils. infiltrates of red pulp 
Capsule normal Normal range 
Terminal congestion and oedema. peribronchial.' perivascular lymphocyte Previous antigenic stimulation. agonal oedema 
nodules 
Normal range 
~~~ 
ZN 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
-ve 
